false Q3 0001521036--12-31 0.1 http://fasb.org/srt/2025#ChiefExecutiveOfficerMember 0001521036 us-gaap:FairValueInputsLevel3Member lnth:SalesMilestoneMember lnth:MeasurementInputRevenueDiscountRateMember srt:MinimumMember lnth:ValuationTechniqueScenarioAnalysisMember 2025-09-30 0001521036 us-gaap:TreasuryStockCommonMember 2024-09-30 0001521036 us-gaap:LicensingAgreementsMember 2025-09-30 0001521036 lnth:NeuraceqMember 2025-07-01 2025-09-30 0001521036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-09-30 0001521036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001521036 us-gaap:LandMember 2024-12-31 0001521036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001521036 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001521036 us-gaap:LineOfCreditMember us-gaap:LetterOfCreditMember 2022-12-31 0001521036 lnth:MeilleurTechnologiesIncMember us-gaap:DevelopedTechnologyRightsMember 2024-06-01 2024-06-30 0001521036 lnth:LifeMolecularImagingLtdMember 2025-07-21 2025-07-21 0001521036 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001521036 lnth:OtherRadiopharmaceuticalOncologyMember 2025-07-01 2025-09-30 0001521036 lnth:DefinityMember 2025-01-01 2025-09-30 0001521036 us-gaap:TrademarksMember srt:MaximumMember 2024-12-31 0001521036 us-gaap:RestrictedStockMember 2024-01-01 2024-09-30 0001521036 lnth:OtherRadiopharmaceuticalOncologyMember 2024-07-01 2024-09-30 0001521036 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember srt:MinimumMember us-gaap:SecuredOvernightFinancingRateSofrMember 2022-12-01 2022-12-31 0001521036 lnth:MachineryEquipmentAndFixturesMember 2024-12-31 0001521036 lnth:RadiopharmTheranosticsLimitedMember 2024-09-30 0001521036 us-gaap:FairValueInputsLevel3Member lnth:SalesMilestoneMember 2025-09-30 0001521036 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001521036 lnth:A1404CommercializationMilestoneMember lnth:ProgenicsMember 2025-09-30 0001521036 us-gaap:CostOfSalesMember 2024-01-01 2024-09-30 0001521036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001521036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001521036 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001521036 lnth:LifeMolecularImagingLtdMember 2024-01-01 2024-09-30 0001521036 lnth:ProgenicsMember 2024-12-31 0001521036 2025-01-01 2025-09-30 0001521036 us-gaap:CommonStockMember 2024-12-31 0001521036 lnth:OtherPrecisionDiagnosticsMember 2025-07-01 2025-09-30 0001521036 srt:MinimumMember lnth:A2625ConvertibleSeniorNotesDue2027Member us-gaap:ConvertibleDebtMember 2025-09-30 0001521036 lnth:A2022FacilityCovenantsMember 2025-01-01 2025-09-30 0001521036 lnth:CurrentlyMarketedProductMember 2024-12-31 0001521036 srt:MinimumMember us-gaap:LicensingAgreementsMember 2024-12-31 0001521036 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-09-30 0001521036 us-gaap:FairValueInputsLevel3Member us-gaap:ValuationTechniqueDiscountedCashFlowMember srt:WeightedAverageMember us-gaap:MeasurementInputDiscountRateMember lnth:DevelopmentAndCommercializationMilestonesMember 2025-09-30 0001521036 us-gaap:TreasuryStockCommonMember 2024-06-30 0001521036 us-gaap:FairValueInputsLevel3Member srt:WeightedAverageMember lnth:AssumedContingentConsiderationPiramalSPAMember us-gaap:MeasurementInputEbitdaMultipleMember lnth:ValuationTechniqueScenarioAnalysisMember 2025-09-30 0001521036 lnth:LicenseAndRoyaltyRevenuesSalesBasedMilestonePaymentMember 2025-01-01 2025-09-30 0001521036 lnth:LifeMolecularImagingLtdMember 2025-07-21 0001521036 us-gaap:FairValueInputsLevel3Member lnth:SalesMilestoneMember srt:MinimumMember lnth:ValuationTechniqueScenarioAnalysisMember lnth:MeasurementInputRevenueVolatilityMember 2025-09-30 0001521036 lnth:LifeMolecularImagingLtdMember lnth:CurrentlyMarketedProductMember 2025-07-21 0001521036 2024-01-01 2024-09-30 0001521036 lnth:PerspectiveTherapeuticsIncFullyDilutedBasisMember 2024-03-06 0001521036 us-gaap:BaseRateMember us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember srt:MinimumMember 2022-12-01 2022-12-31 0001521036 lnth:RegulatoryMilestonesMember lnth:LifeMolecularImagingRM2TechnologyMember 2024-07-03 2024-07-03 0001521036 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001521036 lnth:PerspectiveCommonStockMember 2024-01-22 0001521036 lnth:ReportableSegmentMember 2025-07-01 2025-09-30 0001521036 us-gaap:ValuationTechniqueDiscountedCashFlowMember us-gaap:FairValueInputsLevel3Member lnth:MeasurementInputProbabilityOfPaymentMember lnth:DevelopmentAndCommercializationMilestonesMember srt:MaximumMember 2025-09-30 0001521036 us-gaap:LineOfCreditMember us-gaap:BridgeLoanMember 2022-12-31 0001521036 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember lnth:SPECTBusinessMember 2025-09-30 0001521036 lnth:PerspectiveCommonStockMember 2025-09-30 0001521036 lnth:NeuraceqMember 2025-01-01 2025-09-30 0001521036 lnth:CurrentlyMarketedProductMember srt:MinimumMember 2025-09-30 0001521036 us-gaap:TreasuryStockCommonMember 2024-03-31 0001521036 2025-11-03 0001521036 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0001521036 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember 2025-09-30 0001521036 2023-08-02 2023-08-02 0001521036 lnth:A2625ConvertibleSeniorNotesDue2027Member us-gaap:ConvertibleDebtMember 2024-01-01 2024-09-30 0001521036 lnth:PYLARIFYMember 2025-07-01 2025-09-30 0001521036 2024-01-01 2024-12-31 0001521036 2024-01-01 2024-03-31 0001521036 lnth:TwoThousandTwentyFiveSharePurchaseProgramMember 2025-07-31 0001521036 lnth:OtherRadiopharmaceuticalOncologyMember 2024-01-01 2024-09-30 0001521036 lnth:PerspectiveTherapeuticsIncMember 2024-03-06 0001521036 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001521036 us-gaap:FairValueInputsLevel3Member lnth:DevelopmentAndCommercializationMilestonesMember 2025-09-30 0001521036 lnth:MachineryEquipmentAndFixturesMember 2025-09-30 0001521036 us-gaap:SellingAndMarketingExpenseMember 2025-01-01 2025-09-30 0001521036 lnth:RadiopharmTheranosticsLimitedMember 2025-01-01 2025-01-31 0001521036 us-gaap:ConstructionInProgressMember 2024-12-31 0001521036 2024-06-30 0001521036 lnth:RadiopharmTheranosticsLimitedMember 2025-01-31 0001521036 us-gaap:TreasuryStockCommonMember 2025-09-30 0001521036 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001521036 lnth:PerspectiveTherapeuticsIncMember 2024-06-14 2024-06-14 0001521036 us-gaap:BuildingMember 2024-12-31 0001521036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001521036 srt:MinimumMember us-gaap:DevelopedTechnologyRightsMember 2025-09-30 0001521036 lnth:LicenseandRoyaltyRevenuesMember 2025-01-01 2025-09-30 0001521036 lnth:EvergreenTheragnosticsMember 2025-01-01 2025-09-30 0001521036 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0001521036 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember 2022-12-31 0001521036 srt:MinimumMember us-gaap:TrademarksMember 2024-12-31 0001521036 lnth:DefinityMember 2025-07-01 2025-09-30 0001521036 us-gaap:LandMember 2025-09-30 0001521036 us-gaap:FairValueInputsLevel3Member lnth:EBITDADiscountRateMember srt:MinimumMember lnth:AssumedContingentConsiderationPiramalSPAMember lnth:ValuationTechniqueScenarioAnalysisMember 2025-09-30 0001521036 lnth:CurrentlyMarketedProductMember 2025-09-30 0001521036 lnth:A2625ConvertibleSeniorNotesDue2027Member us-gaap:ConvertibleDebtMember 2024-07-01 2024-09-30 0001521036 lnth:EvergreenTheragnosticsMember 2025-07-01 2025-09-30 0001521036 lnth:AdditionalRemainingPaymentsMember lnth:EvergreenTheragnosticsMember 2025-04-01 0001521036 lnth:ProgenicsMember 2025-01-01 2025-09-30 0001521036 2024-12-31 0001521036 lnth:CurrentlyMarketedProductMember srt:MaximumMember 2024-12-31 0001521036 us-gaap:BaseRateMember us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember srt:MaximumMember 2022-12-01 2022-12-31 0001521036 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001521036 us-gaap:FairValueInputsLevel1Member 2024-12-31 0001521036 us-gaap:FairValueInputsLevel2Member 2024-12-31 0001521036 lnth:SPECTBusinessMember 2025-01-01 2025-09-30 0001521036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001521036 lnth:LifeMolecularImagingIncMember 2025-01-01 2025-09-30 0001521036 us-gaap:TrademarksMember 2025-09-30 0001521036 us-gaap:FairValueInputsLevel3Member lnth:SalesMilestoneMember lnth:MeasurementInputRevenueDiscountRateMember lnth:ValuationTechniqueScenarioAnalysisMember srt:MaximumMember 2025-09-30 0001521036 2025-04-01 2025-06-30 0001521036 lnth:RadiopharmTheranosticsLimitedLicensedAssetsMember 2024-01-01 2024-12-31 0001521036 lnth:OtherPrecisionDiagnosticsMember 2024-01-01 2024-09-30 0001521036 lnth:EvergreenTheragnosticsMember 2025-04-01 2025-04-01 0001521036 2024-09-30 0001521036 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001521036 us-gaap:FairValueInputsLevel2Member 2025-09-30 0001521036 lnth:LifeMolecularImagingLtdMember 2025-01-01 2025-09-30 0001521036 lnth:PerspectiveTherapeuticsIncMember 2024-06-15 0001521036 lnth:TwoThousandTwentyFiveSharePurchaseProgramMember 2025-01-01 2025-09-30 0001521036 us-gaap:ProductMember 2025-07-01 2025-09-30 0001521036 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2025-09-30 0001521036 lnth:ReportableSegmentMember 2025-01-01 2025-09-30 0001521036 us-gaap:CommonStockMember 2024-06-30 0001521036 us-gaap:RetainedEarningsMember 2025-06-30 0001521036 us-gaap:TreasuryStockCommonMember 2023-12-31 0001521036 us-gaap:FairValueInputsLevel3Member us-gaap:ValuationTechniqueDiscountedCashFlowMember srt:MinimumMember lnth:DevelopmentAndCommercializationMilestonesMember us-gaap:MeasurementInputDiscountRateMember 2025-09-30 0001521036 lnth:TechneLiteMember 2025-01-01 2025-09-30 0001521036 lnth:PYLARIFYMember 2024-01-01 2024-09-30 0001521036 us-gaap:FairValueInputsLevel3Member lnth:EBITDADiscountRateMember lnth:AssumedContingentConsiderationPiramalSPAMember lnth:ValuationTechniqueScenarioAnalysisMember srt:MaximumMember 2025-09-30 0001521036 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001521036 lnth:CurrentlyMarketedProductMember srt:MaximumMember 2025-09-30 0001521036 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001521036 lnth:AdditionalMilestonePaymentsMember lnth:EvergreenTheragnosticsMember 2025-04-01 0001521036 2025-09-30 0001521036 us-gaap:TreasuryStockCommonMember 2025-07-01 2025-09-30 0001521036 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2025-09-30 0001521036 us-gaap:FairValueInputsLevel1Member 2025-09-30 0001521036 lnth:A2625ConvertibleSeniorNotesDue2027Member us-gaap:ConvertibleDebtMember 2022-12-05 2022-12-05 0001521036 us-gaap:TreasuryStockCommonMember 2025-04-01 2025-06-30 0001521036 us-gaap:FairValueInputsLevel3Member lnth:SalesMilestoneMember lnth:ValuationTechniqueScenarioAnalysisMember lnth:MeasurementInputRevenueVolatilityMember srt:MaximumMember 2025-09-30 0001521036 lnth:TotalPrecisionDiagnosticsMember 2024-07-01 2024-09-30 0001521036 us-gaap:RestrictedStockMember 2025-01-01 2025-09-30 0001521036 2024-07-01 2024-09-30 0001521036 lnth:MeilleurTechnologiesIncMember 2024-06-01 2024-06-30 0001521036 lnth:TechneLiteMember 2025-07-01 2025-09-30 0001521036 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2024-12-31 0001521036 2025-07-01 2025-09-30 0001521036 us-gaap:MoneyMarketFundsMember 2025-09-30 0001521036 us-gaap:MeasurementInputDiscountRateMember lnth:EvergreenTheragnosticsMember 2025-04-01 0001521036 us-gaap:ResearchAndDevelopmentExpenseMember 2025-01-01 2025-09-30 0001521036 lnth:PYLARIFYMember 2025-01-01 2025-09-30 0001521036 lnth:RadiopharmaceuticalOncologyMember 2024-01-01 2024-09-30 0001521036 lnth:A2625ConvertibleSeniorNotesDue2027Member us-gaap:ConvertibleDebtMember srt:MaximumMember 2025-09-30 0001521036 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2025-09-30 0001521036 lnth:PYLARIFYMember 2024-07-01 2024-09-30 0001521036 lnth:A2022FacilityCovenantsMember lnth:Scenario1Member 2025-01-01 2025-09-30 0001521036 us-gaap:RetainedEarningsMember 2024-12-31 0001521036 lnth:TotalPrecisionDiagnosticsMember 2025-01-01 2025-09-30 0001521036 lnth:AstraZenecaMember 2025-05-01 2025-05-31 0001521036 us-gaap:RetainedEarningsMember 2023-12-31 0001521036 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2025-09-30 0001521036 lnth:A2625ConvertibleSeniorNotesDue2027Member us-gaap:ConvertibleDebtMember 2025-01-01 2025-09-30 0001521036 lnth:PerspectiveTherapeuticsIncMember 2025-07-01 2025-09-30 0001521036 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001521036 us-gaap:FairValueInputsLevel3Member lnth:AssumedContingentConsiderationPiramalSPAMember us-gaap:MeasurementInputEbitdaMultipleMember lnth:ValuationTechniqueScenarioAnalysisMember 2025-09-30 0001521036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001521036 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember us-gaap:SecuredOvernightFinancingRateSofrMember srt:MaximumMember 2022-12-01 2022-12-31 0001521036 us-gaap:FairValueInputsLevel3Member lnth:SalesMilestoneMember srt:WeightedAverageMember lnth:MeasurementInputRevenueDiscountRateMember lnth:ValuationTechniqueScenarioAnalysisMember 2025-09-30 0001521036 us-gaap:TreasuryStockCommonMember 2025-03-31 0001521036 lnth:DefinityMember 2024-01-01 2024-09-30 0001521036 us-gaap:FairValueInputsLevel3Member us-gaap:ValuationTechniqueDiscountedCashFlowMember srt:WeightedAverageMember lnth:DevelopmentAndCommercializationMilestonesMember lnth:MeasurementInputProbabilityOfPaymentMember 2025-09-30 0001521036 us-gaap:RetainedEarningsMember 2025-03-31 0001521036 2025-01-01 2025-03-31 0001521036 us-gaap:FairValueInputsLevel3Member lnth:AssumedContingentConsiderationPiramalSPAMember 2025-09-30 0001521036 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001521036 lnth:A2625ConvertibleSeniorNotesDue2027Member us-gaap:ConvertibleDebtMember 2025-09-30 0001521036 lnth:A2625ConvertibleSeniorNotesDue2027Member us-gaap:ConvertibleDebtMember 2025-07-01 2025-09-30 0001521036 lnth:RadiopharmTheranosticsLimitedMember 2025-07-01 2025-09-30 0001521036 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001521036 us-gaap:FairValueInputsLevel3Member us-gaap:ValuationTechniqueDiscountedCashFlowMember lnth:MeasurementInputProbabilityOfPaymentMember lnth:DevelopmentAndCommercializationMilestonesMember srt:MinimumMember 2025-09-30 0001521036 lnth:StrategicPartnershipsAndOtherMember 2024-07-01 2024-09-30 0001521036 lnth:LifeMolecularImagingLtdMember 2025-07-01 2025-09-30 0001521036 us-gaap:LicensingAgreementsMember 2024-12-31 0001521036 us-gaap:RestrictedStockMember 2024-07-01 2024-09-30 0001521036 us-gaap:CommonStockMember 2025-09-30 0001521036 lnth:RadiopharmaceuticalOncologyMember 2024-07-01 2024-09-30 0001521036 lnth:LicenseandRoyaltyRevenuesMember 2025-07-01 2025-09-30 0001521036 us-gaap:GeneralAndAdministrativeExpenseMember 2025-01-01 2025-09-30 0001521036 lnth:CurrentlyMarketedProductMember srt:MinimumMember 2024-12-31 0001521036 lnth:DefinityMember 2024-07-01 2024-09-30 0001521036 lnth:RM2SublicenseAgreementMember lnth:RegulatoryMilestonesMember 2024-06-27 2024-06-27 0001521036 2024-04-01 2024-06-30 0001521036 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001521036 lnth:LifeMolecularImagingLtdMember 2025-01-01 2025-09-30 0001521036 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001521036 lnth:OtherPrecisionDiagnosticsMember 2025-01-01 2025-09-30 0001521036 lnth:RadiopharmTheranosticsLimitedMember 2025-01-01 2025-09-30 0001521036 2025-06-30 0001521036 lnth:ProgenicsMember lnth:NetSalesTargetsForAzedraMember 2025-09-30 0001521036 lnth:StrategicPartnershipsAndOtherMember 2025-01-01 2025-09-30 0001521036 lnth:MeilleurTechnologiesIncMember 2024-06-18 2024-06-18 0001521036 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001521036 lnth:TwoThousandTwentyFiveSharePurchaseProgramMember 2025-07-01 2025-09-30 0001521036 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001521036 lnth:A2625ConvertibleSeniorNotesDue2027Member us-gaap:ConvertibleDebtMember 2022-12-08 0001521036 lnth:RadiopharmTheranosticsLimitedMember 2024-07-01 2024-09-30 0001521036 lnth:ReportableSegmentMember 2024-07-01 2024-09-30 0001521036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001521036 lnth:A2022FacilityCovenantsMember 2025-09-30 0001521036 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001521036 lnth:A1095CommercializationMember lnth:ProgenicsMember 2025-09-30 0001521036 2024-03-31 0001521036 lnth:PerspectiveTherapeuticsIncMember 2025-01-01 2025-09-30 0001521036 us-gaap:BuildingMember 2025-09-30 0001521036 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001521036 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-12-31 0001521036 lnth:ReportableSegmentMember 2024-01-01 2024-09-30 0001521036 lnth:ProgenicsMember 2025-09-30 0001521036 lnth:TotalPrecisionDiagnosticsMember 2024-01-01 2024-09-30 0001521036 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember 2022-12-01 2022-12-31 0001521036 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0001521036 us-gaap:GeneralAndAdministrativeExpenseMember 2025-07-01 2025-09-30 0001521036 lnth:TwoThousandTwentyFourSharePurchaseProgramMember 2025-01-01 2025-09-30 0001521036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-07-01 2025-09-30 0001521036 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2025-09-30 0001521036 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001521036 lnth:RadiopharmTheranosticsLimitedMember srt:MaximumMember 2025-01-01 2025-09-30 0001521036 lnth:PerspectiveTherapeuticsIncMember 2024-01-01 2024-03-31 0001521036 us-gaap:CostOfSalesMember 2024-07-01 2024-09-30 0001521036 us-gaap:RetainedEarningsMember 2024-03-31 0001521036 lnth:LifeMolecularImagingLtdMember 2025-07-21 2025-07-21 0001521036 us-gaap:CustomerRelationshipsMember 2024-12-31 0001521036 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember 2024-12-31 0001521036 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember srt:MaximumMember lnth:NetLeverageRatioMember 2022-12-01 2022-12-31 0001521036 lnth:LifeMolecularImagingRM2TechnologyMember 2024-01-01 2024-09-30 0001521036 us-gaap:InProcessResearchAndDevelopmentMember lnth:LifeMolecularImagingLtdMember us-gaap:MeasurementInputDiscountRateMember 2025-07-21 0001521036 us-gaap:DevelopedTechnologyRightsMember srt:MaximumMember 2024-12-31 0001521036 lnth:OtherRadiopharmaceuticalOncologyMember 2025-01-01 2025-09-30 0001521036 us-gaap:EmployeeStockOptionMember 2025-07-01 2025-09-30 0001521036 lnth:EvergreenTheragnosticsMember 2024-01-01 2024-09-30 0001521036 us-gaap:CommonStockMember 2025-03-31 0001521036 us-gaap:CustomerRelationshipsMember 2025-09-30 0001521036 us-gaap:ProductMember 2025-01-01 2025-09-30 0001521036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001521036 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001521036 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001521036 lnth:RadiopharmaceuticalOncologyMember 2025-01-01 2025-09-30 0001521036 lnth:PerspectiveCommonStockMember 2024-03-06 0001521036 lnth:MachineryEquipmentAndFixturesMember lnth:SPECTBusinessMember 2025-09-30 0001521036 us-gaap:ConstructionInProgressMember lnth:SPECTBusinessMember 2025-09-30 0001521036 us-gaap:CommonStockMember 2023-12-31 0001521036 2023-12-31 0001521036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001521036 srt:MaximumMember us-gaap:LicensingAgreementsMember 2024-12-31 0001521036 us-gaap:TrademarksMember 2024-12-31 0001521036 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001521036 lnth:AgreementWithPerspectiveTherapeuticsIncMember 2024-01-01 2024-09-30 0001521036 lnth:TwoThousandTwentyFourSharePurchaseProgramMember 2024-11-30 0001521036 lnth:TotalPrecisionDiagnosticsMember 2025-07-01 2025-09-30 0001521036 lnth:NeuraceqMember 2024-01-01 2024-09-30 0001521036 us-gaap:DevelopedTechnologyRightsMember 2025-09-30 0001521036 lnth:RadiopharmTheranosticsLimitedLicensedAssetsMember 2024-06-15 2024-06-15 0001521036 us-gaap:FairValueInputsLevel3Member 2024-12-31 0001521036 us-gaap:FairValueInputsLevel3Member 2025-09-30 0001521036 us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-09-30 0001521036 2024-10-31 0001521036 us-gaap:CommonStockMember 2024-09-30 0001521036 us-gaap:FairValueInputsLevel3Member lnth:SalesMilestoneMember srt:WeightedAverageMember lnth:ValuationTechniqueScenarioAnalysisMember lnth:MeasurementInputRevenueVolatilityMember 2025-09-30 0001521036 lnth:A2625ConvertibleSeniorNotesDue2027Member us-gaap:ConvertibleDebtMember 2022-12-08 2022-12-08 0001521036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0001521036 lnth:A2625ConvertibleSeniorNotesDue2027Member us-gaap:ConvertibleDebtMember 2024-12-31 0001521036 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001521036 srt:MaximumMember us-gaap:LicensingAgreementsMember 2025-09-30 0001521036 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-09-30 0001521036 lnth:StrategicPartnershipsAndOtherMember 2025-07-01 2025-09-30 0001521036 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember srt:MaximumMember 2022-12-31 0001521036 lnth:LifeMolecularImagingRM2TechnologyMember 2025-01-01 2025-03-31 0001521036 us-gaap:RetainedEarningsMember 2024-09-30 0001521036 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001521036 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001521036 us-gaap:TreasuryStockCommonMember 2025-06-30 0001521036 lnth:RadiopharmTheranosticsLimitedMember 2025-09-30 0001521036 lnth:LicenseandRoyaltyRevenuesMember 2024-07-01 2024-09-30 0001521036 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001521036 lnth:TwoThousandTwentyFiveSharePurchaseProgramMember 2025-09-30 0001521036 2024-10-01 2024-10-31 0001521036 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0001521036 lnth:AgreementWithPerspectiveTherapeuticsIncMember 2024-01-08 0001521036 lnth:LifeMolecularImagingRM2TechnologyMember 2024-07-02 2024-07-02 0001521036 lnth:EvergreenTheragnosticsMember 2025-04-01 0001521036 lnth:LicenseAndRoyaltyRevenuesSalesBasedMilestonePaymentMember 2025-07-01 2025-09-30 0001521036 us-gaap:RetainedEarningsMember 2024-06-30 0001521036 lnth:RadiopharmTheranosticsLimitedMember 2024-12-31 0001521036 us-gaap:ResearchAndDevelopmentExpenseMember 2025-07-01 2025-09-30 0001521036 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember srt:MinimumMember lnth:NetLeverageRatioMember 2022-12-01 2022-12-31 0001521036 us-gaap:FairValueInputsLevel3Member lnth:EBITDADiscountRateMember srt:WeightedAverageMember lnth:AssumedContingentConsiderationPiramalSPAMember lnth:ValuationTechniqueScenarioAnalysisMember 2025-09-30 0001521036 lnth:PerspectiveTherapeuticsIncMember us-gaap:LicensingAgreementsMember 2024-01-08 2024-01-08 0001521036 us-gaap:CostOfSalesMember 2025-01-01 2025-09-30 0001521036 us-gaap:ProductMember 2024-01-01 2024-09-30 0001521036 us-gaap:CommonStockMember 2024-03-31 0001521036 us-gaap:ProductMember 2024-07-01 2024-09-30 0001521036 lnth:MeilleurTechnologiesIncMember 2024-08-01 2024-08-31 0001521036 lnth:RadiopharmTheranosticsLimitedLicensedAssetsMember lnth:SalesMilestonesMember 2024-06-15 2024-06-15 0001521036 srt:MinimumMember us-gaap:DevelopedTechnologyRightsMember 2024-12-31 0001521036 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001521036 lnth:AgreementWithPerspectiveTherapeuticsIncMember 2024-01-08 2024-01-08 0001521036 lnth:EvergreenTheragnosticsMember 2025-01-01 2025-09-30 0001521036 lnth:NeuraceqMember 2024-07-01 2024-09-30 0001521036 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2024-12-31 0001521036 lnth:StrategicPartnershipsAndOtherMember 2024-01-01 2024-09-30 0001521036 lnth:LifeMolecularImagingRM2TechnologyMember 2024-07-03 2024-07-03 0001521036 lnth:TechneLiteMember 2024-01-01 2024-09-30 0001521036 us-gaap:CommonStockMember 2025-06-30 0001521036 lnth:MeilleurTechnologiesIncMember lnth:ResearchRevenueMilestonesMember 2024-06-18 2024-06-18 0001521036 us-gaap:MoneyMarketFundsMember 2024-12-31 0001521036 us-gaap:RestrictedStockMember 2025-07-01 2025-09-30 0001521036 us-gaap:RetainedEarningsMember 2025-09-30 0001521036 lnth:TechneLiteMember 2024-07-01 2024-09-30 0001521036 us-gaap:LandMember lnth:SPECTBusinessMember 2025-09-30 0001521036 us-gaap:BuildingMember lnth:SPECTBusinessMember 2025-09-30 0001521036 us-gaap:DevelopedTechnologyRightsMember 2024-12-31 0001521036 lnth:PerspectiveTherapeuticsIncMember 2025-09-30 0001521036 2025-03-31 0001521036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001521036 lnth:LicenseandRoyaltyRevenuesMember 2024-01-01 2024-09-30 0001521036 us-gaap:ValuationTechniqueDiscountedCashFlowMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember lnth:DevelopmentAndCommercializationMilestonesMember srt:MaximumMember 2025-09-30 0001521036 lnth:LifeMolecularImagingRM2TechnologyMember lnth:SalesMilestonesMember 2024-07-03 2024-07-03 0001521036 lnth:LifeMolecularImagingLtdMember lnth:CurrentlyMarketedProductMember us-gaap:MeasurementInputDiscountRateMember 2025-07-21 0001521036 us-gaap:SellingAndMarketingExpenseMember 2024-07-01 2024-09-30 0001521036 us-gaap:TreasuryStockCommonMember 2024-12-31 0001521036 us-gaap:ConstructionInProgressMember 2025-09-30 0001521036 lnth:RadiopharmaceuticalOncologyMember 2025-07-01 2025-09-30 0001521036 us-gaap:CostOfSalesMember 2025-07-01 2025-09-30 0001521036 us-gaap:SellingAndMarketingExpenseMember 2025-07-01 2025-09-30 0001521036 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-01 2024-09-30 0001521036 us-gaap:DevelopedTechnologyRightsMember srt:MaximumMember 2025-09-30 0001521036 us-gaap:InProcessResearchAndDevelopmentMember 2025-09-30 0001521036 lnth:OtherPrecisionDiagnosticsMember 2024-07-01 2024-09-30 0001521036 srt:MinimumMember us-gaap:LicensingAgreementsMember 2025-09-30 0001521036 us-gaap:ConvertibleDebtMember 2022-12-08 2022-12-08 iso4217:EUR lnth:LicensedAsset xbrli:pure lnth:ProductCategory lnth:Segment xbrli:shares lnth:FinancialCovenant iso4217:USD xbrli:shares iso4217:USD lnth:Days

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☑ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2025

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission File Number 001-36569

LANTHEUS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)

Delaware | 35-2318913
(State or other jurisdiction of incorporation or organization) | (IRS Employer Identification No.)
201 Burlington Road, South Building | 01730
Bedford, MA |
(Address of principal executive offices) | (Zip Code)

(978) | 671-8001
(Registrant’s telephone number, including area code)
Not Applicable
(Former name, former address and former fiscal year, if changed since last report

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common stock, par value $0.01 per share | LNTH | The Nasdaq Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer |  | ☑ |  | Accelerated filer |  | ☐
Non-accelerated filer |  | ☐ |  | Smaller reporting company |  | ☐
|  |  |  | Emerging Growth Company |  | ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Act) Yes ☐ No ☑

The registrant had 66,311,779 shares of common stock, $0.01 par value, outstanding as of November 3, 2025.

Table of Contents

LANTHEUS HOLDINGS, INC.

| Page
PART I. FINANCIAL INFORMATION | 1
Item 1. Financial Statements | 1
Condensed Consolidated Balance Sheets | 1
Condensed Consolidated Statements of Operations | 2
Condensed Consolidated Statements of Comprehensive Income | 3
Condensed Consolidated Statements of Changes in Stockholders’ Equity | 4
Condensed Consolidated Statements of Cash Flows | 6
Notes to Condensed Consolidated Financial Statements | 8
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations | 33
Item 3. Quantitative and Qualitative Disclosures About Market Risk | 49
Item 4. Controls and Procedures | 49
PART II. OTHER INFORMATION | 50
Item 1. Legal Proceedings | 50
Item 1A. Risk Factors | 50
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds | 60
Item 3. Defaults Upon Senior Securities | 60
Item 4. Mine Safety Disclosures | 60
Item 5. Other Information | 60
Item 6. Exhibits | 61
SIGNATURES | 62

Table of Contents

PART I. FIN ANCIAL INFORMATION

Ite m 1. Financial Statements

Lantheus Holdings, Inc.

Co ndensed Consolidated Balance Sheets

(Unaudited)

(in thousands, except par value)

|  | September 30, |  |  | December 31, |
|  | 2025 |  |  | 2024 |
Assets |  |  |  |  |  |
Current assets: |  |  |  |  |  |
Cash and cash equivalents |  | $ | 382,006 |  |  | $ | 912,814 |
Accounts receivable, net |  |  | 351,376 |  |  |  | 321,258 |
Inventory, net |  |  | 62,040 |  |  |  | 68,025 |
Income tax receivable |  |  | 31,877 |  |  |  | 8,177 |
Other current assets |  |  | 21,169 |  |  |  | 16,359 |
Assets held for sale |  |  | 76,623 |  |  |  | — |
Total current assets |  |  | 925,091 |  |  |  | 1,326,633 |
Investment in equity securities |  |  | 46,474 |  |  |  | 39,489 |
Property, plant and equipment, net |  |  | 164,072 |  |  |  | 176,798 |
Intangibles, net |  |  | 739,264 |  |  |  | 161,761 |
Goodwill |  |  | 240,328 |  |  |  | 61,189 |
Deferred tax assets, net |  |  | 107,450 |  |  |  | 170,233 |
Other long-term assets |  |  | 53,721 |  |  |  | 44,237 |
Total assets |  | $ | 2,276,400 |  |  | $ | 1,980,340 |
Liabilities and Stockholders’ Equity |  |  |  |  |  |
Current liabilities: |  |  |  |  |  |
Current portion of long-term debt and other borrowings |  | $ | 871 |  |  | $ | 974 |
Accounts payable |  |  | 66,296 |  |  |  | 34,560 |
Accrued expenses and other liabilities |  |  | 251,105 |  |  |  | 204,992 |
Liabilities held for sale |  |  | 28,566 |  |  |  | — |
Total current liabilities |  |  | 346,838 |  |  |  | 240,526 |
Asset retirement obligations |  |  | 137 |  |  |  | 23,344 |
Long-term debt and other borrowings, net of current portion |  |  | 567,937 |  |  |  | 565,279 |
Long-term deferred tax liabilities |  |  | 55,078 |  |  |  | — |
Long-term contingent consideration liabilities |  |  | 71,024 |  |  |  | — |
Other long-term liabilities |  |  | 116,180 |  |  |  | 63,180 |
Total liabilities |  |  | 1,157,194 |  |  |  | 892,329 |
Commitments and contingencies (Note 16) |  |  |  |  |  |
Stockholders' equity: |  |  |  |  |  |
Preferred stock ($0.01 par value, 25,000 shares authorized; no shares issued and outstanding) |  |  | — |  |  |  | — |
Common stock ($0.01 par value; 250,000 shares authorized; 71,770 shares and 70,905 shares issued and outstanding at September 30, 2025, and December 31, 2024, respectively) |  |  | 718 |  |  |  | 709 |
Additional paid-in capital |  |  | 871,193 |  |  |  | 817,972 |
Treasury stock at cost; 5,471 shares and 2,455 shares at September 30, 2025 and December 31, 2024, respectively |  |  | (376,456 | ) |  |  | (175,000 | )
Retained earnings |  |  | 625,416 |  |  |  | 445,945 |
Accumulated other comprehensive loss |  |  | (1,665 | ) |  |  | (1,615 | )
Total stockholders’ equity |  |  | 1,119,206 |  |  |  | 1,088,011 |
Total liabilities and stockholders’ equity |  | $ | 2,276,400 |  |  | $ | 1,980,340 |

The accompanying notes are an integral part of these condensed consolidated financial statements.

1

Table of Contents

Lantheus Holdings, Inc.

Condens ed Consolidated Statements of Operations

(Unaudited)

(in thousands, except per share data)

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Revenues |  | $ | 384,014 |  |  | $ | 378,734 |  |  | $ | 1,134,823 |  |  | $ | 1,142,800 |
Cost of goods sold |  |  | 161,648 |  |  |  | 136,608 |  |  |  | 433,746 |  |  |  | 403,054 |
Gross profit |  |  | 222,366 |  |  |  | 242,126 |  |  |  | 701,077 |  |  |  | 739,746 |
Operating expenses |  |  |  |  |  |  |  |  |  |  |  |
Sales and marketing |  |  | 48,828 |  |  |  | 43,719 |  |  |  | 132,372 |  |  |  | 134,300 |
General and administrative |  |  | 81,898 |  |  |  | 40,516 |  |  |  | 205,229 |  |  |  | 135,820 |
Research and development |  |  | 48,025 |  |  |  | 24,148 |  |  |  | 129,828 |  |  |  | 132,773 |
Total operating expenses |  |  | 178,751 |  |  |  | 108,383 |  |  |  | 467,429 |  |  |  | 402,893 |
Gain on sale of assets |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 6,254 |
Operating income |  |  | 43,615 |  |  |  | 133,743 |  |  |  | 233,648 |  |  |  | 343,107 |
Interest expense |  |  | 4,950 |  |  |  | 4,903 |  |  |  | 14,671 |  |  |  | 14,624 |
Investment in equity securities - unrealized gain |  |  | (1,160 | ) |  |  | (37,325 | ) |  |  | (871 | ) |  |  | (75,492 | )
Other income |  |  | (2,556 | ) |  |  | (9,953 | ) |  |  | (23,579 | ) |  |  | (27,785 | )
Income before income taxes |  |  | 42,381 |  |  |  | 176,118 |  |  |  | 243,427 |  |  |  | 431,760 |
Income tax expense |  |  | 14,610 |  |  |  | 45,025 |  |  |  | 63,956 |  |  |  | 107,528 |
Net income |  | $ | 27,771 |  |  | $ | 131,093 |  |  | $ | 179,471 |  |  | $ | 324,232 |
Net income per common share: |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 0.41 |  |  | $ | 1.89 |  |  | $ | 2.63 |  |  | $ | 4.69 |
Diluted |  | $ | 0.41 |  |  | $ | 1.79 |  |  | $ | 2.60 |  |  | $ | 4.55 |
Weighted average common shares outstanding: |  |  |  |  |  |  |  |  |  |  |  |
Basic |  |  | 67,230 |  |  |  | 69,464 |  |  |  | 68,132 |  |  |  | 69,193 |
Diluted |  |  | 67,663 |  |  |  | 73,065 |  |  |  | 69,038 |  |  |  | 71,331 |

The accompanying notes are an integral part of these condensed consolidated financial statements.

2

Table of Contents

Lantheus Holdings, Inc.

Condense d Consolidated Statements of Comprehensive Income

(Unaudited)

(in thousands)

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Net income |  | $ | 27,771 |  |  | $ | 131,093 |  |  | $ | 179,471 |  |  | $ | 324,232 |
Other comprehensive income (loss): |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency translation |  |  | (183 | ) |  |  | 44 |  |  |  | (50 | ) |  |  | (129 | )
Comprehensive income |  | $ | 27,588 |  |  | $ | 131,137 |  |  | $ | 179,421 |  |  | $ | 324,103 |

The accompanying notes are an integral part of these condensed consolidated financial statements.

3

Table of Contents

Lantheus Holdings, Inc.

Condensed C onsolidated Statements of Changes in Stockholders’ Equity

(Unaudited)

(in thousands)

|  | Nine Months Ended September 30, 2025 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Accumulated |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  | Additional |  |  |  |  |  | Other |  |  | Total |
|  | Common Stock |  |  | Treasury Stock |  |  | Paid-In |  |  | Retained |  |  | Comprehensive |  |  | Stockholders' |
|  | Shares |  |  | Amount |  |  | Shares |  |  | Amount |  |  | Capital |  |  | Earnings |  |  | Income (Loss) |  |  | Equity |
Balance at January 1, 2025 |  |  | 70,905 |  |  | $ | 709 |  |  |  | 2,455 |  |  | $ | (175,000 | ) |  | $ | 817,972 |  |  | $ | 445,945 |  |  | $ | (1,615 | ) |  | $ | 1,088,011 |
Net income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 72,945 |  |  |  | — |  |  |  | 72,945 |
Other comprehensive loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (143 | ) |  |  | (143 | )
Stock option exercises and employee stock plan purchases |  |  | 107 |  |  |  | 1 |  |  |  | — |  |  |  | — |  |  |  | 5,868 |  |  |  | — |  |  |  | — |  |  |  | 5,869 |
Vesting of restricted stock units |  |  | 845 |  |  |  | 8 |  |  |  | — |  |  |  | — |  |  |  | (8 | ) |  |  | — |  |  |  | — |  |  |  | — |
Shares withheld to cover taxes |  |  | (250 | ) |  |  | (2 | ) |  |  | — |  |  |  | — |  |  |  | (23,684 | ) |  |  | — |  |  |  | — |  |  |  | (23,686 | )
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 21,198 |  |  |  | — |  |  |  | — |  |  |  | 21,198 |
Balance at March 31, 2025 |  |  | 71,607 |  |  | $ | 716 |  |  |  | 2,455 |  |  | $ | (175,000 | ) |  | $ | 821,346 |  |  | $ | 518,890 |  |  | $ | (1,758 | ) |  | $ | 1,164,194 |
Net income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 78,755 |  |  |  | — |  |  |  | 78,755 |
Other comprehensive income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 276 |  |  |  | 276 |
Stock option exercises and employee stock plan purchases |  |  | 56 |  |  |  | 1 |  |  |  | — |  |  |  | — |  |  |  | 2,444 |  |  |  | — |  |  |  | — |  |  |  | 2,445 |
Vesting of restricted stock units |  |  | 48 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Shares withheld to cover taxes |  |  | (9 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (963 | ) |  |  | — |  |  |  | — |  |  |  | (963 | )
Repurchase of common stock, including excise tax |  |  | — |  |  |  | — |  |  |  | 1,260 |  |  |  | (100,000 | ) |  |  | (245 | ) |  |  | — |  |  |  | — |  |  |  | (100,245 | )
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 22,321 |  |  |  | — |  |  |  | — |  |  |  | 22,321 |
Balance at June 30, 2025 |  |  | 71,702 |  |  | $ | 717 |  |  |  | 3,715 |  |  | $ | (275,000 | ) |  | $ | 844,903 |  |  | $ | 597,645 |  |  | $ | (1,482 | ) |  | $ | 1,166,783 |
Net income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 27,771 |  |  |  | — |  |  |  | 27,771 |
Other comprehensive loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (183 | ) |  |  | (183 | )
Stock option exercises and employee stock plan purchases |  |  | 41 |  |  |  | 1 |  |  |  | — |  |  |  | — |  |  |  | 1,884 |  |  |  | — |  |  |  | — |  |  |  | 1,885 |
Vesting of restricted stock units |  |  | 40 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Shares withheld to cover taxes |  |  | (13 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (591 | ) |  |  | — |  |  |  | — |  |  |  | (591 | )
Repurchase of common stock, including excise tax |  |  | — |  |  |  | — |  |  |  | 1,756 |  |  |  | (101,456 | ) |  |  | 496 |  |  |  | — |  |  |  | — |  |  |  | (100,960 | )
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 24,501 |  |  |  | — |  |  |  | — |  |  |  | 24,501 |
Balance at September 30, 2025 |  |  | 71,770 |  |  | $ | 718 |  |  |  | 5,471 |  |  | $ | (376,456 | ) |  | $ | 871,193 |  |  | $ | 625,416 |  |  | $ | (1,665 | ) |  | $ | 1,119,206 |

4

Table of Contents

|  | Nine Months Ended September 30, 2024 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Accumulated |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  | Additional |  |  |  |  |  | Other |  |  | Total |
|  | Common Stock |  |  | Treasury Stock |  |  | Paid-In |  |  | Retained |  |  | Comprehensive |  |  | Stockholders' |
|  | Shares |  |  | Amount |  |  | Shares |  |  | Amount |  |  | Capital |  |  | Earnings |  |  | Income (Loss) |  |  | Equity |
Balance at January 1, 2024 |  |  | 69,863 |  |  | $ | 699 |  |  |  | 1,339 |  |  | $ | (75,000 | ) |  | $ | 757,727 |  |  | $ | 133,503 |  |  | $ | (1,037 | ) |  | $ | 815,892 |
Net income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 131,066 |  |  |  | — |  |  |  | 131,066 |
Other comprehensive loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (141 | ) |  |  | (141 | )
Stock option exercises and employee stock plan purchases |  |  | 86 |  |  |  | 1 |  |  |  | — |  |  |  | — |  |  |  | 2,756 |  |  |  | — |  |  |  | — |  |  |  | 2,757 |
Vesting of restricted stock units |  |  | 988 |  |  |  | 9 |  |  |  | — |  |  |  | — |  |  |  | (9 | ) |  |  | — |  |  |  | — |  |  |  | — |
Shares withheld to cover taxes |  |  | (302 | ) |  |  | (3 | ) |  |  | — |  |  |  | — |  |  |  | (19,415 | ) |  |  | — |  |  |  | — |  |  |  | (19,418 | )
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 15,384 |  |  |  | — |  |  |  | — |  |  |  | 15,384 |
Balance at March 31, 2024 |  |  | 70,635 |  |  | $ | 706 |  |  |  | 1,339 |  |  | $ | (75,000 | ) |  | $ | 756,443 |  |  | $ | 264,569 |  |  | $ | (1,178 | ) |  | $ | 945,540 |
Net income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 62,073 |  |  |  | — |  |  |  | 62,073 |
Other comprehensive loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (32 | ) |  |  | (32 | )
Stock option exercises and employee stock plan purchases |  |  | 68 |  |  |  | 1 |  |  |  | — |  |  |  | — |  |  |  | 1,548 |  |  |  | — |  |  |  | — |  |  |  | 1,549 |
Vesting of restricted stock units |  |  | 58 |  |  |  | 1 |  |  |  | — |  |  |  | — |  |  |  | (1 | ) |  |  | — |  |  |  | — |  |  |  | — |
Shares withheld to cover taxes |  |  | (11 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (924 | ) |  |  | — |  |  |  | — |  |  |  | (924 | )
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 18,479 |  |  |  | — |  |  |  | — |  |  |  | 18,479 |
Balance at June 30, 2024 |  |  | 70,750 |  |  | $ | 708 |  |  |  | 1,339 |  |  | $ | (75,000 | ) |  | $ | 775,545 |  |  | $ | 326,642 |  |  | $ | (1,210 | ) |  | $ | 1,026,685 |
Net income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 131,093 |  |  |  | — |  |  |  | 131,093 |
Other comprehensive income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 44 |  |  |  | 44 |
Stock option exercises and employee stock plan purchases |  |  | 76 |  |  |  | 1 |  |  |  | — |  |  |  | — |  |  |  | 2,831 |  |  |  | — |  |  |  | — |  |  |  | 2,832 |
Vesting of restricted stock units |  |  | 40 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Shares withheld to cover taxes |  |  | (12 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (1,312 | ) |  |  | — |  |  |  | — |  |  |  | (1,312 | )
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 20,366 |  |  |  | — |  |  |  | — |  |  |  | 20,366 |
Balance at September 30, 2024 |  |  | 70,854 |  |  | $ | 709 |  |  |  | 1,339 |  |  | $ | (75,000 | ) |  | $ | 797,430 |  |  | $ | 457,735 |  |  | $ | (1,166 | ) |  | $ | 1,179,708 |

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

Table of Contents

Lantheus Holdings, Inc.

Condens ed Consolidated Statements of Cash Flows

(Unaudited)

(in thousands)

|  | Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |
Cash flows from operating activities: |  |  |  |  |  |
Net income |  | $ | 179,471 |  |  | $ | 324,232 |
Adjustments to reconcile net income to net cash flows from operating activities: |  |  |  |  |  |
Depreciation, amortization and accretion |  |  | 47,265 |  |  |  | 47,339 |
Adjustment to the fair value of asset retirement obligation |  |  | (4,727 | ) |  |  | — |
Amortization of debt-related costs |  |  | 3,343 |  |  |  | 3,217 |
Change in fair value of contingent assets and liabilities |  |  | 982 |  |  |  | (1,405 | )
Inventory adjustments |  |  | 2,869 |  |  |  | 738 |
Stock-based compensation |  |  | 68,020 |  |  |  | 54,229 |
Gain on disposal of assets |  |  | — |  |  |  | (6,254 | )
Unrealized gain on investment in equity securities |  |  | (871 | ) |  |  | (75,492 | )
Charges incurred pursuant to acquired in-process research and development |  |  | 5,413 |  |  |  | 66,000 |
Deferred taxes |  |  | 23,379 |  |  |  | (4,402 | )
Long-term income tax payable and other long-term liabilities |  |  | (2,754 | ) |  |  | 2,619 |
Other |  |  | 5,522 |  |  |  | 7,172 |
Changes in operating assets and liabilities, excluding impact of acquisitions: |  |  |  |  |  |
Accounts receivable |  |  | (15,821 | ) |  |  | (44,887 | )
Inventory |  |  | (6,325 | ) |  |  | (7,101 | )
Other current and noncurrent assets |  |  | (6,344 | ) |  |  | 1,335 |
Accounts payable |  |  | 29,473 |  |  |  | 1,151 |
Accrued expenses and other current and noncurrent liabilities |  |  | (28,932 | ) |  |  | 18,529 |
Net cash provided by operating activities |  |  | 299,963 |  |  |  | 387,020 |
Cash flows from investing activities: |  |  |  |  |  |
Capital expenditures |  |  | (27,301 | ) |  |  | (35,256 | )
Acquisition of in-process research and development |  |  | (5,413 | ) |  |  | — |
Proceeds from sale of assets |  |  | — |  |  |  | 8,000 |
Acquisition of assets, net |  |  | — |  |  |  | (80,911 | )
Acquisition of Evergreen, net of cash acquired |  |  | (268,933 | ) |  |  | — |
Acquisition of Life Molecular, net of cash acquired |  |  | (309,011 | ) |  |  | — |
Purchases of investment in equity securities |  |  | (5,000 | ) |  |  | (83,246 | )
Acquisition of exclusive license option |  |  | — |  |  |  | (28,000 | )
Net cash used in investing activities |  |  | (615,658 | ) |  |  | (219,413 | )
Cash flows from financing activities: |  |  |  |  |  |
Payments of long-term debt and other borrowings |  |  | (757 | ) |  |  | (376 | )
Proceeds from stock option exercises |  |  | 6,473 |  |  |  | 3,772 |
Proceeds from employee stock purchase plan |  |  | 3,726 |  |  |  | 3,450 |
Payments for minimum statutory tax withholding related to net share settlement of equity awards |  |  | (25,240 | ) |  |  | (21,723 | )
Repurchase of common stock |  |  | (200,000 | ) |  |  | — |
Net cash used in financing activities |  |  | (215,798 | ) |  |  | (14,877 | )
Effect of exchange rate changes on cash, cash equivalents and restricted cash |  |  | 711 |  |  |  | 34 |
Net (decrease) increase in cash, cash equivalents and restricted cash |  |  | (530,782 | ) |  |  | 152,764 |
Cash, cash equivalents and restricted cash, beginning of period |  |  | 914,486 |  |  |  | 715,285 |
Cash, cash equivalents and restricted cash, end of period |  | $ | 383,704 |  |  | $ | 868,049 |

6

Table of Contents

Lantheus Holdings, Inc.

Condensed Consolidated Statements of Cash Flows (Continued)

(Unaudited)

(in thousands)

|  | Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |
Reconciliation to amounts within the condensed consolidated balance sheets |  |  |  |  |  |
Cash and cash equivalents |  | $ | 382,006 |  |  | $ | 866,386 |
Restricted cash included in other long-term assets |  |  | 1,698 |  |  |  | 1,663 |
Cash, cash equivalents and restricted cash at end of period |  | $ | 383,704 |  |  | $ | 868,049 |

|  | Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |
Schedule of non-cash investing and financing activities |  |  |  |  |  |
Additions of property, plant and equipment included in liabilities |  | $ | 5,317 |  |  | $ | 8,502 |
Contingent consideration liabilities related to acquisitions |  | $ | 96,842 |  |  | $ | — |
Lease liability settled through transfer of lease |  | $ | — |  |  | $ | 762 |
Modification of lease agreement |  | $ | 5,789 |  |  | $ | — |
Right-of-use asset obtained in exchange for finance lease obligation |  | $ | 150 |  |  | $ | 63 |
Excise tax payable on net common stock repurchases |  | $ | 1,205 |  |  | $ | — |

The accompanying notes are an integral part of these condensed consolidated financial statements.

7

Table of Contents

Lantheus Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note Regarding Company References and Trademarks

Unless the context otherwise requires, references to the “Company,” “our Company,” “Lantheus,” “we,” “us” and “our” refer to Lantheus Holdings, Inc. and its direct and indirect wholly-owned subsidiaries; references to “Lantheus Holdings” refer to Lantheus Holdings, Inc. and not to any of its subsidiaries; references to “Lantheus Medical” refer to Lantheus Medical Imaging, Inc., the wholly-owned subsidiary of Lantheus Holdings; references to “Aphelion,” “Lantheus Alpha” and “Meilleur” refer to Aphelion LLC, Lantheus Alpha Therapy, LLC and Meilleur Technologies, Inc., respectively, each a wholly-owned subsidiary of Lantheus Holdings; references to “Cerveau,” “Lantheus Real Estate,” “Progenics,” “Evergreen,” “Lantheus Radiopharm UK”, and “Lantheus Switzerland,” refer to Cerveau Technologies, Inc.; Lantheus MI Real Estate, LLC; Progenics Pharmaceuticals, Inc.; Evergreen Theragnostics, Inc.; Lantheus Radiopharmaceuticals UK Limited and Lantheus Switzerland GmbH, respectively, each a wholly-owned subsidiary of Lantheus Medical, references to “EXINI” refer to EXINI Diagnostics AB, a wholly-owned subsidiary of Progenics, and references to “Life Molecular” refer to Life Molecular Imaging Ltd., a wholly-owned subsidiary of Lantheus Radiopharm UK.

Solely for convenience, the Company refers to trademarks, service marks and trade names in this Quarterly Report on Form 10-Q (“Form 10-Q”) without the TM, SM and ® symbols. Those references are not intended to indicate, in any way, that the Company will not assert, to the fullest extent permitted under applicable law, its rights to its trademarks, service marks and trade names. Each trademark, trade name or service mark of any other company appearing in this Form 10-Q, is, to the Company’s knowledge, owned by that other company.

1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements include the accounts of Lantheus and have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) for interim financial information and with the instructions for Form 10-Q and Article 10 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement have been included. The preparation of the Company’s condensed consolidated financial statements requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue and expenses, and related disclosures. The results of operations for the three and nine months ended September 30, 2025 and 2024 are not necessarily indicative of the results that may be expected for any future period.

The condensed consolidated balance sheet at December 31, 2024 has been derived from the audited consolidated financial statements at that date but does not include all the information and notes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto included in Item 8 of the Company’s most recent Annual Report on Form 10-K (“Form 10-K”) for the year ended December 31, 2024 filed with the Securities Exchange Commission (“SEC”) on February 26, 2025.

2. Summary of Significant Accounting Policies

Assets Held for Sale

The Company classifies an asset as held for sale when management, having the authority to approve the action, commits to a plan to sell the asset, the sale is probable within one year and the asset is available for immediate sale in its present condition. The Company also considers whether an active program to locate a buyer has been initiated, whether the asset is marketed actively for sale at a price that is reasonable in relation to its current fair value and whether actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn. The Company initially measures an asset that is classified as held for sale at the lower of its (i) carrying amount or (ii) fair value less costs to sell. Any loss resulting from this measurement is recognized in the period in which the held for sale criteria are met. Conversely, gains are not recognized until the date of sale. The Company assesses the fair value of an asset less costs to sell each reporting period that the asset remains classified as held for sale and reports any subsequent changes as an adjustment to the carrying amount of the asset, as long as the new carrying amount does not exceed the carrying amount of the asset at the time it was initially classified as held for sale. Assets are not depreciated or amortized while they are classified as held for sale.

Investments

Equity investments with readily determinable fair values for which the Company does not have significant influence over the investee are measured at fair value on a recurring basis. Equity investments without readily determinable fair values for which the Company does not have

8

Table of Contents

Lantheus Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

significant influence over the investee are measured at cost with adjustments for observable changes in price or impairments (referred to as the measurement alternative). For equity investments for which the Company does not have significant influence over the investee, changes in the value of unsold equity investments are recorded in investment in equity securities – unrealized gain. Equity investments for which the Company has significant influence over the investee are measured using the equity method unless the Company elects to apply the fair value option to account for the investment.

Recent Accounting Pronouncements

The Company has considered all new accounting standards issued by the Financial Accounting Standards Board (“FASB”). The Company has not yet adopted the following standards:

In September 2025, the FASB issued Accounting Standards Update (“ASU”) 2025-06, “Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software,” which simplifies the capitalization guidance by removing all references to software development project stages so that the guidance is neutral to different software development methods. Entities will now capitalize costs associated with internal-use software only when management has authorized and committed funding, and it is probable that the project will be completed and the software will be used to perform its intended function. ASU 2025-06 is effective for interim and annual periods beginning after December 15, 2027, with early adoption permitted. The Company is currently in the process of evaluating the effects of this pronouncement on its consolidated financial results and related disclosures.

In July 2025, the FASB issued ASU 2025-05, “Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets,” which provides a practical expedient related to the estimation of expected credit losses for accounts receivable and current contract assets that arise from transactions accounted for under Accounting Standards Codification (“ASC”) 606, “Revenue Recognition.” ASU 2025-05 requires an entity to disclose whether it has elected to use the practical expedient. An entity that makes the accounting policy election is required to disclose the date through which subsequent cash collections are evaluated. The requirements of ASU 2025-05 are effective for annual periods beginning after December 15, 2025, and interim periods beginning in the first quarter of 2026. Early adoption is permitted in both interim and annual reporting periods in which financial statements have not yet been issued or made available for issuance. The Company is currently in the process of evaluating the effects of this pronouncement on its consolidated financial results and related disclosures.

In November 2024, the FASB issued ASU 2024-04, “Debt - Debt with Conversion and Other Options (Subtopic 470-20),” which clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion rather than as extinguishment of debt. The requirements of ASU 2024-04 are effective for the annual periods beginning after December 15, 2025, including interim periods within those fiscal years. Early adoption is permitted. For the Company, the requirements under ASU 2024-04 will be effective for its Form 10-Q for the first quarter of 2026. The Company is currently in the process of evaluating the effects of this pronouncement on its consolidated financial results and related disclosures.

In November 2024, the FASB issued ASU 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40),” and in January 2025, the FASB issued ASU 2025-01, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date.” ASU 2024-03 requires additional income statement disclosures, including the disaggregation of specific categories of expenses underlying the line items presented on the income statement. Additionally, ASU 2024-03 requires enhanced disclosure of selling expenses. As clarified by ASU 2025-01, the requirements of the guidance are effective for annual periods beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. For the Company, annual reporting requirements under ASU 2024-03 will be effective for its Form 10-K for the year ending December 31, 2027 and interim reporting requirements will be effective beginning in the first quarter of 2028. Early adoption is permitted and the amendments should be applied on a prospective basis, however retrospective application is permitted. The Company is currently in the process of evaluating the impact of this pronouncement on its related disclosures.

In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures,” which requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit, and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently in the process of evaluating the impact of this pronouncement on its related disclosures and expects the standard will only impact its income tax disclosures with no impact on its consolidated financial results.

9

Table of Contents

Lantheus Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

3. Revenue from Contracts with Customers

The following table summarizes revenue by source as follows:

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(in thousands) |  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Major Products /Service Lines |  |  |  |  |  |  |  |  |  |  |  |
Product revenue, net(1) |  | $ | 376,687 |  |  | $ | 374,601 |  |  | $ | 1,118,152 |  |  | $ | 1,136,670 |
License and royalty revenues |  |  | 7,327 |  |  |  | 4,133 |  |  |  | 16,671 |  |  |  | 6,130 |
Total revenues |  | $ | 384,014 |  |  | $ | 378,734 |  |  | $ | 1,134,823 |  |  | $ | 1,142,800 |

(1)
The Company’s product revenue includes PYLARIFY, DEFINITY, Neuraceq and TechneLite among other products. This category represents the delivery of physical goods. The Company applies the same revenue recognition policies and judgments for all its principal products.

The Company classifies its revenues into three product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Radiopharmaceutical Oncology consists of PYLARIFY and historically included AZEDRA. In the first quarter of 2024, the Company discontinued the production of AZEDRA. Precision Diagnostics includes DEFINITY, Neuraceq, TechneLite and other diagnostic imaging products. Strategic Partnerships and Other Revenue primarily includes revenue derived from partnerships with pharmaceutical companies and academic institutions that use the Company’s investigational products, such as MK-6240 and NAV-4694, in clinical trials as research tools, royalties and other milestone payments received from the Company’s strategic partners that have commercialized products pursuant to license arrangements with the Company, as well as contract development and manufacturing organization (“CDMO”) revenue generated by Evergreen.

Revenue by product category on a net basis is as follows:

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(in thousands) |  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
PYLARIFY |  | $ | 240,616 |  |  | $ | 259,756 |  |  | $ | 748,912 |  |  | $ | 791,881 |
Other radiopharmaceutical oncology |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 384 |
Total radiopharmaceutical oncology |  |  | 240,616 |  |  |  | 259,756 |  |  |  | 748,912 |  |  |  | 792,265 |
DEFINITY |  |  | 81,785 |  |  |  | 76,965 |  |  |  | 244,935 |  |  |  | 231,629 |
Neuraceq |  |  | 20,442 |  |  |  | — |  |  |  | 20,442 |  |  |  | — |
TechneLite |  |  | 21,127 |  |  |  | 20,480 |  |  |  | 65,820 |  |  |  | 70,380 |
Other precision diagnostics |  |  | 6,339 |  |  |  | 6,282 |  |  |  | 18,672 |  |  |  | 18,039 |
Total precision diagnostics |  |  | 129,693 |  |  |  | 103,727 |  |  |  | 349,869 |  |  |  | 320,048 |
Strategic partnerships and other revenue |  |  | 13,705 |  |  |  | 15,251 |  |  |  | 36,042 |  |  |  | 30,487 |
Total revenues |  | $ | 384,014 |  |  | $ | 378,734 |  |  | $ | 1,134,823 |  |  | $ | 1,142,800 |

The Company is required to allocate a portion of its revenue received from commercial contracts to future reporting periods to the extent the Company had performance obligations that extended beyond one year. However, the Company’s performance obligations are typically part of contracts that have an original expected duration of one year or less. Therefore, since the Company elected the practical expedient under ASC 606-10-50-14, it does not disclose information regarding remaining performance obligations which are part of contracts that have an original expected duration of one year or less.

4. Fair Value of Financial Instruments

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability of fair value measurements, financial instruments are categorized based on a hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:

•
Level 1 — Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

10

Table of Contents

Lantheus Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

•
Level 2 — Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.) and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).
•
Level 3 — Unobservable inputs that reflect the Company’s estimates about the assumptions that market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available, including its own data.

The Company’s financial assets and liabilities that are measured at fair value on a recurring basis consist of money market funds, deferred compensation plan liabilities, contingent consideration liabilities and equity investments.

The Company invests excess cash from its operating cash accounts in overnight investments and reflects these amounts in cash and cash equivalents in the condensed consolidated balance sheets at fair value using quoted prices in active markets for identical assets.

The tables below present information about the Company’s assets and liabilities measured at fair value on a recurring basis:

|  |  |  |  | September 30, 2025 |
|  | Total Fair |  |  |  |  |  |  |  |  |  |
(in thousands) |  | Value |  |  | Level 1 |  |  | Level 2 |  |  | Level 3 |
Assets: |  |  |  |  |  |  |  |  |  |  |  |
Money market funds |  | $ | 108,576 |  |  | $ | 108,576 |  |  | $ | — |  |  | $ | — |
Investment securities |  |  | 45,480 |  |  |  | 45,480 |  |  |  | — |  |  |  | — |
Total assets |  | $ | 154,056 |  |  | $ | 154,056 |  |  | $ | — |  |  | $ | — |
Liabilities: |  |  |  |  |  |  |  |  |  |  |  |
Deferred compensation plan liabilities |  | $ | 942 |  |  | $ | 942 |  |  | $ | — |  |  | $ | — |
Contingent consideration liabilities |  |  | 97,824 |  |  |  | — |  |  |  | — |  |  |  | 97,824 |
Total liabilities |  | $ | 98,766 |  |  | $ | 942 |  |  | $ | — |  |  | $ | 97,824 |
|  |  |  |  | December 31, 2024 |
|  | Total Fair |  |  |  |  |  |  |  |  |  |
(in thousands) |  | Value |  |  | Level 1 |  |  | Level 2 |  |  | Level 3 |
Assets: |  |  |  |  |  |  |  |  |  |  |  |
Money market funds |  | $ | 682,209 |  |  | $ | 682,209 |  |  | $ | — |  |  | $ | — |
Investment securities |  |  | 39,489 |  |  |  | 39,489 |  |  |  | — |  |  |  | — |
Total assets |  | $ | 721,698 |  |  | $ | 721,698 |  |  | $ | — |  |  | $ | — |

Nonqualified Deferred Compensation Plan

The Company maintains the Lantheus Nonqualified Deferred Compensation Plan (the “LDCP”) for the benefit of certain key, highly-compensated employees and non-employee directors. The assets of the LDCP are invested in corporate-owned life insurance (“COLI”) and mutual funds at September 30, 2025. The mutual funds are classified as Level 1 of the fair value hierarchy because they are valued using quoted market prices. There were no assets or liabilities balances in the LDCP at December 31, 2024. The liabilities of the LDCP are presented in other long-term liabilities in the Company’s condensed consolidated balance sheets. See Note 17, “Benefit Plans” for more information on the LDCP.

Perspective Therapeutics Inc. Equity Securities

At September 30, 2025, the Company held 11,677,339 shares of Perspective common stock (“Perspective Shares”). The Company accounts for its investment in Perspective Shares as an equity investment with a readily determinable fair value, as the securities are publicly traded on the New York Stock Exchange (“NYSE”). The fair value of the Perspective Shares is based on its closing price on the NYSE at the end of the fiscal period and is classified within Level 1 of the fair value hierarchy because the equity securities are valued using quoted market prices. The fair value of the Perspective Shares as of September 30, 2025 was approximately $40.1 million based on a closing market price of $3.43 per share on September 30, 2025, resulting in an unrealized loss of $0.1 million and an unrealized gain of $2.8 million for the three and nine months ended September 30, 2025, respectively. See Note 18, “Acquisitions” for further discussion of the Perspective transaction.

Radiopharm Theranostics Limited Equity Securities

The Company held 149,625,180 shares of Radiopharm common stock (“Radiopharm Shares”) as of December 31, 2024. In January 2025, the Company purchased via private placement, an additional 133,333,333 Radiopharm Shares for $5.0 million. At September 30, 2025, the

11

Table of Contents

Lantheus Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Company held 282,958,513 Radiopharm Shares. The Company accounts for its investment in Radiopharm Shares as an equity investment with a readily determinable fair value, as the securities are publicly traded on the Australian Stock Exchange (“ASX”). The fair value of the Radiopharm Shares is based on the closing price on the ASX at the end of the fiscal period and is classified within Level 1 of the fair value hierarchy because the equity securities are valued using quoted market prices. The fair value of the Radiopharm Shares as of September 30, 2025 was approximately $5.4 million based on the converted closing market price of approximately $0.02 per share on September 30, 2025, resulting in an unrealized gain on equity securities of $1.2 million and an unrealized loss on equity securities of $2.0 million for the three and nine months ended September 30, 2025, respectively. See Note 18, “Acquisitions” for further discussion of the Radiopharm transaction.

Contingent Consideration

Progenics

The Company assumed contingent consideration liabilities related to a previous acquisition completed by Progenics in 2013 (“2013 Acquisition”). These contingent consideration liabilities include potential payments of up to $70.0 million if the Company attains certain net sales targets primarily for AZEDRA and 1095 (also known as 131 I-MIP-1095) and a $5.0 million 1095 commercialization milestone. Additionally, there is a potential payment of up to $10.0 million for a commercialization milestone related to a prostate cancer product candidate the Company refers to as “1404” that was out-licensed to ROTOP Pharmaka GmbH. The Company’s total potential payments related to the 2013 Acquisition are approximately $85.0 million. The Company considers the contingent consideration liabilities relating to the 2013 Acquisition each a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. The estimated fair value of these was determined based on probability adjusted discounted cash flows and Monte Carlo simulation models that included significant estimates and assumptions pertaining to commercialization events and sales targets. The most significant unobservable inputs with respect to 1095 and 1404 are the probabilities of achieving regulatory approval of those development projects and subsequent commercial success.

Significant changes in any of the probabilities of success, the probabilities as to the periods in which sales targets and milestones will be achieved, discount rates or underlying revenue forecasts would result in a higher fair value measurement. The Company records the contingent consideration liabilities at fair value with changes in estimated fair values recorded in general and administrative expenses in the condensed consolidated statements of operations. The Company can give no assurance that the actual amounts paid, if any, in connection with the contingent consideration liabilities, will be consistent with any recurring fair value estimate of such contingent consideration liabilities. The Company estimated that the probability of successfully meeting the sales targets and commercialization milestones described above was zero, as the Company discontinued the production of AZEDRA in the first quarter of 2024 and the Company is not actively advancing 1095. As a result of this assessment, the Company determined the value of the contingent consideration liabilities to be $0 at September 30, 2025 and December 31, 2024.

Evergreen Theragnostics, Inc.

Pursuant to the terms of the Agreement and Plan of Merger (the “Evergreen Merger Agreement”) with Evergreen and Shareholder Representative Services LLC governing the Company's acquisition of Evergreen in April 2025 (see Note 18, “Acquisitions”), the Company is required to pay up to $727.5 million in cash upon the achievement of specified milestones in connection with the development and commercialization of certain milestone products, as defined in the Evergreen Merger Agreement, and Octevy (also referred to as LNTH-2501), a registrational-stage positron emission tomography (“PET”) diagnostic imaging agent targeting neuroendocrine tumors. The Company records these possible payments as contingent consideration liabilities that are classified within Level 3 of the fair value hierarchy. The Company estimated the fair value of the contingent consideration liabilities associated with the sales milestones using a Monte Carlo simulation in a risk-neutral framework, whereby the achievement of the future revenue associated with the sales milestones was simulated using a geometric Brownian motion model. The Company estimated the fair value of the contingent consideration liability associated with the development and commercialization milestones using a probability-weighted discounted cash flow (“DCF”) approach.

Life Molecular Imaging Ltd.

Pursuant to the terms of the Sale and Purchase Agreement (the “LMI Purchase Agreement”) with Life Medical Group Limited (“Life Medical”) in connection with the Company’s acquisition of Life Molecular in July 2025 (see Note 18, “Acquisitions”), the Company is required to make certain earn-out and milestone payments as a percentage of and upon achievement of specified net sales thresholds, respectively, of Neuraceq and certain other imaging and tracing agents in Life Molecular’s pipeline. These contingent cash earn-out and milestone payments total up to $400.0 million. In addition to the net sales earn-out and milestone payments, the Company also assumed a contingent consideration liability owed to Piramal Holdings SA (“Piramal”), pursuant to an assumed contract (the “Piramal SPA”). The Company is required to make cash payments of up to $30.0 million upon the achievement of specified earnings metrics of Life Molecular, as defined in the Piramal SPA. The

12

Table of Contents

Lantheus Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Company estimated the fair value of the contingent consideration liabilities using a Monte Carlo simulation model in a risk-neutral framework, whereby the achievement of the future revenue and other specified earnings metrics associated with the contingent payments were simulated using a geometric Brownian motion model.

The following table reflects the activity for the Company’s contingent consideration measured at fair value using Level 3 inputs for the nine months ended September 30, 2025:

|  | Level 3 |
|  | Accrued Contingent |
(in thousands) |  | Consideration |
Balance December 31, 2024 |  | $ | — |
Evergreen acquisition |  |  | 43,042 |
Life Molecular acquisition |  |  | 53,800 |
Changes in fair value included in net income |  |  | 982 |
Balance September 30, 2025 |  | $ | 97,824 |

Significant changes in any of the probabilities of success, the probabilities as to the periods in which sales targets and milestones will be achieved, discount rates or underlying revenue forecasts would result in a higher or lower fair value measurement. The Company records the contingent consideration liabilities at fair value with changes in estimated fair values recorded within operating expenses in the condensed consolidated statements of operations. The Company can give no assurance that the actual amounts paid, if any, in connection with the contingent consideration liabilities, will be consistent with any recurring fair value estimate of such contingent consideration liabilities. As a result of this assessment, the Company determined the value of the contingent consideration liabilities to be $97.8 million at September 30, 2025.

The recurring Level 3 fair value measurements of the Company's contingent consideration liabilities include the following significant unobservable inputs (in thousands, except percent data):

|  | Fair Value at |  |  |  |  |  |  |  |  |
Contingent Consideration Liability |  | September 30, 2025 |  |  | Valuation Technique |  | Unobservable Inputs |  | Range |  | Weighted Average
Development and commercialization milestones |  |  | 40,965 |  |  | Discounted cash flow |  | Payment discount rate |  | 8.1% - 13.3% |  | 8.3%
|  |  |  |  |  |  | Probability of payment |  | 0.0% - 100.0% |  | 87.3%
|  |  |  |  |  |  | Range of expected payment dates |  | 2026 - 2037 |  | N/A
Sales milestones |  |  | 30,059 |  |  | Scenario analysis |  | Revenue volatility |  | 37.0% - 48.0% |  | 46.9%
|  |  |  |  |  |  | Revenue discount rate |  | 9.4% - 19.3% |  | 17.8%
Assumed contingent consideration from Piramal SPA |  |  | 26,800 |  |  | Scenario analysis |  | EBITDA volatility |  | 60.0% |  | 60.0%
|  |  |  |  |  |  | EBITDA discount rate |  | 21.4% - 22.0% |  | 21.4%
Total contingent consideration liabilities |  | $ | 97,824 |  |  |  |  |  |  |  |  |

5. Income Taxes

The Company calculates income taxes at the end of each reporting period based on the estimated effective tax rate for the full year, adjusted for any discrete events which are recorded in the period they occur. Cumulative adjustments to the tax provision are recorded in the reporting period in which a change in the estimated annual effective tax rate is determined. The Company’s income tax expense and effective tax rate are presented below:

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(in thousands) |  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Income tax expense |  | $ | 14,610 |  |  | $ | 45,025 |  |  | $ | 63,956 |  |  | $ | 107,528 |
Effective tax rate |  |  | 34.5 | % |  |  | 25.6 | % |  |  | 26.3 | % |  |  | 24.9 | %

13

Table of Contents

Lantheus Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

The increase in the effective income tax rate for the three and nine months ended September 30, 2025 is primarily due to the change in the Company’s non-deductible stock compensation and acquisition-related costs, partially offset by an increase in tax credits.

On July 4, 2025, H.R.1, the One Big Beautiful Bill Act (“OBBBA”) was signed into law. The OBBBA provides for significant U.S. tax law changes, including the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework, and the restoration of favorable tax treatment for certain business provisions. These provisions did not have a material impact on the Company’s effective income tax rate for the three and nine months ended September 30, 2025.

The change in the Company’s deferred tax balances for the nine months ended September 30, 2025 was primarily related to the acquisitions of Life Molecular and Evergreen and the expensing of previously capitalized research and development (“R&D”) expenses under the OBBBA.

6. Inventory

Inventory, net of related reserves, consisted of the following:

|  | September 30, |  |  | December 31, |
(in thousands) |  | 2025 |  |  | 2024 |
Raw materials |  | $ | 24,960 |  |  | $ | 29,080 |
Work in process |  |  | 15,156 |  |  |  | 15,870 |
Finished goods |  |  | 21,924 |  |  |  | 23,075 |
Total inventory, net(1) |  | $ | 62,040 |  |  | $ | 68,025 |

(1)
As of September 30, 2025, amounts totaling $3.5 million, $0.1 million and $7.0 million were reclassified to assets held for sale, from raw materials, work in process and finished goods, respectively, as a result of the pending sale of the Company’s single-photon emission computerized tomography (“SPECT”) business. See Note 8, “Assets and Liabilities Held for Sale” for more information.

The majority of the value of the inventory relates to non-radioactive products. With respect to the Company’s products that are radiopharmaceuticals, due to the limited shelf life of such products, they are generally not held as finished goods.

14

Table of Contents

Lantheus Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

7. Property, Plant and Equipment, Net

Property, plant and equipment, net, consisted of the following:

|  | September 30, |  |  | December 31, |
(in thousands) |  | 2025 |  |  | 2024 |
Land |  | $ | 3,020 |  |  | $ | 9,480 |
Buildings |  |  | 49,994 |  |  |  | 85,523 |
Machinery, equipment and fixtures |  |  | 104,331 |  |  |  | 114,357 |
Computer software |  |  | 54,248 |  |  |  | 48,702 |
Construction in progress |  |  | 22,604 |  |  |  | 27,498 |
Total gross property, plant and equipment |  |  | 234,197 |  |  |  | 285,560 |
Less - accumulated depreciation and amortization |  |  | (70,125 | ) |  |  | (108,762 | )
Total property, plant and equipment, net(1) |  | $ | 164,072 |  |  | $ | 176,798 |

(1)
As of September 30, 2025, amounts totaling $6.5 million in land, $48.4 million in buildings, $39.2 million in machinery, equipment and fixtures, $0.4 million in computer software, $2.8 million in construction in progress and $52.0 million in accumulated depreciation and amortization were reclassified to assets held for sale as a result of the pending sale of the Company’s SPECT business. See Note 8, “Assets and Liabilities Held for Sale” for more information.

Depreciation and amortization expense related to property, plant and equipment, net, was $5.6 million and $5.1 million for the three months ended September 30, 2025 and 2024, respectively, and $16.3 million and $15.1 million for the nine months ended September 30, 2025 and 2024, respectively.

On January 8, 2024, the Company entered into an agreement with Perspective to transfer the sublease for the property at 110 Clyde Rd, Somerset, New Jersey (the “Somerset Facility”) and sell the associated assets at the Somerset Facility for $8.0 million. The transfer of the sublease and completion of the asset sale occurred on March 1, 2024. The sale of assets resulted in a derecognition to the right-of-use asset of $0.4 million, the lease liability of $0.4 million and remaining property, plant and equipment of $0.8 million. The Company also incurred commission expense of $1.0 million related to the transaction. The Company recorded a gain of $6.3 million for the nine months ended September 30, 2024 within operating income.

See Note 18, “Acquisitions” for further discussion of the Perspective transaction.

8. Assets and Liabilities Held for Sale

SPECT Business

On May 1, 2025, the Company entered into a definitive agreement to sell its SPECT business to SHINE Technologies, LLC (“SHINE”), a wholly-owned subsidiary of Illuminated Holdings, Inc. Under the terms of the agreement, SHINE will acquire the assets and liabilities associated with the Company’s SPECT business, including its diagnostics agents (TechneLite, NEUROLITE, Xenon Xe-133 Gas, and Cardiolite) and the portion of the North Billerica, Massachusetts campus that manufactures the Company’s SPECT products and SPECT-related Canadian operations. The transaction is subject to customary closing conditions and is expected to be completed around the end of the calendar year.

As of September 30, 2025, assets and liabilities associated with the Company’s SPECT business have been presented in the Company’s condensed consolidated balance sheets as assets and liabilities held for sale as it was determined that these assets and liabilities met the criteria of held-for-sale under ASC 360, “Impairment or disposal of long-lived assets,” and will continue to be classified as such until the transaction is completed. The Company determined that the fair value less costs to sell exceeded the carrying value of the assets and liabilities associated with the SPECT business, and therefore no indicator of impairment was present with respect to these assets during the three and nine months ended September 30, 2025. The Company does not believe the sale represents a strategic shift having a major effect on the Company's consolidated financial results and therefore does not meet the criteria for classification as discontinued operations.

15

Table of Contents

Lantheus Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

The table below presents the carrying amounts of assets and liabilities held for sale related to the SPECT transaction:

|  | September 30, |
(in thousands) |  | 2025 |
Assets: |  |  |
Accounts receivable, net |  | $ | 14,984 |
Inventory |  |  | 10,578 |
Other current assets |  |  | 2,733 |
Property, plant and equipment, net |  |  | 45,319 |
Intangible assets, net |  |  | 871 |
Goodwill |  |  | 2,138 |
Total assets held-for-sale |  | $ | 76,623 |
Liabilities: |  |  |
Accounts payable |  |  | 6,993 |
Accrued expenses and other liabilities |  |  | 3,802 |
Asset retirement obligation |  |  | 17,771 |
Total liabilities held-for-sale |  | $ | 28,566 |

9. Accrued Expenses, Other Liabilities and Other Long-Term Liabilities

Accrued expenses, other liabilities and other long-term liabilities are comprised of the following:

|  | September 30, |  |  | December 31, |
(in thousands) |  | 2025 |  |  | 2024 |
Compensation and benefits |  | $ | 53,323 |  |  | $ | 48,263 |
Freight, distribution and operations |  |  | 76,010 |  |  |  | 85,966 |
Accrued rebates, discounts and chargebacks |  |  | 63,812 |  |  |  | 25,248 |
Accrued professional fees |  |  | 24,553 |  |  |  | 20,308 |
Accrued research and development expenses |  |  | 11,069 |  |  |  | 13,219 |
Income taxes payable |  |  | 1,405 |  |  |  | 1,591 |
Other |  |  | 20,933 |  |  |  | 10,397 |
Total accrued expenses and other liabilities |  | $ | 251,105 |  |  | $ | 204,992 |
Operating lease liabilities |  | $ | 50,629 |  |  | $ | 53,185 |
Other long-term liabilities |  |  | 65,551 |  |  |  | 9,995 |
Total other long-term liabilities |  | $ | 116,180 |  |  | $ | 63,180 |

10. Asset Retirement Obligations

The Company considers its legal obligation to remediate its facilities upon a potential decommissioning of its radioactive-related operations an asset retirement obligation (“ARO”). The Company has a production facility that manufactures and processes radioactive materials at its North Billerica, Massachusetts site. As of September 30, 2025, the ARO is measured at the present value of the expenses estimated to be incurred in such remediation, and is approximately $20.4 million.

The following table provides a summary of the changes in the Company’s carrying value of its ARO:

(in thousands) |  | Amount |
Balance at January 1, 2025 |  | $ | 23,344 |
Revision of estimated decommissioning costs |  |  | (4,727 | )
Remediation costs |  |  | (1,079 | )
Reclassification to liabilities held-for-sale(1) |  |  | (17,771 | )
Accretion expense |  |  | 370 |
Balance at September 30, 2025 |  | $ | 137 |

16

Table of Contents

Lantheus Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

(1)
Amount reclassified to liabilities held for sale as a result of the pending sale of the assets and liabilities associated with the Company’s SPECT business. See Note 8, “Assets and Liabilities Held for Sale” for more information.

In the first quarter of 2025, the Company revised certain inputs to its estimate of decommissioning costs expected to be incurred throughout the period of remediation, which reduced the estimate of remediation costs by $4.7 million. This reduction was primarily the result of changes in the technology and processes used for the remediation activities from those contemplated in the estimate previously provided in 2022, and was recorded in other income on the Company's condensed consolidated statements of operations in the first quarter of 2025. During the three months ended September 30, 2025, the Company recorded an additional reduction of $1.1 million to the ARO for remediation efforts completed during the period.

The Company is required to provide the Massachusetts Department of Public Health financial assurance demonstrating the Company’s ability to fund any decommissioning of its North Billerica, Massachusetts production facility in the event of any closure. The Company has provided this financial assurance in the form of a $30.3 million surety bond.

11. Goodwill and Intangibles, Net

Goodwill

The following table represents the change in the carrying value of goodwill for the nine months ended September 30, 2025:

(in thousands) |  | Amount |
Balance at January 1, 2025 |  | $ | 61,189 |
Acquisition of Evergreen |  | $ | 116,221 |
Acquisition of Life Molecular |  | $ | 64,464 |
Reclassification to assets held for sale(1) |  | $ | (2,138 | )
Foreign currency translation adjustments |  | $ | 592 |
Balance at September 30, 2025 |  | $ | 240,328 |

(1)
Amounts reclassified to assets held for sale as a result of the pending sale of the assets and liabilities associated with the Company’s SPECT business. See Note 8, “Assets and Liabilities Held for Sale”, for more information.

Intangibles, net, consisted of the following:

|  | September 30, 2025 |
(in thousands) |  | Useful Lives (in years) |  | Amortization Method |  | Gross |  |  | Accumulated Amortization |  |  | Net |
Amortizable: |  |  |  |  |  |  |  |  |  |  |  |  |
Trademarks |  | 25 |  | Straight-line |  | $ | 13,540 |  |  | $ | (12,473 | ) |  | $ | 1,067 |
Customer relationships |  | 5 |  | Accelerated |  |  | 102,908 |  |  |  | (88,781 | ) |  |  | 14,127 |
Currently marketed products |  | 9 - 10.5 |  | Straight-line |  |  | 492,800 |  |  |  | (70,788 | ) |  |  | 422,012 |
Licenses |  | 13 - 16 |  | Straight-line |  |  | 22,233 |  |  |  | (13,926 | ) |  |  | 8,307 |
Developed technology |  | 7 - 9 |  | Straight-line |  |  | 55,982 |  |  |  | (11,231 | ) |  |  | 44,751 |
Total amortizable intangibles |  |  |  |  |  |  | 687,463 |  |  |  | (197,199 | ) |  |  | 490,264 |
Non-amortizable: |  |  |  |  |  |  |  |  |  |  |  |  |
In-process research and development |  | Indefinite |  |  |  |  | 249,000 |  |  |  | — |  |  |  | 249,000 |
Total intangibles, net |  |  |  |  |  | $ | 936,463 |  |  | $ | (197,199 | ) |  | $ | 739,264 |

17

Table of Contents

Lantheus Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

|  | December 31, 2024 |
(in thousands) |  | Useful Lives (in years) |  | Amortization Method |  | Gross |  |  | Accumulated Amortization |  |  | Net |
Trademarks |  | 15 - 25 |  | Straight-line |  | $ | 13,540 |  |  | $ | (12,363 | ) |  | $ | 1,177 |
Customer relationships |  | 15 - 25 |  | Accelerated |  |  | 157,742 |  |  |  | (136,647 | ) |  |  | 21,095 |
Currently marketed products |  | 9 -15 |  | Straight-line |  |  | 132,800 |  |  |  | (53,033 | ) |  |  | 79,767 |
Licenses |  | 11 - 16 |  | Straight-line |  |  | 22,233 |  |  |  | (13,203 | ) |  |  | 9,030 |
Developed technology |  | 7 - 9 |  | Straight-line |  |  | 55,982 |  |  |  | (5,290 | ) |  |  | 50,692 |
Total intangibles, net |  |  |  |  |  | $ | 382,297 |  |  | $ | (220,536 | ) |  | $ | 161,761 |

The Company recorded amortization expense for its intangible assets of $14.6 million and $11.9 million for the three months ended September 30, 2025 and 2024, respectively and $30.6 million and $32.0 million for the nine months ended September 30, 2025 and 2024, respectively.

On August 2, 2023, the Company sold the right to its RELISTOR royalty asset under its license agreement with Bausch Health Companies, Inc.; the Company retained the rights to future sales-based milestone payments. The Company received an initial payment of approximately $98.0 million in connection with the sale and has the right to receive an additional payment from the buyer of $5.0 million, if worldwide net sales of RELISTOR in 2025 exceed specified thresholds. No sales-based milestone payment was earned in the three and nine months ended September 30, 2025.

In the first quarter of 2024, the Company discontinued the production and promotion of AZEDRA and no AZEDRA was manufactured after March 1, 2024, when the Company transferred the tangible assets and associated lease of its Somerset Facility to Perspective. See Note 7, “Property, Plant and Equipment, Net” for impairment analysis.

In June 2024, the Company entered into an agreement with the stockholders of Meilleur (“Meilleur Stockholders”) to purchase all of the outstanding capital stock of Meilleur (which holds the rights under a license agreement to develop and commercialize NAV-4694) for approximately $32.9 million. The Company recorded a developed technology intangible asset of $40.3 million as a result of the purchase price and the specific assets and liabilities of Meilleur that were acquired as part of the asset acquisition based on their value at the agreed upon closing date. In August 2024, upon successful completion of a technology transfer, the Company paid $10.0 million to the Meilleur Stockholders. This additional contingent payment was capitalized as part of the asset cost and increased the total value of the Company’s developed technology intangible assets. See Note 18, “Acquisitions” for further discussion of the Meilleur acquisition.

The below table summarizes the estimated aggregate amortization expense expected to be recognized on the above intangible assets:

(in thousands) |  | Amount |
Remainder of 2025 |  | $ | 16,521 |
2026 |  |  | 66,891 |
2027 |  |  | 61,380 |
2028 |  |  | 58,074 |
2029 |  |  | 57,930 |
2030 and thereafter |  |  | 229,468 |
Total |  | $ | 490,264 |

12. Long-Term Debt, and Other Borrowings, Net of Current Portion

The carrying value of the Company’s long-term debt and other borrowings, net of current portion is comprised of the following:

|  | September 30, |  |  | December 31, |
(in thousands) |  | 2025 |  |  | 2024 |
Principal amount 2.625% Convertible Senior Notes due 2027 |  | $ | 574,996 |  |  | $ | 575,000 |
Unamortized debt issuance costs |  |  | (7,720 | ) |  |  | (10,392 | )
Finance lease liabilities |  |  | 1,532 |  |  |  | 1,645 |
Total |  |  | 568,808 |  |  |  | 566,253 |
Less: current portion of long-term debt and other borrowings |  |  | (871 | ) |  |  | (974 | )
Total long-term debt and other borrowings, net of current portion |  | $ | 567,937 |  |  | $ | 565,279 |

18

Table of Contents

Lantheus Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

2022 Revolving Facility

In December 2024, the Company entered into an amendment to its $350.0 million five-year revolving credit facility originally entered into in December 2022. The amendment, among other things, increased the facility from $350.0 million to $750.0 million (as amended, the “2022 Revolving Facility”) and extended the maturity date from December 2, 2027 to December 19, 2029. Under the terms of the 2022 Revolving Facility, the lenders are committed to extending credit to the Company from time to time consisting of revolving loans (the “Revolving Loans”) in an aggregate principal amount not to exceed $750.0 million (the “Revolving Commitment”) at any time, including a $40.0 million sub-facility for the issuance of letters of credit (the “Letters of Credit”) and a $20.0 million sub-facility for swingline loans (the “Swingline Loans”). The Revolving Loans, Letters of Credit, and the Swingline Loans, if used, are expected to be used for working capital and for other general corporate purposes.

The Revolving Loans bear interest, with pricing based from time to time at the Company’s election, at (i) the secured overnight financing rate as published by the Federal Reserve Bank of New York on its website plus an applicable margin that ranges from 1.25% to 2.00% based on the Company’s total net leverage ratio or (ii) the alternative base rate plus an applicable margin that ranges from 0.25% to 1.00%, in either case, based on the Company’s total net leverage ratio. The 2022 Revolving Facility also includes an unused commitment fee at a rate ranging from 0.15% to 0.30% per annum based on the Company’s total net leverage ratio. Interest associated with the unused commitment is recorded to accrued expenses and other liabilities on the condensed consolidated balance sheets and paid out on a quarterly basis.

The Company is permitted to voluntarily prepay the Revolving Loans, in whole or in part, or reduce or terminate the Revolving Commitment, in each case, without premium or penalty. On any business day on which the total amount of outstanding Revolving Loans, Letters of Credit, and Swingline Loans exceeds the total Revolving Commitment, the Company must prepay the Revolving Loans in an amount equal to such excess. The Company is not required to make mandatory prepayments under the 2022 Revolving Facility. As of September 30, 2025, there were no outstanding borrowings under the 2022 Revolving Facility.

The Company has the right to request an increase to the Revolving Commitment in an aggregate principal amount of up to the greater of $685.0 million or 100% of consolidated earnings before interest, taxes, depreciation and amortization for the four consecutive fiscal quarters most recently ended, plus additional amounts in certain circumstances (collectively, the “Incremental Cap”), minus certain incremental term loans made pursuant to specified incremental term loan commitments (“Incremental Term Loans”). The Company has the right to request Incremental Term Loans in an aggregate principal amount of up to the Incremental Cap less any incremental increases to the Revolving Commitment. Proceeds of Incremental Term Loans may be used for working capital and for other general corporate purposes and will bear interest at rates agreed between the Company and the lenders providing the Incremental Term Loans.

2022 Revolving Facility Covenants

The 2022 Revolving Facility contains a number of affirmative, negative and reporting covenants, as well as financial maintenance covenants pursuant to which the Company is required to be in quarterly compliance, measured on a trailing four quarter basis, with two financial covenants. The minimum interest coverage ratio must be at least 3.00 to 1.00. The maximum total net leverage ratio permitted by the financial covenant is 3.50 to 1.00, other than in connection with certain acquisitions, in which case, the maximum total net leverage ratio permitted can be increased to 4.00 to 1.00.

The 2022 Revolving Facility contains usual and customary restrictions on the ability of the Company and its subsidiaries to: (i) incur additional indebtedness (ii) create liens; (iii) consolidate, merge, sell or otherwise dispose of all or substantially all of its assets; (iv) sell certain assets; (v) pay dividends on, repurchase or make distributions in respect of capital stock or make other restricted payments; (vi) make certain investments; (vii) repay subordinated indebtedness prior to stated maturity; and (viii) enter into certain transactions with its affiliates.

Upon an event of default, the Administrative Agent, as defined in the 2022 Revolving Facility, will have the right to declare the loans and other obligations outstanding under the 2022 Revolving Facility immediately due and payable and all commitments immediately terminated.

The 2022 Revolving Facility is guaranteed by Lantheus Holdings, and certain subsidiaries of Lantheus Medical, including Progenics and Lantheus Real Estate, and obligations under the 2022 Revolving Facility are generally secured by first priority liens over substantially all of the assets of each of Lantheus Medical, Lantheus Holdings, and certain subsidiaries of Lantheus Medical, including Progenics and Lantheus Real Estate (subject to customary exclusions set forth in the transaction documents) owned as of December 2, 2022 or thereafter acquired.

2.625% Convertible Senior Notes due 2027

On December 8, 2022, the Company issued $575.0 million in aggregate principal amount of 2.625% Convertible Senior Notes due 2027 (the “Notes”), which includes $75.0 million in aggregate principal amount of Notes sold pursuant to the full exercise of the initial purchasers’

19

Table of Contents

Lantheus Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

option to purchase additional Notes. The Notes were issued under an indenture, dated as of December 8, 2022 (the “Indenture”), among the Company, Lantheus Medical as Guarantor, and U.S. Bank Trust Company, National Association, as Trustee. The net proceeds from the issuance of the Notes were approximately $557.8 million after deducting the initial purchasers’ discounts and offering expenses payable by the Company.

The Notes are senior unsecured obligations of the Company. The Notes are fully and unconditionally guaranteed on a senior unsecured basis by the Guarantor. The Notes bear interest at a rate of 2.625% per year, payable semi-annually in arrears on June 15 and December 15 of each year, beginning on June 15, 2023, and will mature on December 15, 2027 unless earlier redeemed, repurchased or converted in accordance with their terms. The initial conversion rate for the Notes is 12.5291 shares of the Company’s common stock per $1,000 in principal amount of Notes (which is equivalent to an initial conversion price of approximately $79.81 per share of the Company’s common stock, representing an initial conversion premium of approximately 42.5% above the closing price of $56.01 per share of the Company’s common stock on December 5, 2022). In no event shall the conversion rate per $1,000 in principal amount of the Notes exceed 17.8539 shares of the Company’s common stock. Prior to the close of business on the business day immediately preceding September 15, 2027, the Notes may be converted at the option of the holders only upon occurrence of specified events and during certain periods, and thereafter until the close of business on the business day immediately preceding the maturity date, the Notes may be converted at any time. The Company will satisfy any conversion by paying cash up to the aggregate principal amount of the Notes to be converted and by paying or delivering, as the case may be, cash, shares of the Company’s common stock, or a combination of cash and shares of the Company’s common stock, at its election, in respect of the remainder, if any, of its conversion obligation in excess of the aggregate principal amount of the Notes being converted. The Company may redeem for cash all or any portion of the Notes, at its option, on or after December 22, 2025 if the closing sale price per share of the Company’s common stock exceeds 130% of the conversion price of the Notes (currently $103.75 per share) for at least 20 trading days (whether or not consecutive) during the last 30 consecutive trading days of the quarter (the “Stock Price Conversion Threshold”). The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.

The Company evaluated the Notes upon completion of the sale and concluded on the following features:

•
Conversion Feature: The Company determined that the conversion feature qualifies for the classification of equity. As a result, the conversion feature should not be bifurcated as a derivative instrument and the Notes were accounted for as a single liability.
•
Redemption Features: The redemption features were reviewed within the Notes and the Company determined that the redemption features are closely related to the Notes and as such should not be separately accounted for as a bifurcated derivative instrument.
•
Additional Interest Features: The Notes may result in additional interest if the Company fails to timely file any document that the Company is required to file with the SEC pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company will pay additional interest on the notes at a rate equal to 0.25% to 0.50% per annum based on the principal amount of Notes outstanding for each day the Company failure to file has occurred or the Notes are not otherwise freely tradable. Further, if the Notes are assigned a restricted CUSIP number or the Notes are not otherwise freely tradable pursuant to Rule 144 under the Securities Act of 1933, as amended, by holders other than Company affiliates or holders that were Company affiliates at any time during the three months immediately preceding as of the 385th day after the last date of original issuance of the Notes, the Company will pay additional interest on the Notes at a rate equal to (i) 0.25% to 0.50% per annum based on the principal amount of Notes outstanding for each day until the restrictive legend has been removed from the Notes, the Notes are assigned an unrestricted CUSIP and the Notes are freely tradable. The Company concluded that the interest feature is unrelated to the credit risk and should be bifurcated from the Notes, however, the Company assessed the probabilities of triggering events occurring under these features and does not expect to trigger the aforementioned events. These events will continue to be monitored to determine whether the interest feature will be bifurcated if it has value.

Holders of the Notes may require the Company to repurchase their Notes upon the occurrence of a fundamental change prior to the maturity at a repurchase price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but excluding, the date of repurchase. In connection with certain triggering events, the Company will, under certain circumstances, increase the conversion rate for holders of the Notes who elect to convert their Notes in connection with such corporate events.

During the third quarter of 2025, the closing price of the Company’s common stock did not exceed the Stock Price Conversion Threshold, so the Notes are not convertible at the option of the holders of the Notes during the fourth quarter of 2025. Because the Notes are not considered

20

Table of Contents

Lantheus Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

convertible under the terms of the Notes and pursuant to ASC 470, “Debt,” the Company classified the carrying value of the Notes as long-term debt, net and other borrowings on the Company’s condensed consolidated balance sheets as of September 30, 2025.

As of September 30, 2025, the carrying value of the Notes was $575.0 million, the Notes had an unamortized discount of $7.7 million, and the fair value of the liability was $604.4 million. The Company recorded interest expense of $3.8 million and $11.3 million related to the Notes for the three and nine months ended September 30, 2025 and 2024, respectively.

21

Table of Contents

Lantheus Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

13. Stockholders' Equity and Stock-Based Compensation

On July 31, 2025, the Board of Directors (“Board”) authorized a program to repurchase up to $400.0 million of shares of the Company’s common stock through December 31, 2027 (the “2025 Program”). The 2025 Program replaces the program authorized in November 2024 to repurchase up to $250.0 million of shares of the Company’s common stock (the “2024 Program”), including the remaining unused amounts under the 2024 Program, so there can be no additional repurchases under the 2024 Program. During the three months ended September 30, 2025, the Company repurchased 1.8 million shares for approximately $100.0 million under the 2025 Program. During the nine months ended September 30, 2025, the Company also repurchased 1.3 million shares for approximately $100.0 million under the 2024 Program. As of September 30, 2025, the Company had repurchased a total of approximately 1.8 million shares under the 2025 Program and 2.4 million shares under the 2024 Program for a total of approximately $300.0 million. A total of approximately $300.0 million of shares of the Company’s common stock remain available for repurchase under the 2025 Program.

The following table presents stock-based compensation expense recognized in the Company’s accompanying condensed consolidated statements of operations:

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(in thousands) |  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Cost of goods sold |  | $ | 3,897 |  |  | $ | 3,614 |  |  | $ | 10,133 |  |  | $ | 9,116 |
Sales and marketing |  |  | 4,471 |  |  |  | 3,813 |  |  |  | 12,514 |  |  |  | 9,681 |
General and administrative |  |  | 12,609 |  |  |  | 9,926 |  |  |  | 35,793 |  |  |  | 27,457 |
Research and development |  |  | 3,524 |  |  |  | 3,013 |  |  |  | 9,580 |  |  |  | 7,975 |
Total stock-based compensation expense |  | $ | 24,501 |  |  | $ | 20,366 |  |  | $ | 68,020 |  |  | $ | 54,229 |

14. Net Income Per Common Share

A summary of net income per common share is presented below:

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(in thousands, except per share amounts) |  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Net income |  | $ | 27,771 |  |  | $ | 131,093 |  |  | $ | 179,471 |  |  | $ | 324,232 |
Basic weighted-average common shares outstanding |  |  | 67,230 |  |  |  | 69,464 |  |  |  | 68,132 |  |  |  | 69,193 |
Effect of dilutive stock options |  |  | 125 |  |  |  | 352 |  |  |  | 193 |  |  |  | 273 |
Effect of dilutive restricted stock |  |  | 308 |  |  |  | 1,580 |  |  |  | 612 |  |  |  | 1,309 |
Effect of convertible notes |  |  | — |  |  |  | 1,669 |  |  |  | 101 |  |  |  | 556 |
Diluted weighted-average common shares outstanding |  |  | 67,663 |  |  |  | 73,065 |  |  |  | 69,038 |  |  |  | 71,331 |
Net income per common share: |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 0.41 |  |  | $ | 1.89 |  |  | $ | 2.63 |  |  | $ | 4.69 |
Diluted |  | $ | 0.41 |  |  | $ | 1.79 |  |  | $ | 2.60 |  |  | $ | 4.55 |
Antidilutive securities excluded from diluted net income per common share |  |  | 1,862 |  |  |  | 144 |  |  |  | 1,623 |  |  |  | 855 |

Impact of the Convertible Notes

The Company considered whether the Notes are participating securities through the two-class method. Per the terms of the Indenture, the Company determined that if a cash dividend is paid that is greater than the stock price, the holder of Notes will receive cash on an if-converted basis. While this feature is considered to be a participating right, basic earnings per share is only impacted if the Company’s earnings per share exceeds the current share price, regardless of whether such dividend is declared. During the three and nine months ended September 30, 2025 and 2024, no such dividend was declared. In addition, the Company is required to settle the principal amount of the Notes in cash upon conversion, and therefore, the Company uses the if-converted method for calculating any potential dilutive effect of the conversion option on

22

Table of Contents

Lantheus Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

diluted net income per share, if applicable, unless the application of the two-class method is dilutive. The conversion option has a dilutive impact on net income per share of Common Stock when the average price per share of the Company's common stock for a given period exceeds the conversion price of the Notes of $79.81 per share. See Note 12, “Long-Term Debt, Net, and Other Borrowings” for further discussion on the Notes.

23

Table of Contents

Lantheus Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

15. Other Income

Other income consisted of the following:

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(in thousands) |  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Foreign currency loss (gain) |  | $ | 269 |  |  | $ | (46 | ) |  | $ | 689 |  |  | $ | 192 |
Interest income |  |  | (3,623 | ) |  |  | (9,801 | ) |  |  | (20,318 | ) |  |  | (27,273 | )
Revision of estimated decommissioning costs related to asset retirement obligation(1) |  |  | — |  |  |  | — |  |  |  | (4,727 | ) |  |  | — |
Other |  |  | 798 |  |  |  | (106 | ) |  |  | 777 |  |  |  | (704 | )
Total other income, net |  | $ | (2,556 | ) |  | $ | (9,953 | ) |  | $ | (23,579 | ) |  | $ | (27,785 | )

(1)
See Note 10, “Asset Retirement Obligations,” for more information.

16. Commitments and Contingencies

Legal Proceedings

From time to time, the Company is a party to various legal proceedings arising in the ordinary course of business. In addition, the Company has in the past been, and may in the future be, subject to investigations by governmental and regulatory authorities, which expose it to greater risks associated with litigation, regulatory or other proceedings, as a result of which the Company could be required to pay significant fines or penalties. The costs and outcome of litigation, regulatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company and could have a material adverse effect on the Company’s results of operations or financial condition. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations. If a matter is both probable to result in material liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible material loss or range of loss. If such loss is not probable or cannot be reasonably estimated, a liability is not recorded in its condensed consolidated financial statements.

As of September 30, 2025, the Company did not have any material ongoing litigation to which the Company was a party.

On January 26, 2024, the Company was sued in the United States District Court for the District of Delaware by Advanced Accelerator Applications USA, Inc. and Advanced Accelerator Applications SA, each a Novartis entity, for patent infringement in response to the filing of the Company’s Abbreviated New Drug Application and Paragraph IV certification in connection with PNT2003, consistent with the process established by the Hatch-Waxman Act. Because the outcome of litigation is uncertain, the Company cannot predict how or when this matter will ultimately be resolved.

On February 23, 2024, the Company filed a patent infringement lawsuit against a healthcare-related imaging software developer, and that developer filed a motion to dismiss the case based on grounds of invalidity for certain patents and failure to state a claim for infringement for other patents. The court dismissed the developer’s motion to dismiss as to invalidity, and granted the motion as to certain allegations of infringement. Because the outcome of litigation is uncertain, the Company cannot predict how or when this matter will ultimately be resolved.

On September 9, 2025, an alleged stockholder of the Company initiated a putative securities class action against the Company in the United States District Court for the Southern District of New York, styled Margolis v. Lantheus Holdings, Inc., et al. The operative complaint also asserts claims against certain of the Company’s named executives. The plaintiff alleges that the defendants made materially false or misleading statements (or omitted material facts) in violation of the Exchange Act. Under the operative scheduling order in the case, members of the putative class of stockholders have an opportunity to move the court for appointment as lead plaintiff, after which there is an opportunity for the lead plaintiff to file an amended complaint. Because the outcome of litigation is uncertain, the Company cannot predict how or when this matter will ultimately be resolved.

On October 31, 2025, another alleged stockholder of the Company filed a shareholder derivative action in the same court, styled Jones v. Markison et al., nominally on behalf of the Company and naming as defendants the current directors of the Company’s Board and the same officers named in the securities class action described in the preceding paragraph. The derivative complaint largely repeats the allegations asserted in the securities class action, and asserts claims for alleged breaches of fiduciary duties, gross mismanagement, corporate waste, unjust

24

Table of Contents

Lantheus Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

enrichment, and violation of Section 14(a) of the Exchange Act. The plaintiff seeks damages and other relief on behalf of the Company. Because the outcome of litigation is uncertain, the Company cannot predict how or when this matter will ultimately be resolved.

Technology License and Other Commitments

The Company has licensed from third parties the rights to use certain technologies in its R&D processes as well as in other products it may develop, commercialize, or sell. In accordance with the related license or sublicense agreements, the Company is contractually required to make certain future payments to these third parties contingent upon i) the achievement of regulatory, development and/or commercialization milestones and ii) future sales of specified products in the form of royalty payments. Milestone payments are generally recognized in the period in which the achievement of the underlying milestone becomes probable, which is generally the period in which it is actually achieved. Royalty payments are generally recognized in the period in which the associated revenue is recognized.

25

Table of Contents

Lantheus Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

17. Benefit Plans

Nonqualified Deferred Compensation Plan

In October 2024, the Company adopted the LDCP to provide key, highly-compensated employees and non-employee directors an additional opportunity for personal financial planning by allowing an option to defer a portion of their base salary and variable compensation each year. Under the LDCP, which is an elective nonqualified deferred compensation plan, employee participants are eligible to defer up to 80% of base salary and up to 80% of any bonus award beginning in 2025. For 2024, employee participants were not eligible to defer any base salary and could only defer up to 25% of their 2024 bonus award. Non-employee directors that are participants of the LDCP are eligible to defer up to 100% of their Board fees. Additionally, Company matching or employer contributions may be credited to the plan, although no such matching or employer contributions were made for 2024. Any matching or employer contributions cliff vest after the earlier of (i) five years, (ii) the participant reaching age 55, (iii) death, or (iv) disability. All amounts deferred or credited to a participant’s account (the “Deferred Amounts”) are held in a separate trust which was established by the Company to administer the LDCP. The LDCP assets held in trust by the Company to offset its obligation, which currently consist of COLI and could include mutual funds in future periods, are subject to the claims of the Company’s creditors in the event that the Company becomes insolvent. Consequently, the trust qualifies as a grantor trust for income tax purposes, or a Rabbi Trust (the “Trust”). Amounts deferred (and earnings on those amounts) are generally distributed following termination of employment unless the participant has elected an earlier distribution date, which may be no earlier than January 1st of the second year following the year of deferral. Vested Company matching or employer contributions (and earnings on those amounts) are generally distributed following termination of employment. Participants can elect to receive distributions in a lump sum, in annual installments over a period of not more than ten years for a qualifying distribution event (as defined in the LDCP), or in annual installments over a period of not more than five years if distributions are made prior to termination of employment.

As of September 30, 2025, assets and liabilities held by the Trust were $1.0 million and $0.9 million, respectively, and were included in other long-term assets, accrued expenses and other liabilities, and other long-term liabilities, in the Company’s consolidated balance sheets. There were no assets and liabilities held by the Trust as of December 31, 2024. Changes in the value of the LDCP assets and liabilities are charged to investment in equity securities - unrealized gain and to general and administrative expenses, respectively, in the Company’s condensed consolidated statements of operations and were de minimis for the three and nine months ended September 30, 2025.

18. Acquisitions

Acquisition of Businesses

Evergreen Theragnostics, Inc.

On April 1, 2025 (the “ Evergreen Closing Date”), the Company acquired all the issued and outstanding shares of Evergreen by means of a statutory merger of a subsidiary of the Company with and into Evergreen, with Evergreen surviving as the Company’s wholly-owned subsidiary (the “Evergreen Merger”), pursuant to the terms of the Evergreen Merger Agreement. Evergreen is a clinical-stage radiopharmaceutical company engaged in CDMO services as well as drug discovery and commercialization of proprietary products.

As consideration for the Evergreen Merger, the Company remitted an upfront payment of $276.4 million in cash. The upfront cash consideration included a $25.0 million milestone payment that was triggered prior to the Evergreen Closing Date, the cash settlement of the options and restricted stock units granted to certain Evergreen equity holders related to pre-acquisition services, which was recorded as a component of consideration transferred of $6.1 million, the settlement by the Company of the pre-existing Evergreen debt of $4.3 million, and the payment of transaction expenses paid by the Company on behalf of Evergreen of $11.6 million. In connection with the Evergreen Merger, certain equity awards that were outstanding and unvested prior to the acquisition became fully vested per terms of the merger agreement. The Company recognized $7.5 million of nonrecurring post-combination expense related to the acceleration and cash settlement of unvested historical Evergreen employee stock awards, which was recorded to operating expenses in the Company’s condensed consolidated statements of operations for the nine months ended September 30, 2025.

In the event of achievement of specified milestones, t he Company would be required to pay up to an additional $727.5 million in cash pursuant to the Evergreen Merger Agreement. The potential remaining milestone payments are accounted for as contingent consideration, the fair value of which is determined using a Monte-Carlo simulation for sales milestones and a probability-weighted DCF approach for

26

Table of Contents

Lantheus Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

development and commercialization milestones. The fair value of the total contingent consideration is included in other long-term liabilities in the Company’s condensed consolidated balance sheets at September 30, 2025.

The acquisition date fair value of the consideration transferred in the Evergreen Merger consisted of the following (in thousands):

(in thousands) |  |  |
Cash consideration |  | $ | 276,424 |
Fair value of contingent consideration |  |  | 43,042 |
Total purchase consideration |  | $ | 319,466 |

The Evergreen Merger was accounted for as an acquisition of a business under ASC 805, “Business Combinations (“ASC 805”),” which requires that assets acquired and liabilities assumed on the acquisition date be recognized at their fair values as of the acquisition date. While the Company uses its best estimates and assumptions as part of the purchase price allocation process to value the assets acquired and liabilities assumed, its estimates and assumptions are subject to refinement. Fair value estimates are based on a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact the Company’s consolidated statements of operations.

As of September 30, 2025, the purchase accounting for the Evergreen Merger has not been finalized. As additional information becomes available, the Company may further revise its preliminary purchase price allocation during the remainder of the measurement period. The following table summarizes the fair values of assets acquired and liabilities assumed as of the date of acquisition:

(in thousands) |  | Estimated Fair Value |
Assets acquired: |  |  |
Cash and cash equivalents |  | $ | 8,065 |
Accounts receivable, other(1) |  |  | 2,758 |
Prepaid expenses and other current assets |  |  | 459 |
Property, plant and equipment, net |  |  | 16,711 |
Intangibles(2) |  |  | 215,000 |
Deferred tax assets |  |  | 18,112 |
Other long-term assets |  |  | 1,424 |
Total identifiable assets acquired |  |  | 262,529 |
Liabilities assumed: |  |  |
Accounts payable |  |  | (1,964 | )
Accrued expenses and other liabilities |  |  | (754 | )
Deferred tax liabilities |  |  | (55,718 | )
Other long-term liabilities |  |  | (848 | )
Total liabilities assumed |  |  | (59,284 | )
Net assets acquired |  | $ | 203,245 |
Purchase consideration |  | $ | 319,466 |
Goodwill(3) |  | $ | 116,221 |

(1)
The value approximates the gross contractual amount of accounts receivables. The contractual amount not expected to be collected is immaterial.
(2)
Intangible assets acquired consisted of in-process research and development (“IPR&D”). The estimated fair values of the IPR&D assets were determined based on the present values of the expected cash flows to be generated by the respective underlying assets. The Company used a discount rate of 11.5% and cash flows that have been probability adjusted to reflect the risks of product commercialization, which the Company believes are appropriate and representative of market participant assumptions.
(3)
The goodwill recognized is attributable to future technologies that are not separately identifiable that could potentially add to the currently developed and pipeline products and Evergreen’s assembled workforce. Future technologies did not meet the criteria for

27

Table of Contents

Lantheus Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

recognition separately from goodwill because they are part of the future development and growth of the business. Goodwill of $116.2 million recognized in connection with the Evergreen Merger is not deductible for tax purposes.

Acquisition-related costs are not included as a component of consideration transferred but are expensed in the periods in which costs are incurred. The Company incurred $5.8 million and $23.3 million of acquisition- and integration-related costs, including legal, accounting, compensation arrangements and other related fees in the three and nine months ended September 30, 2025, respectively. These costs are recorded in operating expenses in the condensed consolidated statements of operations.

The results of operations attributable to the Evergreen Merger for the three and nine months ended September 30, 2025 were not material. Pro forma information has not been included as this acquisition did not have a material impact on the Company’s condensed consolidated statements of operations for the three and nine months ended September 30, 2025.

Life Molecular Imaging Ltd.

On July 21, 2025, Lantheus Radiopharm UK acquired the entire issued share capital of Life Molecular pursuant to the LMI Purchase Agreement with Life Medical, Life Healthcare Group Holdings Limited and Lantheus Medical as Lantheus Radiopharm UK’s guarantor (such acquisition, the “LMI Acquisition”). Life Molecular possesses an Alzheimer’s disease radiodiagnostic commercial infrastructure, research and development capabilities, and an established international footprint. The LMI Acquisition includes Neuraceq, an Alzheimer’s disease radiodiagnostic. Neuraceq is commercially approved in the United States, Canada, Europe, the United Kingdom, Switzerland, China, Japan, South Korea, Taiwan, among other markets worldwide. As consideration for the LMI Acquisition, the Company remitted an upfront payment of $355.2 million in cash to Life Medical.

In connection with the LMI Acquisition, t he Company could be required to pay up to an additional $400.0 million in potential earn-out and milestone payments as a percentage of and upon achievement of specified net sales thresholds, respectively, of Neuraceq and other pipeline assets. Additionally, the Company assumed a contingent consideration liability owed to Piramal (see Note 4, “Fair Value of Financial Instruments”), which is excluded from the computation of provisional purchase consideration.

The potential remaining earn-out and milestone payments are accounted for as contingent consideration, the fair value of which is determined using a Monte-Carlo simulation in a risk-neutral framework. The fair value of the total contingent consideration is included in other long-term liabilities in the Company’s condensed consolidated balance sheets at September 30, 2025.

The acquisition date fair value of the provisional consideration transferred in the LMI Acquisition consisted of the following:

(in thousands) |  |  |
Cash consideration |  | $ | 355,204 |
Fair value of contingent consideration |  |  | 27,000 |
Total purchase consideration |  | $ | 382,204 |

The LMI Acquisition was accounted for as an acquisition of a business under ASC 805, which requires that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. While the Company uses its best estimates and assumptions as part of the purchase price allocation process to value the assets acquired and liabilities assumed, its estimates and assumptions are subject to refinement. Fair value estimates are based on a complex series of judgments about future events and uncertainties and rely heavily on estimates and

28

Table of Contents

Lantheus Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

assumptions. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact the Company’s consolidated statements of operations.

As of September 30, 2025, the purchase accounting for the LMI Acquisition has not been finalized. As additional information becomes available, the Company may further revise its preliminary purchase price allocation during the remainder of the measurement period. The following table summarizes the fair values of assets acquired and liabilities assumed as of the date of acquisition:

(in thousands) |  | Estimated Fair Value |
Assets acquired: |  |  |
Cash and cash equivalents |  | $ | 46,193 |
Accounts receivable, other(1) |  | $ | 25,123 |
Inventory |  | $ | 1,125 |
Prepaid expenses and other current assets |  | $ | 1,974 |
Property, plant and equipment, net |  | $ | 4,979 |
Intangibles(2) |  | $ | 394,000 |
Deferred tax assets |  | $ | 15,993 |
Other long-term assets |  | $ | 11,524 |
Total identifiable assets acquired |  | $ | 500,911 |
Liabilities assumed: |  |  |
Accounts payable |  | $ | (5,715 | )
Accrued expenses and other liabilities |  | $ | (24,655 | )
Deferred tax liabilities |  | $ | (72,897 | )
Other long-term liabilities |  | $ | (79,904 | )
Total liabilities assumed |  | $ | (183,171 | )
Net assets acquired |  | $ | 317,740 |
Purchase consideration |  | $ | 382,204 |
Goodwill(3) |  | $ | 64,464 |

(1)
The value approximates the gross contractual amount of accounts receivables. The contractual amount not expected to be collected is immaterial.
(2)
Intangible assets acquired consisted of IPR&D and currently marketed products. The estimated fair values of the IPR&D and currently marketed product assets were determined based on the present values of the expected cash flows to be generated by the respective underlying assets. The Company used a discount rate of 23.5% and 23.0% for IPR&D and currently marketed products, respectively. IPR&D cash flows have been probability-adjusted to reflect the risks of technical and regulatory success of the products, which the Company believes are appropriate and representative of market participant assumptions. The Company estimates that the acquired currently marketed product asset has a useful life of 10.5 years.
(3)
The goodwill recognized is attributable to future technologies that are not separately identifiable that could potentially add to the currently developed and pipeline products and Life Molecular’s assembled workforce. Future technologies did not meet the criteria for recognition separately from goodwill because they are part of the future development and growth of the business. Goodwill of $64.5 million recognized in connection with the Life Molecular Merger is not deductible for tax purposes.

Acquisition-related costs are not included as a component of consideration transferred but are expensed in the periods in which costs are incurred. The Company incurred $22.2 million and $27.6 million of acquisition- and integration-related costs, including legal, accounting, compensation arrangements and other related fees in the three and nine months ended September 30, 2025. These costs are recorded in operating expenses in the condensed consolidated statements of operations.

The results of operations attributable to the LMI Acquisition for the three and nine months ended September 30, 2025 were not material. Pro forma information has not been included as this acquisition did not have a material impact on the Company’s condensed consolidated statements of operations for the three and nine months ended September 30, 2025.

Acquisition of Assets

Strategic Agreements with Perspective Therapeutics, Inc.

29

Table of Contents

Lantheus Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

On January 8, 2024, the Company entered into an agreement with Perspective to participate in Perspective’s next qualified financing to purchase Perspective Shares. On January 22, 2024, the Company purchased 56,342,355 Perspective Shares, representing 11.39% of the outstanding Perspective Shares, at the fair market offering price of $0.37 per share. Included within the agreement is a covenant which allows for the Company to designate one observer to Perspective’s board of directors. The observer has the option to attend any or all board meetings in a nonvoting capacity and the right to receive any board materials, except under certain instances where attorney-client privilege is necessary, where the material relates to a business or contractual relationship with the Company, to avoid bona fide conflict of interest, exposure of trade secrets or relating to a change of control transaction. The Company purchased an additional 60,431,039 Perspective Shares at a fair market purchase price of $0.95 per share as an investor in a private placement transaction on March 6, 2024, which resulted in the Company holding a cumulative 19.90% of the outstanding Perspective Shares (or 17.35% on a fully diluted basis) after giving effect to the closing of the private placement transaction. On June 14, 2024, Perspective effected a 1-for-10 reverse stock split, after which the Company held 11,677,339 shares of Perspective’s common stock. At September 30, 2025, the Company held 11,677,339 Perspective Shares, which represents approximately 16.0% of Perspective Shares outstanding. The Company holds less than 20% of the outstanding Perspective Shares and therefore does not have the ability to exercise significant influence over the operating and financial policies of Perspective because the Company’s board observer has no voting rights and there is otherwise no participation in policy-making processes, no interchange of managerial personnel, and no sharing of technology between the Company and Perspective. See Note 4, “Fair Value of Financial Instruments,” for more information on the Company’s investment in Perspective Shares.

Also effective January 8, 2024, the Company obtained certain options and rights from Perspective for an aggregate upfront payment of $28.0 million in cash. The options and rights received from Perspective that remain open are as follows:

•
An exclusive option from Perspective to negotiate for an exclusive license under the rights of Perspective and its affiliates to Perspective’s Pb212-VMT-α-NET, a clinical stage alpha therapy developed for the treatment of neuroendocrine tumors, to develop, manufacture, commercialize and otherwise exploit the VMT-α-NET Product.
•
A right to co-fund the investigational new drug application (“IND”) enabling studies for early-stage therapeutic candidates targeting prostate-specific membrane antigen and gastrin releasing peptide receptor and, prior to IND filing, a right to negotiate for an exclusive license to such candidates.

None of these options and rights have been exercised as of September 30, 2025.

Costs of IPR&D projects acquired as part of an asset acquisition that have no alternative future use are expensed when incurred, and therefore, a charge of $28.0 million was recognized in R&D expenses during the three months ended March 31, 2024.

Also effective January 8, 2024, the Company entered into an agreement with Perspective to transfer the Somerset Facility and the associated assets at the Somerset Facility for $8.0 million. The transfer of the sublease and completion of the asset sale occurred on March 1, 2024 at which time the Company had no further continuing legal obligations related to the lease. See Note 7, “Property, Plant and Equipment, Net” to these condensed consolidated financial statements for additional details.

Exclusive License for Radiopharm Theranostics Limited

On June 15, 2024, the Company entered into an agreement with Radiopharm to acquire all of Radiopharm’s rights to two licensed preclinical assets for an upfront payment of $2.0 million. The Company acquired global exclusive rights to both a leucine-rich repeat-containing protein 15 (“LRRC15”)-targeted monoclonal antibody and to a Trophoblast cell surface antigen 2 (“TROP2”)-targeted nanobody. LRRC15, which is also known as LNTH-2403, is a potential first-in-class, highly specific monoclonal antibody radio-conjugate with both Orphan Drug and Rare Pediatric Disease designations from the U.S. Food and Drug Administration for the treatment of osteosarcoma. The agent is designed to target the surrounding tumor micro-environment cells expressing the protein potentially treating a broad range of cancers. The TROP2-targeted nanobody radio-conjugate, which is also known as LNTH-2404, is designed to target TROP2, an intracellular calcium signal transducer that is overexpressed in various types of adenocarcinomas with minimal expression in normal tissues and is associated with tumor aggressiveness, poor prognosis and drug resistance.

30

Table of Contents

Lantheus Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

In connection with this acquisition, the Company assumed the underlying license agreements related to the two preclinical assets, together with their respective milestone and royalty payment obligations. The Company could pay up to an additional $20.0 million in milestone payments upon achievement of specified regulatory milestones. The Company could also pay up to an additional $6.5 million in sales milestone payments upon the achievement of specified annual commercial sales thresholds in the event the Company pursues commercialization, as well as royalty payments for commercial sales. Costs of IPR&D projects acquired as part of an asset acquisition that have no alternative future use are expensed when incurred, and therefore, a charge of $2.0 million was recognized in R&D expenses in 2024 related to the Radiopharm transaction.

During the third quarter of 2024, the Company purchased 149,625,180 Radiopharm Shares at the fair market offering price of approximately $0.03 per share, for an aggregate purchase price of approximately $5.0 million. In January 2025, the Company purchased an additional 133,333,333 Radiopharm Shares at the fair market offering price of approximately $0.04 per share, for $5.0 million in the aggregate. At September 30, 2025, the Company held 282,958,513 Radiopharm Shares, which represents approximately 12.0% of Radiopharm Shares outstanding. Since the Company holds less than 20% of the outstanding Radiopharm Shares, it does not have the ability to exercise significant influence over the operating and financial policies of Radiopharm. See Note 4, “Fair Value of Financial Instruments,” for more information on the Company’s investment in Radiopharm.

Acquisition of NAV-4694

On June 18, 2024, the Company acquired Meilleur, including its asset NAV-4694, an investigational late-stage F-18-labeled PET imaging agent that targets beta amyloids in Alzheimer’s disease. The Company determined that upon review of the Meilleur acquisition, the transaction did not meet the definition of a business combination and is therefore treated as an asset acquisition.

The Company made an upfront payment of approximately $32.9 million to the Meilleur Stockholders on June 18, 2024, and paid an additional $10.0 million in August 2024 after the successful completion of a technology transfer. The Company could pay up to an additional $43.0 million in milestone payments upon achievement of specified U.S. regulatory milestones related to NAV-4694 and $4.0 million in remaining research milestones upon achievement of specified clinical studies at academic institutions. Additionally, in May 2025, the Company paid AstraZeneca AB (“AstraZeneca”) a $10.0 million one-time, non-refundable upfront payment to reduce the future commercial royalty obligations owed to AstraZeneca, pursuant to a NAV-4694 license agreement between AstraZeneca and Meilleur.

Research revenue is derived from existing partnerships with pharmaceutical companies and academic institutions that use NAV-4694 in clinical trials. Additionally, the Company is required to pay the Meilleur Stockholders up to double-digit royalty payments for any research revenue and commercial sales.

RM2 Asset Purchase

On July 3, 2024, the Company acquired from Life Molecular th e global rights to RM2, a gastrin-releasing peptide receptor-targeting agent, including the associated novel, clinical-stage radiotherapeutic and radiodiagnostic pair, referred to as 177Lu-DOTA-RM2 and 68Ga-DOTA-RM2, for an upfront payment of $35.0 million plus a $1.0 million payment made prior to the acquisition (the “RM2 Asset Purchase”), pursuant to the Sublicense, Development and Collaboration Agreement, by and between the Company and Life Molecular, dated as of June 27, 2024 (the “RM2 Sublicense Agreement”). Pursuant to the RM2 Sublicense Agreement, the Company made a €5.0 million milestone payment related to regulatory activities, and could have paid up to an additional €127.5 million in regulatory and development milestone payments upon achievement of clinical trial thresholds and approvals in different regions, up to €280 million in net sales milestones if products were commercialized and met certain sales thresholds, and royalties on net sales of RM2.

Costs of IPR&D projects acquired as part of an asset acquisition that have no alternative future use are expensed when incurred, and therefore, charges of $5.4 million in the first quarter of 2025 and $36.0 million in the third quarter of 2024 were recognized in R&D expenses related to the RM2 Asset Purchase.

In connection with the LMI Acquisition, the RM2 Sublicense Agreement was amended to (i) reduce the contingent regulatory and development milestones by €45.0 million; (ii) assign the right to future payments from Life Molecular to its former parent, Life Medical; and (iii) eliminate certain other non-substantive rights contained in the RM2 Sublicense Agreement (the “RM2 Amendment”). The Company determined that the RM2 Amendment did not constitute settlement of a pre-existing relationship in accordance with ASC 805, and concluded that the amendment represented a modification to the RM2 Sublicense Agreement, whereby the Company did not reacquire any incremental rights or assets. Accordingly, the Company will continue to account for the RM2 Sublicense Agreement as an asset acquisition, separate from the LMI Acquisition.

31

Table of Contents

Lantheus Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

19. Segment Information

The Company operates as one business segment. The results of this operating segment are regularly reviewed by the Company’s chief operating decision maker (“CODM”), the Chief Executive Officer. The CODM does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results. In order to evaluate the reportable segment’s performance, the CODM uses net income and gross margin based on the condensed consolidated statements of operations. The CODM uses net income to monitor budget and forecast versus actual results in assessing segment performance and to evaluate income generated from segment assets in deciding how to allocate resources. The measure of segment assets is reported on the condensed consolidated balance sheets as total consolidated assets.

Significant segment expenses reviewed by the CODM include sales and marketing, general and administrative, and R&D expenses as reported in the Company’s condensed consolidated statements of operations. However, the CODM reviews R&D expenses in more detail for certain expenses related to the Company’s development of new products and clinical programs. The approximate disaggregated amounts that comprise R&D expenses regularly reviewed by the CODM are as follows:

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(in thousands) |  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Program third-party research and development expenses |  | $ | 15,453 |  |  | $ | 7,739 |  |  | $ | 32,820 |  |  | $ | 17,542 |
Other research and development expenses(1) |  |  | 32,572 |  |  |  | 16,409 |  |  |  | 97,008 |  |  |  | 115,231 |
Total research and development expenses |  | $ | 48,025 |  |  | $ | 24,148 |  |  | $ | 129,828 |  |  | $ | 132,773 |

(1)
Other R&D expenses consist of all other R&D costs incurred for the benefit of multiple R&D programs, including legal, employee costs, depreciation, information technology, other facility-bases expenses and other third-party costs.

32

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Note Regarding Forward-Looking Statements

Some of the statements contained in this Quarterly Report on Form 10-Q (“Form 10-Q”) are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements, including, in particular, statements about our plans, strategies, prospects and industry estimates, are subject to risks and uncertainties. These statements identify prospective information and can generally be identified by words such as “anticipates,” “believes,” “can,” “commitment,” “could,” “designed,” “estimates,” “expects,” “generate,” “impact,” “increasing,” “hopes,” “intends,” “launch,” “likely,” “long-term,” “maintain,” “may,” “pipeline,” “plans,” “potential,” “predict,” “remain,” “seek,” “should,” “sustain,” “target,” “will,” “would” and similar expressions, or by express or implied discussions regarding potential or pending acquisitions, dispositions, collaborations, development and commercialization plans described in this Form 10-Q, or regarding potential future revenues and expenses from such acquisitions, collaborations, development and commercialization plans. Examples of forward-looking statements include statements we make relating to our outlook and expectations including, without limitation, in connection with: (i) continued market expansion and penetration for our established commercial products, particularly PYLARIFY, DEFINITY and Neuraceq, in a competitive environment and our ability to clinically and commercially differentiate our products; (ii) our ability to have third parties manufacture our products and our ability to manufacture DEFINITY in our in-house manufacturing facility, in amounts and at the times needed; (iii) the availability of raw materials, key components, and equipment, either used in the production of our products and product candidates, or by healthcare professionals (“HCPs”) of our products and product candidates, including, but not limited to positron emission tomography (“PET”) scanners for PYLARIFY, Neuraceq, MK-6240 and NAV-4694; (iv) our ability to obtain U.S. Food and Drug Administration (“FDA”) approval for our new formulation of our F-18 prostate-specific membrane antigen (“PSMA”) PET imaging agent, to complete the technology transfer across our PET manufacturing facilities (“PMF”) network for such new formulation, and to obtain adequate coding, coverage and payment, including transitional pass-through payment status (“TPT Status”), for such new formulation; (v) our ability to satisfy our obligations under our existing clinical development partnerships using MK-6240 or NAV-4694 as a research tool and under the license agreements through which we have rights to MK-6240 and NAV-4694, and to further develop and commercialize MK-6240 and NAV-4694 as approved products; (vi) our ability to successfully integrate acquisitions, including of Life Molecular and Evergreen, including the potential for unforeseen expenses related to integration activities, the accuracy of our financial models, the potential for unforeseen liabilities within those businesses, the ability to integrate disparate information technology systems, retain key talent and create a merged corporate culture that successfully realizes the full potential of the combined organization; (vii) our ability to complete the sale of our single-photon emission computerized tomography (“SPECT”) business to SHINE Technologies, LLC (“SHINE”), a wholly-owned subsidiary of Illuminated Holdings, Inc. on the proposed terms and on the anticipated timeline, or at all, including risks and uncertainties related to securing the necessary regulatory approvals and satisfaction of other closing conditions to consummate the transaction, unforeseen expenses related to the divestiture, and failure to realize the expected benefits of the transaction; (viii) our ability to obtain FDA approval for LNTH-2501, our investigational kit for the preparation of Gallium-68 edotreotide Injection, which may be used in conjunction with a PET scan to stage and localize gastroenteropancreatic neuroendocrine tumors in adult and pediatric patients, and approval for PNT2003, and to be successful in the patent litigation associated with PNT2003; (ix) the cost, efforts and timing for clinical development, regulatory approval, adequate coding, coverage and payment and successful commercialization of our product candidates and new clinical applications and territories for our products, in each case, that we or our strategic partners may undertake; (x) our ability to identify opportunities to collaborate with strategic partners and to acquire or in-license additional diagnostic and therapeutic product opportunities in oncology, neurology and other strategic areas and continue to grow and advance our pipeline of products; and (xi) the effect that changes to management, including turnover in our leadership and senior management team, could have on our business.

Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, such statements are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. These statements are neither statements of historical fact nor guarantees or assurances of future performance. The matters referred to in the forward-looking statements contained in this Form 10-Q may not in fact occur. We caution you, therefore, against relying on any of these forward-looking statements. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K (“Form 10-K”) for the year ended December 31, 2024, and in Part II, Item 1A. “Risk Factors” in this Form 10-Q.

Any forward-looking statement made by us in this Form 10-Q speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

33

Table of Contents

Available Information

Our global Internet site is www.lantheus.com. We routinely make available important information, including copies of our Form 10-K, Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after those reports are electronically filed with, or furnished to, the Securities and Exchange Commission (“SEC”), free of charge on our website at investor.lantheus.com. We recognize our website as a key channel of distribution to reach public investors and as a means of disclosing material non-public information to comply with our disclosure obligations under SEC Regulation FD. Information contained on our website shall not be deemed incorporated into, or to be part of this Form 10-Q, and any website references are not intended to be made through active hyperlinks.

Our reports filed with, or furnished to, the SEC are also available on the SEC’s website at www.sec.gov, and for Form 10-Ks and Form 10-Qs, in an Inline Extensible Business Reporting Language (“iXBRL”) format. iXBRL is an electronic coding language used to create interactive financial statement data over the Internet. The information on our website is neither part of nor incorporated by reference into this Form 10-Q.

The following discussion and analysis of our financial condition and results of operations should be read together with the condensed consolidated financial statements and the related notes included in Item 1 of this Form 10-Q as well as the other factors described in Part I, Item 1A. “Risk Factors” in our Form 10-K for the year ended December 31, 2024, and in Part II, Item 1A. “Risk Factors” in this Form 10-Q.

Overview

Our Business

We are the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes. We classify our revenues into three product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Our leading Radiopharmaceutical Oncology products help HCPs Find, Fight and Follow cancer. Our leading Precision Diagnostic products assist HCPs to Find and Follow diseases. Our Strategic Partnerships include biomarkers and digital solutions in support of our partners’ therapeutic development, out-licensing agreements for non-core assets and optimization of our assets geographically. We are headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Switzerland, Sweden and the United Kingdom.

Our commercial products are used by cardiologists, internal medicine physicians, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists working in a variety of clinical settings. We believe that our diagnostic products provide information that enables HCPs to better detect and characterize, or rule out, disease, with the potential to achieve better patient outcomes, reduce patient risk, and limit overall costs.

We produce and market our products throughout the United States (the “U.S.”), selling primarily to hospitals, independent diagnostic testing facilities, and radiopharmacies. We generally sell our products outside the U.S. through a combination of direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America, and South America.

Recent Developments

We continue to execute on our strategy to evolve into a fully integrated radiopharmaceutical company, supported by our increasingly diversified portfolio and our targeted initiatives to expand our pipeline, commercial, development and manufacturing capabilities. Over the past year, we announced multiple strategic transactions, which furthered our goal to focus on new markets and expand and diversify our capabilities and development pipeline with complementary assets. Some of our recent developments include the following:

Leadership Transition Plan

On November 6, 2025, we announced that Brian Markison, our Chief Executive Officer (“CEO”), notified us that he will retire from the Company effective December 31, 2025 (the “Effective Date”). In connection with his retirement, Mr. Markison will also resign from our Board of Directors (“Board”) on the Effective Date. We also announced that Mary Anne Heino, the Chair of our Board, has been appointed to serve as our Executive Chair effective November 7, 2025 (the “Appointment Date”) and will serve as our principal executive officer as of the Appointment Date. Following Mr. Markison’s retirement at the end of the year, Ms. Heino will lead the Company as interim CEO until such

34

Table of Contents

time as the Board completes the comprehensive search process that it initiated to identify and appoint the Company’s next CEO. Mr. Markison has agreed to serve as a strategic advisor to the Company through at least March 31, 2026.

Separately, we announced that Paul Blanchfield, our President, has accepted a role at another company and is leaving the Company. In addition, Amanda Morgan will return from leave and continue in her role as Chief Commercial Officer, reporting directly to Ms. Heino.

Grant of Prescription Drug User Fee Act (“PDUFA”) Date for LNTH-2501

On October 30, 2025, we announced that the FDA had established a PDUFA date for LNTH-2501. LNTH-2501 is a diagnostic kit for the preparation of Gallium-68 edotreotide Injection, indicated for use with PET imaging for localization of somatostatin receptor-positive neuroendocrine tumors in adult and pediatric patients. The FDA has set a PDUFA target action date of March 29, 2026.

Acceptance of New Drug Application for MK-6240

On October 27, 2025, we announced that the FDA had accepted our New Drug Application (“NDA”) for MK-6240, our investigational F-18 tau-targeted PET imaging agent for the detection of tau neurofibrillary tangle pathology in patients with cognitive impairment being evaluated for Alzheimer’s disease. During the second quarter of 2025, we announced that MK-6240 successfully met its co-primary endpoints in two pivotal studies assessing its sensitivity and specificity. This data from these two studies supported our NDA submission to the FDA. MK-6240 previously received Fast Track designation from the FDA for its potential to address an unmet medical need in Alzheimer’s disease diagnostics. The FDA has set a PDUFA target action date of August 13, 2026.

Exclusive License for Prostate Cancer Imaging Agent Piflufolastat F-18 in Japan

On September 24, 2025, we announced an exclusive licensing agreement for GE HealthCare Limited (“GE HealthCare”) to develop, manufacture, and commercialize Lantheus’ piflufolastat F-18 PET imaging agent (marketed in the U.S. as PYLARIFY) in Japan for prostate cancer diagnostics and companion diagnostic use. Under the terms of the agreement, GE HealthCare will pay us an upfront license fee, development milestones and tiered royalties based on product sales in Japan.

Acceptance of NDA for PSMA PET Imaging Agent

On August 6, 2025, we announced that the FDA had accepted our NDA for a new formulation of our F-18 PSMA PET imaging agent, filed by our subsidiary Aphelion, and that the FDA set a PDUFA target action date of March 6, 2026. The new formulation was designed to optimize the manufacturing process and potentially increase the batch size of our F-18 PSMA PET imaging agent by approximately 50%. If the NDA is approved, we plan to work closely with clinicians and PMF sites to ensure a smooth rollout of the new formulation, including providing clear guidance on ordering, handling, and clinical use to support continuity of care for patients, and we plan to apply for reimbursement from the Centers for Medicare and Medicaid Services (“CMS”) for the new formulation, including obtaining three years of TPT Status.

Share Repurchase Program

On July 31, 2025, our Board authorized a program to repurchase up to $400.0 million of shares of our common stock through December 31, 2027 (the “2025 Program”). The 2025 Program replaces the program authorized by the Board in November 2024 to repurchase up to $250 million of our common stock during the twelve months following the authorization (the “2024 Program”), including the remaining unused amounts under the 2024 Program, and authorizes us to purchase shares of our common stock from time to time via open market purchases at prevailing market prices, in privately negotiated transactions, block trades, or pursuant to trades intending to comply with Rule 10b5-1 under the Exchange Act or through other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations. The timing, manner, price and amount of any repurchase will be subject to the discretion of our Management. The 2025 Program does not obligate us to acquire any particular amount of its common stock, and we may suspend or discontinue the 2025 Program at any time. We repurchased 1.8 million shares for approximately $100.0 million under the 2025 Program, in the three months ended September 30, 2025 .

Acquisition of Life Molecular Imaging Ltd.

On July 21, 2025, we acquired Life Molecular, pursuant to the terms of the Sale and Purchase Agreement with Life Medical Group Limited (“Life Medical”) and Life Healthcare Group Holdings Limited (the “Sale and Purchase Agreement” and, such acquisition, the “LMI Acquisition”). Life Molecular is dedicated to advancing novel PET radiopharmaceutical diagnostics and is based in Berlin, Germany. Life Molecular possesses an Alzheimer’s disease radiodiagnostic commercial infrastructure, research and development capabilities, and an established international footprint. The LMI Acquisition includes Neuraceq, an Alzheimer’s disease radiodiagnostic. Neuraceq is commercially approved in the United States, Canada, Europe, the United Kingdom, Switzerland, China, Japan, South Korea, and Taiwan, among other markets worldwide.

35

Table of Contents

As consideration for the LMI Acquisition, we remitted an upfront payment of $355.2 million in cash, and could be required to pay up to an additional $400.0 million in potential earn-out and milestone payments. Additionally, we assumed a contingent consideration liability owed to Piramal Holdings SA (“Piramal”), pursuant to a Securities Purchase Agreement between Piramal and Life Molecular.

Previously, on July 3, 2024,we acquired from Life Molecular the global rights to RM2, its clinical stage, gastrin-releasing peptide receptor (“GRPR”)-targeting agent, including the associated novel, clinical-stage radiotherapeutic and radiodiagnostic pair, previously referred to as 177Lu-DOTA-RM2 and 68Ga-DOTA-RM2 (and which we now refer to as LNTH-2402 and LNTH-2401, respectively), for an upfront payment of $35.0 million plus a $1.0 million payment made prior to the acquisition (the “RM2 Asset Purchase”), pursuant to the Sublicense, Development and Collaboration Agreement, by and between us and Life Molecular, dated as of June 27, 2024 (the “RM2 Sublicense Agreement”). In addition and pursuant to the RM2 Sublicense Agreement, we paid a €5.0 million milestone payment related to regulatory activities in March 2025.

In connection with the LMI Acquisition, the RM2 Sublicense Agreement was amended to (i) reduce the contingent regulatory and development milestones by €45.0 million; (ii) assign the right to future payments from Life Molecular to its former parent, Life Medical; and (iii) eliminate certain other non-substantive rights contained in the RM2 Sublicense Agreement (the “RM2 Amendment”). We determined that the RM2 Amendment did not constitute settlement of a pre-existing relationship in accordance with Accounting Standards Codification 805, “Business Combinations”, and concluded that the amendment represented a modification to the RM2 Sublicense Agreement, whereby we did not reacquire any incremental rights or assets. Accordingly, we will continue to account for the RM2 Sublicense Agreement as an asset acquisition, separate from the LMI Acquisition. We may be required to pay Life Medical additional milestone payments and royalties in connection with the RM2 Asset Purchase. GRPR is a member of the bombesin G protein-coupled receptor family, which has been found to be overexpressed in multiple cancers, including prostate, breast and lung. First-in-human dosimetry showed a favorable safety and dosimetry profile and confirmed preclinical data demonstrating dose-dependent efficacy of LNTH-2402. We intend to submit investigational new drug applications in support of a Phase 1b/2 clinical trial with the LNTH-2401/LNTH-2402 theranostic pair in prostate cancer patients in the fourth quarter of 2025.

For more information on the acquisition of the global rights to RM2, see Note 18, “Acquisitions” in our condensed consolidated financial statements herein.

Acquisition of Evergreen Theragnostics, Inc.

On April 1, 2025, we acquired all the issued and outstanding shares of Evergreen by means of a statutory merger of our subsidiary with and into Evergreen, with Evergreen surviving as our wholly-owned subsidiary (the “Evergreen Merger”), pursuant to the terms of the Agreement and Plan of Merger (the “Evergreen Merger Agreement”) with Evergreen and Shareholder Representative Services LLC. Evergreen is a clinical-stage radiopharmaceutical company engaged in contract development and manufacturing services as well as drug discovery and commercialization of proprietary products.

As consideration for the Evergreen Merger, we remitted an upfront payment of $276.4 million in cash. In the event of achievement of specified milestones, we would be required to pay up to an additional $727.5 million in cash, which may be adjusted pursuant to the Evergreen Merger Agreement, as described therein.

For more information, see Note 18, “Acquisitions” in our condensed consolidated financial statements herein.

Sale of SPECT business

On May 1, 2025, we entered into a definitive agreement to sell our SPECT business to SHINE, a wholly-owned subsidiary of Illuminated Holdings, Inc. Under the terms of the agreement, SHINE will acquire the assets and liabilities associated with our SPECT business, including its diagnostic agents (TechneLite, NEUROLITE, Xenon Xe-133 Gas, and Cardiolite), the portion of the North Billerica, Massachusetts campus that manufactures our SPECT products and the SPECT-related Canadian operations. The transaction allows us to focus on growing our commercial portfolio of innovative PET radiodiagnostics and microbubbles, while advancing our pipeline of radiopharmaceuticals. The transaction is subject to customary closing conditions and is expected to be completed around the end of the calendar year.

Acquisition of NAV-4694

On June 18, 2024, we acquired Meilleur, including its asset NAV-4694, an investigational late-stage F-18-labeled PET imaging agent that targets beta amyloids in Alzheimer’s disease. Under the terms of the agreement, we paid the stockholders of Meilleur (“Meilleur Stockholders”) an upfront payment of $32.9 million and paid an additional $10.0 million in August 2024 after the successful completion of a technology transfer. We could pay additional milestone payments upon achievement of specified U.S. regulatory and commercial milestones related to NAV-4694. We will also be required to pay a double-digit royalty on research revenue and commercial sales. Research revenue is derived from partnerships with pharmaceutical companies and academic institutions that use NAV-4694 in clinical trials. NAV-4694 is

36

Table of Contents

currently in Phase 3 development and is also being used in academic and industry sponsored clinical trials. We expect to submit an NDA for NAV-4694 in 2026. In May 2025, we paid AstraZeneca AB (“AstraZeneca”), a $10.0 million one-time, non-refundable upfront payment to reduce the future royalty obligations owed to AstraZeneca, pursuant to a license agreement between AstraZeneca and Meilleur related to NAV-4694.

For more information, see Note 18, “Acquisitions” in our condensed consolidated financial statements herein.

Exclusive License for Radiopharm Theranostics Limited

On June 15, 2024, we entered into an agreement with Radiopharm to acquire all of Radiopharm’s rights to two licensed preclinical assets for an upfront payment of $2.0 million (the “Radiopharm Asset Purchase”). We acquired global, exclusive rights to both a leucine-rich repeat-containing protein 15 (“LRRC15”)-targeted monoclonal antibody, which we refer to as LNTH-2403, and a Trophoblast cell surface antigen 2 targeted nanobody, which we refer to as LNTH-2404, each of which is a preclinical therapeutic candidate. LNTH-2403 is our pre-clinical therapeutic targeting LRRC15, which is strongly expressed in multiple malignancies, including head and neck, breast, lung, and pancreatic cancers. We are initially focusing on osteosarcoma, for which the FDA has granted both Orphan Drug and Rare Pediatric Disease designations. Osteosarcoma is a malignant bone tumor that primarily develops in children and teenagers. Osteosarcoma is the most common childhood bone cancer, though it is still rare, with around 1,000 new cases diagnosed annually in the U.S.

In connection with this acquisition, we assumed the underlying license agreements related to the two preclinical assets, together with their respective milestone and royalty payment obligations.

During the third quarter of 2024, we purchased 149,625,180 shares of Radiopharm common stock (“Radiopharm Shares”) at the fair market offering price of approximately $0.03 per share, for an aggregate purchase price of approximately $5.0 million. In January 2025, we purchased an additional 133,333,333 Radiopharm Shares at the fair market price of approximately $0.04, for an aggregate purchase price of approximately $5.0 million. At September 30, 2025, we held 282,958,513 Radiopharm Shares.

For more information, see Note 18, “Acquisitions” and Note 4, “Fair Value of Financial Instruments” in our condensed consolidated financial statements herein.

Strategic Agreements with Perspective Therapeutics, Inc.

On January 8, 2024, we entered into multiple strategic agreements with Perspective, a radiopharmaceutical company that is pursuing advanced treatment applications for cancers throughout the body. Under the agreements, we obtained an option to exclusively license Perspective’s Pb212-VMT-α-NET, a clinical stage alpha therapy in development for the treatment of neuroendocrine tumors, and an option to co-develop certain early-stage therapeutic candidates targeting prostate cancer using Perspective’s innovative platform technology for an aggregate upfront payment of $28.0 million in cash.

On January 22, 2024, we purchased 56,342,355 shares of Perspective’s common stock (“Perspective Shares”) at a purchase price of $0.37 per share in a private placement transaction for approximately $20.8 million in cash. We were also granted certain pro rata participation rights to maintain our ownership position in Perspective in the event that Perspective makes any public or non-public offering of any equity or voting securities, subject to certain exceptions.

On March 1, 2024, we transferred the fixed assets and associated lease for the property at 110 Clyde Rd., Somerset, New Jersey (the “Somerset Facility”) to Perspective, and the parties entered into a transition services arrangement pursuant to which we provided Perspective certain services relating to final disposal of radioactive waste and certain other related services.

On March 6, 2024, we purchased an additional 60,431,039 Perspective Shares at a price of $0.95 per share. The total consideration for this additional purchase was approximately $57.4 million, resulting in Lantheus Alpha holding approximately 19.90% of the outstanding Perspective Shares (or 17.35% on a fully diluted basis) as of March 6, 2024.

On June 14, 2024, Perspective effected a 1-for-10 reverse stock split, after which we held 11,677,339 Perspective Shares.

For more information, see Note 18, “Acquisitions” in our condensed consolidated financial statements herein.

Amendment of Credit Facility

In December 2024, we amended our five-year revolving credit facility (as amended, the “2022 Revolving Facility”). The amendment, among other things, extended the maturity date from December 2, 2027 to December 19, 2029, increased the 2022 Revolving Facility from $350.0 million to $750.0 million and increased the additional amount that we may request to add to the increased revolving commitment by $350.0 million. The amendment also, among other things, (i) reduces the ranges of margins based on our Total Net Leverage Ratio (as defined

37

Table of Contents

in the 2022 Revolving Facility) used to calculate interest for the revolving loans and (ii) reduces the maximum unused commitment fee from 0.35% per annum to 0.30% per annum.

Key Factors Affecting Our Results

Our business and financial performance have been, and continue to be, impacted by the following:

PYLARIFY and PSMA PET Revenue

PYLARIFY, an F-18-labeled PET imaging agent targeting PSMA, was approved by the FDA in May 2021 and commercially launched in the U.S. in June 2021. PYLARIFY is indicated for PET imaging of PSMA-positive lesions in patients with prostate cancer with suspected metastasis who are candidates for initial definitive therapy and in patients with suspected recurrence based on elevated prostate-specific antigen levels. PYLARIFY is available through a diverse, multi-partner network of PMFs, including both commercial and academic partners.

The successful growth of PYLARIFY is dependent on our ability to maintain PYLARIFY as the most utilized PSMA PET imaging agent in an increasingly competitive space. PYLARIFY’s competition includes three Gallium-68-based PSMA imaging agents, an F-18-based PSMA imaging agent, and other non-PSMA-based imaging agents commonly referred to as conventional imaging. The potential for future generic entrants to the market due to the expiry of PYLARIFY’s new chemical entity exclusivity period in 2026 could also generate increased competition for PYLARIFY. We will continue to make investments necessary to drive PYLARIFY awareness and adoption.

Growth and revenue contribution from PYLARIFY will also depend on our ability to clinically differentiate PYLARIFY from competitive products so that customers continue to choose PSMA PET with PYLARIFY for appropriate patients because of its clinical differentiation and despite the loss of TPT Status and the related changes to Medicare fee-for-service (“FFS”) hospital outpatient payment. Our Healthcare Procedure Coding System code, which enables streamlined billing, went into effect as of January 1, 2022. In addition, from January 1, 2022 to December 31, 2024, PYLARIFY had TPT Status from CMS in the hospital outpatient setting, enabling traditional Medicare FFS to provide separate payment for PYLARIFY in addition to the payment for the PET/computed tomography procedure in that setting. In November 2024, CMS released the final rule for its calendar year 2025 Medicare Hospital Outpatient Prospective Payment System (the “CMS 2025 OPPS Rule”), which recognized the value and need for broad access to diagnostic radiopharmaceuticals. The CMS 2025 OPPS Rule provided separate payment for those diagnostic radiopharmaceuticals with per day costs greater than $630 based on their mean unit cost (“MUC”) for the approximately 20% of patients with traditional Medicare FFS insurance coverage who are treated in the hospital outpatient setting. Effective January 1, 2025, CMS began maintaining separate payment for PYLARIFY based on MUC in the hospital outpatient setting, which is lower than payments based on the average selling price that were made during TPT Status. Although PYLARIFY continues to be paid separately, other competitive PSMA PET imaging agents continue to have TPT Status after December 31, 2024, and hospital use of those products, for the approximately 20% of patients with traditional Medicare FFS in the hospital outpatient setting, generally will be paid separately based on ASP plus six percent rather than on MUC. In July 2025, CMS released the proposed rule for its calendar year 2026 Medicare Hospital Outpatient Prospective Payment System (the “CMS 2026 Proposed OPPS Rule”). In the CMS 2026 Proposed OPPS Rule, CMS stated that it continues to believe Average Sales Price (“ASP”) data from manufacturers generally is insufficient for payment and that it is seeking comments on how CMS can ensure more consistent, validated, and universal reporting. We have repeatedly engaged CMS on methodology for reporting ASP, and we will continue to work with coalition partners and CMS to support using ASP to calculate payment for diagnostic radiopharmaceuticals in future years similar to the way Medicare Outpatient Prospective Payment System (“OPPS”) currently pays for other drugs, biologics, and therapeutic radiopharmaceuticals.

Our plan to successfully grow our PSMA PET franchise includes obtaining approval for and commercializing a new formulation of our F-18 PSMA PET imaging agent, conveying our product’s commercial and clinical value, negotiating and realizing the benefits from strategic contracts with customers in the U.S., expanding PSMA PET in appropriate new patient populations, and through strategic partnerships and collaborations, including outside of the U.S. On August 6, 2025, we announced that the FDA has accepted our NDA for a new formulation of our F-18 PSMA PET imaging agent. Internationally, we previously licensed exclusive rights to Curium Pharma (“Curium”) to develop and commercialize piflufolastat F-18 in Europe, where it is being commercialized in the European Union under the brand name PYLCLARI. In September 2025, we entered into an exclusive licensing agreement for GE HealthCare to develop, manufacture, and commercialize piflufolastat F-18 in Japan for prostate cancer diagnostics and companion diagnostic use. We have also entered into strategic collaborations with pharmaceutical companies for the use of PYLARIFY in connection with the development of PSMA-targeted therapeutics. Additional information on these collaborations are described further under Part I, Item 1. “Business - Strategic Partnerships and Other Revenue – Oncology” in our Form 10-K for the year ended December 31, 2024.

DEFINITY Revenue

We believe we will be able to increase use of DEFINITY through continued education of physicians and HCPs about the benefits of ultrasound enhancing agents in suboptimal echocardiograms. The U.S. market currently has three echocardiography ultrasound enhancing

38

Table of Contents

agents approved by the FDA; we estimate that DEFINITY will continue to hold at least an 80% share of the U.S. segment for ultrasound enhancing agents in echocardiography procedures.

As we continue to grow our microbubble platform, our activities include:

•
Expansion of Label – In March 2024, we received FDA approval for our supplemental NDA for the use of DEFINITY in pediatric patients with suboptimal echocardiograms. The FDA decision was based on usage data from three pediatric clinical trials conducted with DEFINITY.
•
Patents – We continue to actively pursue additional patents in connection with DEFINITY, both in the U.S. and internationally. In the U.S. for DEFINITY, we have Orange Book-listed method-of-use patents, as well as additional manufacturing patents that are not Orange Book-listed.

Neuraceq Revenue

Neuraceq, an F-18 labeled PET imaging agent that binds selectively to beta-amyloid plaques in the brain, was approved by the FDA in 2014. Neuraceq is a radioactive diagnostic agent indicated for PET imaging of the brain to estimate amyloid beta neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease and other causes of cognitive decline, and selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutics products. Additional indications of Neuraceq were approved in 2025 to include selection of patients for amyloid-targeting therapies and quantitative PET analysis.

We believe future growth in Neuraceq revenue will depend on: (i) increased adoption and utilization of beta-amyloid PET and anti-amyloid therapeutics; (ii) increased educational efforts to drive awareness and adoption; (iii) increased utilization based on the updated Neuraceq package insert providing for use in patient selection for anti-amyloid therapies; and (iv) our ability to quantify amyloid beta neuritic plaque levels. Additionally, Neuraceq revenue growth depends on expanded geographical access to Neuraceq, which in turn depends on our ability to increase Neuraceq manufacturing capacity at existing manufacturing sites, and enhance utilization at organic and new contracted imaging centers.

Expansion of Strategic Partnerships and Other Revenue

We continue to seek ways to further increase the overall value of our portfolio of products and product candidates. We are evaluating a number of different opportunities to collaborate, in-license or acquire additional products, product candidates, businesses and technologies to drive our future growth. In particular, with respect to our Strategic Partnerships and Other Revenue category, we are focused on radiopharmaceutical diagnostic and therapeutic product opportunities in oncology, neurology, and other strategic areas that will complement our existing portfolio.

Our Strategic Partnerships and Other Revenue category includes our Strategic Partnerships, Digital Solutions, Biomarker Solutions and contract development and manufacturing organization (“CDMO”) services and is focused on enabling precision medicine with biomarkers, digital solutions and CDMO services.

•
Strategic Partnerships – We seek to monetize our assets through our Strategic Partnerships business, which includes biomarkers and digital solutions in support of our partners’ therapeutic development, out-licensing agreements for non-core assets and optimization of our assets geographically. For example, we licensed the commercialization rights for piflufolastat F-18 in Europe to Curium, where it is now commercialized under the brand name PYLCLARI, for flurpiridaz, which received FDA approval in 2024 under the brand name Flyrcado, to GE HealthCare for coronary artery disease diagnosis, and for piflufolastat F-18 in Japan to GE HealthCare for prostate cancer diagnostics and companion diagnostic use.
•
Digital Solutions – Our Digital Solutions are designed to enhance imaging value and the throughput, reproducibility and reliability of image analysis, as well as to inform treatment selection and response to therapy. We offer our Digital Solutions to HCPs for clinical use and to pharmaceutical companies for development purposes, and in some cases, we also obtain clinical imaging data that we may use to further develop artificial intelligence solutions. Our Digital Solutions include artificial intelligence medical device software, such as aPROMISE and Automated Bone Scan Index, both of which are FDA cleared and received a European Conformity Marking.
•
Biomarker Solutions – We use our Biomarker Solutions business to offer our Biomarker and Microbubble Platforms to pharmaceutical companies to support their research and development (“R&D”) of therapeutic drugs and devices. The strategic goal of our Biomarker Solutions business is to gain early access to innovation, de-risk the development, generate data, embed our technologies in the clinical ecosystem and establish the clinical utility of product candidates and research tools in our pipeline. Our biomarkers are intended to support patient selection and the monitoring of disease progression. MK-6240 is a widely utilized tau

39

Table of Contents

PET tracer in Alzheimer’s disease studies with over 100 ongoing academic and industry sponsored clinical trials, many for late-stage therapeutic candidates. NAV-4694 is also being used in academic and industry sponsored clinical trials.
•
CDMO – Through the Evergreen Merger, we acquired a Good Manufacturing Practices certified radiopharmaceutical manufacturing facility that provides end-to-end manufacturing services for alpha- and beta-emitting radiopharmaceuticals, from early clinical development through commercial supply. Our CDMO offerings include process and analytical method development, technology transfer, process validation, production of clinical and commercial batches, release and stability testing, and integrated quality oversight under fully electronic Quality Management and Laboratory Information Management Systems. In addition, we coordinate raw material sourcing, just-in-time logistics, and packaging to facilitate timely delivery of finished product globally. Our CDMO’s strategic location near major transportation hubs enables reliable distribution for short half-life products and supports customers across diagnostic and therapeutic indications.

Inventory Supply & Third-Party Suppliers

We obtain a substantial portion of our imaging agents from third-party suppliers. Although we manufacture DEFINITY at our facility in North Billerica, Massachusetts, Jubilant HollisterStier (“JHS”) is currently a significant supplier of DEFINITY and our sole source manufacturer of NEUROLITE, CARDIOLITE and evacuation vials, the latter being an ancillary component for our TechneLite generators. Our manufacturing and supply agreement with JHS (the “JHS MSA”) runs through December 31, 2027 and can be further extended by mutual agreement of the parties. The JHS MSA requires us to purchase from JHS specified percentages of our total requirements for DEFINITY, as well as specified quantities of NEUROLITE, CARDIOLITE and evacuation vial products, each year during the contract term. Either party can terminate the JHS MSA upon the occurrence of certain events, including the material breach or bankruptcy of the other party.

Radiopharmaceuticals are decaying radioisotopes with half-lives ranging from a few hours to several days. Radiopharmaceutical finished goods, such as doses of PYLARIFY and Neuraceq, cannot be kept in inventory because of their limited shelf lives and are subject to just-in-time manufacturing, processing and distribution, which takes place at multiple PMF manufacturing partner sites that produce and deliver doses for us across the U.S. Our TechneLite generators and Xenon-133 are manufactured at our facilities in North Billerica, Massachusetts.

Research and Development Expenses

To ensure we remain the leading radiopharmaceutical-focused company, we have historically made and will continue to make substantial investments in new product development and lifecycle management for existing products, including:

•
For PYLARIFY, we are conducting a clinical trial to determine whether PYLARIFY can detect the presence or absence of additional prostate cancer lesions in patients with favorable intermediate-risk prostate cancer, as well as how it may change the patient’s intended management. We are also conducting a study using piflufolastat to diagnose and describe the extent of clear cell renal carcinoma in patients.
•
For our PSMA PET franchise, we developed a new formulation of our F-18 PSMA PET imaging agent and filed an NDA, which was accepted by the FDA. The new formulation was designed to optimize the manufacturing process and potentially increase the batch size of our F-18 PSMA PET imaging agent by approximately 50%.
•
For PNT2002 and PNT2003, we were granted a license to exclusive worldwide rights (excluding certain countries) for $260.0 million in upfront payments during the fourth quarter of 2022 and will potentially make additional payments as described below. We also filed an Abbreviated New Drug Application (“ANDA”) for PNT2003 as described further in the section entitled “Exclusive License for PNT2002 and PNT2003” in Part I, Item 1. “Business - Other Notable Transactions” of our Form 10-K for the year ended December 31, 2024.
•
For LNTH-2501, we acquired the rights to the investigational asset through our acquisition of Evergreen. The FDA established a PDUFA target action date for LNTH-2501 of March 29, 2026. The application for approval of LNTH-2501 was submitted under FDA’s 505(b)(2) pathway.
•
For MK-6240, we acquired the right to the investigational asset for an upfront payment of $35.3 million in February 2023 and an additional $10.0 million in May 2023 upon the successful completion of a technology transfer and will potentially make additional milestone and royalty payments. In 2024, we held a pre-NDA meeting with the FDA, and during the second quarter of 2025, we announced that MK-6240 successfully met its co-primary endpoints in two pivotal studies assessing its sensitivity and specificity. The data from these two studies support an NDA submission to the FDA that we filed during the third quarter of 2025. The FDA accepted our NDA and set a PDUFA target action date of August 13, 2026.
•
For NAV-4694, we acquired the rights to the investigational asset for an upfront payment of $32.9 million in June 2024 and an additional $10.0 million in August 2024 upon the successful completion of a technology transfer and will potentially make

40

Table of Contents

additional milestone and royalty payments. We intend to submit an NDA for NAV-4694 in 2026. In May 2025, we paid AstraZeneca a $10.0 million one-time, non-refundable upfront payment to reduce the future royalty obligations owed to AstraZeneca, pursuant to a license agreement between AstraZeneca and Meilleur related to NAV-4694.
•
For LNTH-2515 (florbetaben F18 injection) is approved in the US and certain other countries for a different indication and is commercialized under the brand name Neuraceq, The FDA has granted Fast Track designation for the development of LNTH-2515 imaging for the diagnosis of amyloid light chain and transthyretin amyloid cardiomyopathy cardiac amyloidosis.
•
For LNTH-1363S, in collaboration with Ratio Therapeutics LLC (previously NoriaTherapeutics Inc.), we completed a Phase 1 study to evaluate the pharmacokinetics, biodistribution, and radiation dosimetry in adult healthy volunteers. We initiated a Phase 1/2a study in patients in 2024.
•
For RM2, we acquired global rights for an upfront payment of $35.0 million plus a $1.0 million payment made prior to the acquisition, paid a $5.4 million milestone payment related to regulatory activities, and could potentially make additional milestone and royalty payments in the future. We plan to initiate a Phase 1b/2 study in prostate cancer patients in 2026.
•
For LNTH-2403 and LNTH-2404, we acquired the rights to the preclinical assets and the underlying license agreements for $2.0 million and will potentially make additional milestone and royalty payments.

See Note 18, “Acquisitions” in our condensed consolidated financial statements herein for additional information on potential milestone and royalty payments related to the product candidates listed above.

Our investments in these additional clinical activities and lifecycle management opportunities will increase our operating expenses and impact our results of operations and cash flow, and we can give no assurances as to whether any of these clinical development candidates or lifecycle management opportunities will be successful.

PNT2002

Under the terms of the PNT2002 License Agreement, we paid POINT Biopharma Global Inc. (“POINT”) an upfront cash payment of $250.0 million. The Phase 3 registrational clinical trial for PNT2002, known as the “SPLASH” study, reached 100% of prespecified overall survival events. The results of the readout were comparable to the previously reported 46% and 75% readouts and remain confounded by the overwhelming number of patients who crossed over within the study to receive PNT2002. While we continue to review the available PNT2002 data, we do not currently plan to pursue an NDA or further invest in this asset.

PNT2003

Under the terms of the PNT2003 License Agreement, we paid POINT an upfront payment of $10.0 million, and could pay up to an additional $34.5 million in milestone payments upon the achievement of specified U.S. and ex-U.S. regulatory milestones. POINT is also eligible to receive up to $275.0 million in sales milestone payments upon the achievement of specified annual sales thresholds of PNT2003. In addition, POINT is eligible to receive royalty payments of 15% of net sales of PNT2003.

Our investments in these additional clinical activities and lifecycle management opportunities will increase our operating expenses and impact our results of operations and cash flow, and we can give no assurances as to whether any of these clinical development candidates or lifecycle management opportunities will be successful.

41

Table of Contents

Results of Operations

The following is a summary of our consolidated results of operations:

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(in thousands, except percent data) |  | 2025 |  |  | 2024 |  |  | Change $ |  |  | Change % |  |  | 2025 |  |  | 2024 |  |  | Change $ |  |  | Change % |
Revenues |  | $ | 384,014 |  |  | $ | 378,734 |  |  | $ | 5,280 |  |  |  | 1.4 | % |  | $ | 1,134,823 |  |  | $ | 1,142,800 |  |  | $ | (7,977 | ) |  |  | (0.7 | %)
Cost of goods sold |  |  | 161,648 |  |  |  | 136,608 |  |  |  | 25,040 |  |  |  | 18.3 | % |  |  | 433,746 |  |  |  | 403,054 |  |  |  | 30,692 |  |  |  | 7.6 | %
Gross profit |  |  | 222,366 |  |  |  | 242,126 |  |  |  | (19,760 | ) |  |  | (8.2 | %) |  |  | 701,077 |  |  |  | 739,746 |  |  |  | (38,669 | ) |  |  | (5.2 | %)
Operating expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales and marketing |  |  | 48,828 |  |  |  | 43,719 |  |  |  | 5,109 |  |  |  | 11.7 | % |  |  | 132,372 |  |  |  | 134,300 |  |  |  | (1,928 | ) |  |  | (1.4 | %)
General and administrative |  |  | 81,898 |  |  |  | 40,516 |  |  |  | 41,382 |  |  |  | 102.1 | % |  |  | 205,229 |  |  |  | 135,820 |  |  |  | 69,409 |  |  |  | 51.1 | %
Research and development |  |  | 48,025 |  |  |  | 24,148 |  |  |  | 23,877 |  |  |  | 98.9 | % |  |  | 129,828 |  |  |  | 132,773 |  |  |  | (2,945 | ) |  |  | (2.2 | %)
Total operating expenses |  |  | 178,751 |  |  |  | 108,383 |  |  |  | 70,368 |  |  |  | 64.9 | % |  |  | 467,429 |  |  |  | 402,893 |  |  |  | 64,536 |  |  |  | 16.0 | %
Gain on sale of assets |  |  | — |  |  |  | — |  |  |  | — |  |  | N/A |  |  |  | — |  |  |  | 6,254 |  |  |  | (6,254 | ) |  |  | (100.0 | %)
Operating income |  |  | 43,615 |  |  |  | 133,743 |  |  |  | (90,128 | ) |  |  | (67.4 | %) |  |  | 233,648 |  |  |  | 343,107 |  |  |  | (109,459 | ) |  |  | (31.9 | %)
Interest expense |  |  | 4,950 |  |  |  | 4,903 |  |  |  | 47 |  |  |  | 1.0 | % |  |  | 14,671 |  |  |  | 14,624 |  |  |  | 47 |  |  |  | 0.3 | %
Investment in equity securities - unrealized gain |  |  | (1,160 | ) |  |  | (37,325 | ) |  |  | 36,165 |  |  |  | (96.9 | %) |  |  | (871 | ) |  |  | (75,492 | ) |  |  | 74,621 |  |  |  | (98.8 | %)
Other income |  |  | (2,556 | ) |  |  | (9,953 | ) |  |  | 7,397 |  |  |  | (74.3 | %) |  |  | (23,579 | ) |  |  | (27,785 | ) |  |  | 4,206 |  |  |  | (15.1 | %)
Income before income taxes |  |  | 42,381 |  |  |  | 176,118 |  |  |  | (133,737 | ) |  |  | (75.9 | %) |  |  | 243,427 |  |  |  | 431,760 |  |  |  | (188,333 | ) |  |  | (43.6 | %)
Income tax expense |  |  | 14,610 |  |  |  | 45,025 |  |  |  | (30,415 | ) |  |  | (67.6 | %) |  |  | 63,956 |  |  |  | 107,528 |  |  |  | (43,572 | ) |  |  | (40.5 | %)
Net income |  | $ | 27,771 |  |  | $ | 131,093 |  |  | $ | (103,322 | ) |  |  | (78.8 | %) |  | $ | 179,471 |  |  | $ | 324,232 |  |  | $ | (144,761 | ) |  |  | (44.6 | %)

Comparison of the Periods Ended September 30, 2025 and 2024

Revenues

We classify our revenues into three product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Radiopharmaceutical Oncology includes PYLARIFY and historically included AZEDRA. In the first quarter of 2024, we discontinued the production of AZEDRA. Precision Diagnostics includes DEFINITY, Neuraceq (which we acquired on July 21, 2025 as part of our acquisition of Life Molecular), TechneLite, and other diagnostic imaging products. Strategic Partnerships and Other Revenue primarily includes revenue derived from partnerships with pharmaceutical companies and academic institutions that use our investigational products, such as MK-6240 and NAV-4694 in clinical trials as research tools. This category of revenues also includes royalties and other milestone payments received from our strategic partners that have commercialized products pursuant to license arrangements with us as well as CDMO revenue generated by Evergreen, which we acquired on April 1, 2025.

Revenues are summarized by product category on a net basis as follows:

|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 30, |  |  | September 30, |
(in thousands) |  | 2025 |  |  | 2024 |  |  | Change $ |  |  | Change % |  |  | 2025 |  |  | 2024 |  |  | Change $ |  |  | Change % |
PYLARIFY |  | $ | 240,616 |  |  | $ | 259,756 |  |  | $ | (19,140 | ) |  |  | (7.4 | )% |  | $ | 748,912 |  |  | $ | 791,881 |  |  | $ | (42,969 | ) |  |  | (5.4 | )%
Other radiopharmaceutical oncology |  |  | — |  |  | — |  |  | — |  |  |  | — | % |  |  | — |  |  |  | 384 |  |  |  | (384 | ) |  |  | (100.0 | )%
Total radiopharmaceutical oncology |  |  | 240,616 |  |  |  | 259,756 |  |  |  | (19,140 | ) |  |  | (7.4 | )% |  |  | 748,912 |  |  |  | 792,265 |  |  |  | (43,353 | ) |  |  | (5.5 | )%
DEFINITY |  |  | 81,785 |  |  |  | 76,965 |  |  |  | 4,820 |  |  |  | 6.3 | % |  |  | 244,935 |  |  |  | 231,629 |  |  |  | 13,306 |  |  |  | 5.7 | %
Neuraceq |  |  | 20,442 |  |  |  | — |  |  |  | 20,442 |  |  |  | 100.0 | % |  |  | 20,442 |  |  |  | — |  |  |  | 20,442 |  |  |  | 100.0 | %
TechneLite |  |  | 21,127 |  |  |  | 20,480 |  |  |  | 647 |  |  |  | 3.2 | % |  |  | 65,820 |  |  |  | 70,380 |  |  |  | (4,560 | ) |  |  | (6.5 | )%
Other precision diagnostics |  |  | 6,339 |  |  |  | 6,282 |  |  |  | 57 |  |  |  | 0.9 | % |  |  | 18,672 |  |  |  | 18,039 |  |  |  | 633 |  |  |  | 3.5 | %
Total precision diagnostics |  |  | 129,693 |  |  |  | 103,727 |  |  |  | 25,966 |  |  |  | 25.0 | % |  |  | 349,869 |  |  |  | 320,048 |  |  |  | 29,821 |  |  |  | 9.3 | %
Strategic partnerships and other revenue |  |  | 13,705 |  |  |  | 15,251 |  |  |  | (1,546 | ) |  |  | (10.1 | )% |  |  | 36,042 |  |  |  | 30,487 |  |  |  | 5,555 |  |  |  | 18.2 | %
Total revenues |  | $ | 384,014 |  |  | $ | 378,734 |  |  | $ | 5,280 |  |  |  | 1.4 | % |  | $ | 1,134,823 |  |  | $ | 1,142,800 |  |  | $ | (7,977 | ) |  |  | (0.7 | )%

The increase in revenues for the three months ended September 30, 2025, as compared to the same period of 2024, was primarily driven by revenues generated from sales of Neuraceq subsequent to our acquisition of Life Molecular in July 2025 and an increase in revenue from contract manufacturing services generated subsequent to our acquisition of Evergreen in April 2025, in both cases for which there were no comparable amounts in the same period of 2024, as well as an increase in DEFINITY sales volume. These increases were partially offset by a decrease in the net sales price of PYLARIFY.

The decrease in revenues for the nine months ended September 30, 2025, as compared to the same period of 2024, was primarily driven by a decrease in net sales price of PYLARIFY and a decrease in sales volume of TechneLite. These decreases were partially offset by revenues generated from sales of Neuraceq subsequent to our acquisition of Life Molecular in July 2025 and revenue from contract manufacturing

42

Table of Contents

services generated subsequent to our acquisition of Evergreen in April 2025, in both cases, for which there were no comparable amounts in the same period of 2024, as well as by an increase in DEFINITY sales volume and a milestone achievement for the first commercial sale of Flyrcado by GE HealthCare.

Rebates and Allowances

Estimates for rebates and allowances represent our estimated obligations under contractual arrangements with third parties. Rebate accruals and allowances are recorded in the same period the related revenue is recognized, resulting in a reduction in revenue and the establishment of a liability which is included in accrued expenses and other liabilities in our condensed consolidated balance sheets. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes and growth, Medicaid rebate programs for our products, administrative fees of group purchasing organizations, and certain distributor related commissions. The calculation of the accrual for these rebates and allowances is based on an estimate of the third-party’s expected purchases and the resulting applicable contractual rebate to be earned over a contractual period.

An analysis of the amount of, and change in, reserves for rebates and allowances is summarized as follows:

(in thousands) |  | Rebates and Allowances |
Balance at January 1, 2025 |  | $ | 25,248 |
Provision related to current period revenues |  |  | 115,560 |
Payments or credits made during the period |  |  | (76,996 | )
Balance at September 30, 2025 |  | $ | 63,812 |

Gross Profit

The decrease in gross profit for the three and nine months ended September 30, 2025, as compared to the prior year periods, is primarily due to the decrease in PYLARIFY net sales price. These decreases were partially offset by an increase in gross profit resulting from sales of Neuraceq subsequent to our acquisition of Life Molecular in July 2025 and revenue generated from contract manufacturing services subsequent to our acquisition of Evergreen in April 2025.

Sales and Marketing

Sales and marketing expenses consist primarily of salaries and other related costs for personnel in field sales, marketing, and customer service functions. Other costs in sales and marketing expenses include the development of advertising and promotional material, professional services, market research, and sales meetings.

Sales and marketing expenses increased $5.1 million for the three months ended September 30, 2025 due primarily to the increased sales costs in connection with sales of Neuraceq and provision of contract manufacturing services and employee-related costs subsequent to our acquisitions of Life Molecular and Evergreen, respectively.

Sales and marketing expenses decreased $1.9 million for the nine months ended September 30, 2025, as compared to the prior year period primarily due to an overall decrease in third-party vendor and other marketing spend. In addition, the decrease for the nine months ended September 30, 2025 included a one-time investment in a brand campaign launch for PYLARIFY that took place during the three months ended March 31, 2024, as well as the cessation in 2025 of launch support related to PNT2002. This was partially offset by increased sales and employee-related costs in connection with sales of Neuraceq and provision of contract manufacturing services subsequent to our acquisitions of Life Molecular and Evergreen, respectively.

General and Administrative

General and administrative expenses consist of salaries and other related costs for personnel in executive, finance, legal, information technology, and human resource functions. Other costs included in general and administrative expenses are professional fees for information technology services, external legal fees, consulting and accounting services as well as bad debt expense, certain facility and insurance costs, including director and officer liability insurance.

General and administrative expenses increased $41.4 million and $69.4 million for the three and nine months ended September 30, 2025, respectively, as compared to prior year periods. This was primarily driven by the impact of the acquisitions of Evergreen in April 2025 and Life Molecular in July 2025, including increased professional fees and employee-related costs, such as stock-based compensation expense, in the three and nine months ended September 30, 2025, as compared to the same prior year periods.

43

Table of Contents

Research and Development

R&D expenses relate primarily to salaries and costs related to the development of product candidates to add to our portfolio and costs related to our medical affairs, medical information and regulatory functions.

R&D expenses increased $23.9 million for the three months ended September 30, 2025, as compared to the same prior year period. This was primarily driven by the impact of the acquisitions of Life Molecular in July 2025 and Evergreen in April 2025. In addition, investments to advance late-stage assets MK-6240 and NAV-4694, as well as investments to progress LNTH-2403, also resulted in higher R&D costs.

R&D expenses decreased $2.9 million for the nine months ended September 30, 2025, as compared to the same period of 2024. This was primarily driven by the upfront payment of $36.0 million to Life Molecular to sublicense LNTH-2401 and LNTH-2402, an upfront option payment of $28.0 million to Perspective, as well as $2.0 million to Radiopharm to sublicense LNTH-2403 and LNTH-2404, in each case during the prior year period for which there were no comparable amounts paid during the nine months ended September 30, 2025. These decreases were partially offset by a payment to AstraZeneca of $10.0 million to reduce future royalty obligations for NAV-4694, expenses related to the acquisitions of Evergreen and Life Molecular and increases in project costs related to assets acquired in 2024 including LNTH-2401, LNTH-2402, LNTH-2403, and NAV-4694.

Investment in Equity Securities - Unrealized Gain

Each quarter, our investments in equity securities of Radiopharm and Perspective are revalued to market price. Investment in equity securities - unrealized gain decreased $36.2 million for the three months ended September 30, 2025, as compared to the same period of 2024. We recorded an unrealized gain on the investment in Radiopharm of $1.2 million and an unrealized loss on the investment in Perspective of $0.1 million during the three months ended September 30, 2025, compared to an unrealized gain on the investment in Perspective of $39.5 million offset by an unrealized loss on the investment in Radiopharm of $2.1 million for the three months ended September 30, 2024.

Investment in equity securities - unrealized gain decreased $74.6 million for the nine months ended September 30, 2025, compared to the same period of 2024. For the nine months ended September 30, 2025, we recorded an unrealized loss on the investment in Radiopharm of $2.0 million and recorded an unrealized gain on the investment in Perspective of $2.8 million. This is compared to an unrealized gain on the investment in Perspective of $77.6 million offset by an unrealized loss on the investment in Radiopharm of $2.1 million for the nine months ended September 30, 2024.

Other Income

Other income decreased $7.4 million and $4.2 million for the three and nine months ended September 30, 2025 compared to the same periods of 2024, primarily due to a decrease in interest income on lower average cash balances after the acquisitions of Evergreen in April 2025 and Life Molecular in July 2025. The decrease for the nine month period was partially offset by a $4.7 million adjustment recorded in the first quarter of 2025 to reduce the previous estimate of remediation costs related to the potential decommissioning of our facilities of their radioactive-related operations. See Note 10, “Asset Retirement Obligations,” for more information on our asset retirement obligation.

Income Tax Expense

Our effective tax rate for each reporting period is presented as follows:

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Effective tax rate |  |  | 34.5 | % |  |  | 25.6 | % |  |  | 26.3 | % |  |  | 24.9 | %

Our effective tax rate for the three months ended September 30, 2025 differs from the U.S. statutory rate of 21% primarily due to state income taxes, non-deductible stock compensation and non-deductible acquisition-related costs, partially offset by tax credits. Our effective tax rate for the nine months ended September 30, 2025 differs from the U.S. statutory rate of 21% primarily due to state income taxes and non-deductible acquisition-related costs, partially offset by tax credits.

The increase in the effective income tax rate for the three and nine months ended September 30, 2025 is primarily due to the increase in non-deductible stock compensation and non-deductible acquisition-related costs, partially offset by tax credits.

44

Table of Contents

Liquidity and Capital Resources

Cash Flows

The following table provides information regarding our cash flows:

|  | Nine Months Ended September 30, |
(in thousands) |  | 2025 |  |  | 2024 |
Net cash provided by operating activities |  | $ | 299,963 |  |  | $ | 387,020 |
Net cash used in investing activities |  | $ | (615,658 | ) |  | $ | (219,413 | )
Net cash used in financing activities |  | $ | (215,798 | ) |  | $ | (14,877 | )

Net Cash Provided by Operating Activities

Net cash provided by operating activities of $300.0 million in the nine months ended September 30, 2025 was primarily comprised of net income adjusted for the net effect of non-cash items such as unrealized gain on investment in equity securities, charges incurred in connection with the RM2 license, adjustments to the fair value of asset retirement obligation and contingent assets and liabilities, depreciation, amortization and accretion expense, deferred taxes and stock-based compensation expense. The primary working capital sources of cash include an increase in accounts payable which was attributable to the timing of payments to large vendors. The primary working capital uses of cash include an increase in trade receivables associated primarily with the timing of billings and collections, an increase in inventory related to the timing of batch processes and an increase in income tax receivable. In addition, we recognized a nonrecurring post-combination expense attributed to the acceleration of historical Evergreen stock awards of $7.5 million.

Net cash provided by operating activities of $387.0 million in the nine months ended September 30, 2024 was primarily comprised of net income adjusted for the net effect of non-cash items such as unrealized gain on investment in equity securities, charges incurred in connection with the Perspective in-process research and development exclusive license options, charges related to Radiopharma’s licensed assets, charges related to Life Molecular’s RM2 license, depreciation, amortization and accretion expense and stock-based compensation expense. The primary working capital sources of cash were the timing of payments to large vendors. The primary working capital uses of cash were an increase in trade receivables associated primarily with the increase in PYLARIFY revenues, and an increase in inventory related to the timing of batch processes.

Net Cash Used in Investing Activities

Net cash used in investing activities during the nine months ended September 30, 2025 was driven by $268.9 million paid to the former holders of Evergreen Shares for the acquisition of Evergreen, net of cash acquired, $309.0 million paid for the acquisition of Life Molecular net of cash acquired, $5.0 million used to purchase equity securities, a $5.4 million milestone payment made related to RM2 and $27.3 million of capital expenditures.

Net cash used in investing activities during the nine months ended September 30, 2024 was driven by an upfront option payment of $28.0 million to Perspective, $36.0 million of payments for the Life Molecular asset purchase, $42.9 million payments to Meilleur Stockholders for the acquisition of Meilleur, $2.0 million for the Radiopharm asset purchase $83.2 million for the purchase of equity securities, and $35.3 million of capital expenditures, partially offset by net cash proceeds of $8.0 million from the sale of the Somerset Facility sublease and associated assets.

Net Cash Used in Financing Activities

Net cash used in financing activities during the nine months ended September 30, 2025 is primarily attributable to the repurchase of our common stock for approximately $200.0 million, the payments for minimum statutory tax withholding related to net share settlement of equity awards of $25.2 million and payments for finance leases of $0.8 million, offset by proceeds of $10.2 million from stock option exercises and issuance of common stock.

Net cash used in financing activities during the nine months ended September 30, 2024 is primarily attributable to the payments for minimum statutory tax withholding related to net share settlement of equity awards of $21.7 million, offset by proceeds of $7.2 million from stock option exercises and issuance of common stock.

External Sources of Liquidity

In December 2024, we entered into an amendment to the 2022 Revolving Facility that, among other things, extended the maturity date from December 2, 2027 to December 19, 2029, increased the 2022 Revolving Facility from $350.0 million to $750.0 million and increased the additional amount that Lantheus Medical may request to add to the increased revolving commitment by $350.0 million. The amendment also,

45

Table of Contents

among other things, (i) reduces the ranges of margins based on our Total Net Leverage Ratio (as defined in the 2022 Revolving Facility) used to calculate interest for the revolving loans and (ii) reduces the maximum unused commitment fee from 0.35% per annum to 0.30% per annum. The full terms of the 2022 Revolving Facility are set forth in the Credit Agreement, dated as of December 2, 2022, by and among us, the lenders from time to time party thereto and Citizens Bank, N.A., as administrative agent and collateral agent, as amended. We have the right to request an increase to the 2022 Revolving Facility or request the establishment of one or more new incremental term loan facilities, in an aggregate principal amount of up to the greater of $685.0 million (so that the total amount available is $1.44 billion) or 100% of consolidated earnings before interest, taxes, depreciation and amortization for the four consecutive fiscal quarters most recently ended, plus additional amounts, in certain circumstances.

Under the terms of the 2022 Revolving Facility, the lenders thereunder agreed to extend credit to us from time to time until December 19, 2029 consisting of revolving loans in an aggregate principal amount not to exceed $750.0 million at any time. The 2022 Revolving Facility includes a $40.0 million sub-facility for the issuance of letters of credit (the “Letters of Credit”). The 2022 Revolving Facility includes a $20.0 million sub-facility for swingline loans (the “Swingline Loans”). The Letters of Credit, Swingline Loans and the borrowings under the 2022 Revolving Facility are expected to be used for working capital and other general corporate purposes.

Please refer to Note 12. “Long-Term Debt, Net, and Other Borrowings” to our condensed consolidated financial statements for further details on the 2022 Revolving Facility.

As of September 30, 2025, we were in compliance with all financial and other covenants under the 2022 Credit Agreement.

On December 8, 2022, we issued $575.0 million in aggregate principal amount of 2.625% Convertible Senior Notes due 2027 (the “Notes”), which includes $75.0 million in aggregate principal amount of Notes sold pursuant to the full exercise of the initial purchasers’ option to purchase additional Notes. The Notes were issued under an indenture, dated as of December 8, 2022 (the “Indenture”), among the Company, Lantheus Medical, as guarantor, and U.S. Bank Trust Company, National Association, as Trustee. The net proceeds from the issuance of the Notes were approximately $557.8 million, after deducting the initial purchasers’ discounts and offering expenses payable by us.

On July 31, 2025, the Board authorized the 2025 Program, which replaces the 2024 Program, including the remaining unused portion of the 2024 Program. Pursuant to the 2025 Program, we may repurchase up to $400.0 million in shares of our common stock through December 31, 2027, from time to time via open market purchases at prevailing market prices, in privately negotiated transactions, block trades, or pursuant to trades intending to comply with Rule 10b5-1 under the Exchange Act or through other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations. The actual timing, number and dollar amount of repurchase transactions will be determined by our management, in its discretion and will depend on a number of factors, including but not limited to, the market price of our common stock. During the three months ended September 30, 2025, we repurchased 1.8 million shares of our common stock for an aggregate purchase price of approximately $100.0 million under the 2025 Program. During the nine months ended September 30, 2025, we also repurchased 1.3 million shares for approximately $100.0 million under the 2024 Program. As of September 30, 2025, we have repurchased a total of approximately 1.8 million shares under the 2025 Program and 2.4 million shares under the 2024 Program for a total of approximately $300.0 million. A total of approximately $300.0 million of shares of our common stock remain available for repurchase under the 2025 Program.

Our ability to fund our future capital needs will be affected by our ability to continue to generate cash from operations and may be affected by our ability to access the capital markets, money markets or other sources of funding, as well as the capacity and terms of our financing arrangements.

We may from time to time repurchase or otherwise retire our debt and take other steps to reduce our debt or otherwise improve our balance sheet. These actions may include prepayments of our term loans or other retirements or refinancing of outstanding debt, privately negotiated transactions or otherwise. The amount of debt that may be retired, if any, could be material and would be decided at the sole discretion of our Board and will depend on market conditions, our cash position, and other considerations.

Funding Requirements

Our future capital requirements will depend on many factors, including:

•
The level of product sales and the pricing environment of our currently marketed products, particularly PYLARIFY, DEFINITY and Neuraceq (which we acquired on July 21, 2025 as part of our acquisition of Life Molecular), as well as any additional products that we may market in the future;
•
Revenue mix shifts and associated volume and selling price changes that could result from additional competition or changes in customers’ product demand;
•
The continued costs of the ongoing commercialization of our products;

46

Table of Contents

•
The costs involved in launch preparation activities in anticipation of potential regulatory approvals;
•
The costs to successfully integrate acquisitions, including of Life Molecular and Evergreen, including the potential for unforeseen expenses related to integration activities and liabilities within those businesses, costs to integrate disparate information technology systems, retain key talent and create a merged corporate culture that successfully realizes the full potential of the combined organization;
•
Our investment in the further clinical development and commercialization of products and development candidates, as well as whether we exercise our option and co-development rights under the Perspective agreements;
•
The costs of acquiring or in-licensing, developing, obtaining regulatory approval for, and commercializing, new products, businesses or technologies, including any potential related milestone or royalty payments, together with the costs of pursuing opportunities that are not eventually consummated;
•
The costs of investing in our facilities, equipment and technology infrastructure;
•
The costs and timing of establishing or amending manufacturing and supply arrangements for commercial supplies of our products and raw materials and components;
•
Our ability to have products manufactured and released from manufacturing sites in a timely manner in the future, or to manufacture products at our in-house manufacturing facilities in amounts sufficient to meet our supply needs;
•
The costs of further commercialization of our existing products, particularly in international markets, including product marketing, sales and distribution and whether we obtain local partners to help share such commercialization costs;
•
The legal costs relating to maintaining, expanding and enforcing our intellectual property portfolio, pursuing insurance or other claims and defending against product liability, regulatory compliance, intellectual property, security law or other claims, including the patent infringement claim related to the filing of our ANDA for PNT2003, our patent infringement lawsuit against a healthcare-related imaging software developer and the putative securities class action against us;
•
The cost of interest on any additional borrowings which we may incur under our financing arrangements; and
•
The impact of sustained inflation on our costs of goods sold and operating expenses.

Disruption in our financial performance could occur if we experience significant adverse changes in product or customer mix, significant changes in our competitive or regulatory environment, broad economic downturns, sustained inflation, adverse industry or company conditions or catastrophic external events, including pandemics, natural disasters and political or military conflict. If we experience one or more of these events in the future, we may be required to implement expense reductions, such as a delay or elimination of discretionary spending in all functional areas, as well as scaling back select operating and strategic initiatives.

If our capital resources become insufficient to meet our future capital requirements, we would need to finance our cash needs through public or private equity offerings, debt financings, assets securitizations, sale-leasebacks or other financing or strategic alternatives, to the extent such transactions are permissible under the covenants of our 2022 Credit Agreement. Additional equity or debt financing, or other transactions, may not be available on acceptable terms, if at all. If any of these transactions require an amendment or waiver under the covenants in our 2022 Credit Agreement, which could result in additional expenses associated with obtaining the amendment or waiver, we will seek to obtain such an amendment or waiver to remain in compliance with those covenants. However, we cannot provide assurance that such an amendment or waiver would be granted, or that additional capital will be available on acceptable terms, if at all.

At September 30, 2025, our only current committed external source of funds is our borrowing availability under our 2022 Revolving Facility. We had $382.0 million of cash and cash equivalents as of September 30, 2025. Our 2022 Revolving Facility contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. Incremental borrowings under the 2022 Revolving Facility may affect our ability to comply with the covenants including the financial covenants restricting consolidated net leverage and interest coverage. Accordingly, we may be limited in utilizing the full amount of our 2022 Revolving Facility as a source of liquidity.

Based on our current operating plans, we believe our balance of cash and cash equivalents, along with cash generated by ongoing operations and continued access to our 2022 Revolving Facility, will be sufficient to satisfy our cash requirements over the next twelve months and beyond.

47

Table of Contents

Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations are based on our condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect our reported assets and liabilities, revenues and expenses, and other financial information. Actual results may differ materially from these estimates under different assumptions and conditions. In addition, our reported financial condition and results of operations could vary due to a change in the application of a particular accounting standard.

There have been no significant changes to our critical accounting policies or in the underlying accounting assumptions and estimates used in such policies in the nine months ended September 30, 2025. For further information, refer to our summary of significant accounting policies and estimates in our Form 10-K for the year ended December 31, 2024.

Off-Balance Sheet Arrangements

We are required to provide the Massachusetts Department of Public Health financial assurance demonstrating our ability to fund any decommissioning of our North Billerica, Massachusetts production facility in the event of any closure. We have provided this financial assurance in the form of a $30.3 million surety bond.

We have not engaged in any other off-balance sheet arrangements, including structured finance, special purpose entities or variable interest entities.

48

Table of Contents

Item 3. Quantitat ive and Qualitative Disclosures About Market Risk

For quantitative and qualitative disclosures about market risk, see Part II, Item 7A. “Quantitative and Qualitative Disclosures About Market Risk,” of our Form 10-K for the year ended December 31, 2024. Our exposures to market risk have not changed materially since December 31, 2024.

Equity Investment Risk

As of September 30, 2025, our recorded carrying value of investments in equity securities was $45.5 million, comprised of our equity investments in Perspective and Radiopharm, and is recorded at fair value, subject to market price volatility. We record our equity investments in public companies at fair value and adjust our equity investments in public companies for observable price changes or impairments. Valuations of public companies are variable and subject to change in share price at the applicable measurement period.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

The Company’s management, with the participation of the Company’s Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), its principal executive officer and principal financial officer, respectively, has evaluated the effectiveness of the Company’s disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, the Company’s CEO and CFO concluded that the Company’s disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) were effective as of the period covered by this report.

Changes in Internal Controls Over Financial Reporting

There were no changes in our internal control over financial reporting during the three months ended September 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

49

Table of Contents

PART II. OTHER I NFORMATION

Item 1. Legal Proceedings

Information with respect to certain legal proceedings is included in Note 16, “Commitments and Contingencies”, to the condensed consolidated financial statements contained in Part I, Item 1. Financial Statements of this Form 10-Q and is incorporated herein by reference.

Item 1A. Risk Factors

There have been no material changes to the risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2024, except as set forth below:

Risks Related to Our Portfolio of Commercial Products

Our ability to grow PYLARIFY as a commercial product is dependent on (A) the ability of positron emission tomography (“PET”) manufacturing facilities (“PMFs”) to manufacture PYLARIFY to meet product demand, including ensuring that PYLARIFY is available at the specific time of day preferred by the end-user, (B) our ability to maintain adequate coding, coverage and payment for PYLARIFY, (C) our ability to promote PYLARIFY to customers and to maintain PYLARIFY as the most utilized prostate-specific membrane antigen (“PSMA”) PET imaging agent, which has been impacted by the expiration of transitional pass-through payment status (“TPT Status”) on December 31, 2024, (D) whether and when a potential generic version of PYLARIFY may enter the market and (E) our ability to clinically and commercially differentiate PYLARIFY from an increasing number of potentially competitive products.

To manufacture PYLARIFY, we assembled and qualified a nationwide network of PMFs with radioisotope-producing cyclotrons that make F-18, which has a 110-minute half-life, so PYLARIFY is manufactured and distributed rapidly to end-users. Because each of the PMFs manufacturing these products is deemed by the U.S. Food and Drug Administration (“FDA”) to be a separate manufacturing site, each has to be separately approved by the FDA. Although PYLARIFY is broadly available across the U.S., we continue to seek qualification for additional PMFs in 2025 and can give no assurance that the FDA will continue to approve PMFs in accordance with our expansion plans to meet product demand or that PYLARIFY will be available at the specific time of day preferred by the end-users or that our expansion plans accurately predict demand growth. To the extent that PYLARIFY is not available at preferred times, end users have, in some instances, switched all or a portion of their use to available competitive products. If FDA approval of manufacturing sites is delayed or withdrawn or if FDA requirements relating to site approval change impacting our ability to meet demand for PYLARIFY or end users scheduling needs or if we invest to extend our PMF network and demand does not grow to meet the expanded capacity, our business, results of operations, financial condition and cash flows would be adversely affected.

Obtaining adequate coding, coverage, and payment for PYLARIFY is critical, including not only coverage from Medicare, Medicaid and other government payors, as well as private payors, but also appropriate payment levels to adequately cover our customers’ costs of using PYLARIFY in PET/computed tomography (“CT”) imaging procedures. The Healthcare Procedure Coding System code for PYLARIFY, which enables streamlined billing, went into effect as of January 1, 2022. PYLARIFY also had TPT Status from January 1, 2022 until December 31, 2024, which enabled traditional Medicare to provide an incremental payment for PET/CT scans performed with PYLARIFY in the hospital outpatient setting. After expiry of TPT Status, diagnostic radiopharmaceuticals, such as, PYLARIFY, historically would not have been separately reimbursed in the hospital outpatient setting but rather would be bundled into the facility payment a hospital receives for a PET/CT imaging procedure, and the facility payment may not have adequately covered the total cost of the procedure with the diagnostic radiopharmaceutical for all hospitals. In November 2024, the Centers for Medicare and Medicaid Services (“CMS”) released the final rule for its calendar year 2025 Medicare Hospital Outpatient Prospective Payment System (the “CMS 2025 OPPS Rule”). The CMS 2025 OPPS Rule became effective on January 1, 2025, pursuant to which previously packaged diagnostic radiopharmaceuticals are now “unbundled” with payments being made separately for any diagnostic radiopharmaceutical with a per day cost greater than $630 based on their mean unit cost (“MUC”). For approximately 20% of patients estimated to be impacted by changes in reimbursement in the hospital outpatient setting, these changes enable hospitals that use innovative diagnostic radiopharmaceuticals, including PYLARIFY, to continue to be paid separately by CMS following the expiry of TPT Status at a rate that reflects MUC. The calendar year 2025 payment rate for PYLARIFY is based on MUC and is less than the Average Sales Price (“ASP”)-based amount that was paid during TPT Status. Although PYLARIFY continues to be paid separately, other competitive PSMA PET imaging agents continue to have TPT Status after December 31, 2024, including a new PSMA PET imaging agent with TPT Status effective on October 1, 2025, and hospital use of those products, for the approximately 20% of patients with traditional Medicare fee-for-service (“FFS”) in the hospital outpatient setting, generally will be paid separately based on ASP plus six percent rather than on MUC, which could provide a financial incentive to use an imaging agent other than PYLARIFY. In July 2025, CMS released the proposed rule for its calendar year 2026 Medicare Hospital Outpatient Prospective Payment System (the “CMS 2026 Proposed OPPS Rule”). In the CMS 2026 Proposed OPPS Rule, CMS stated that it continues to believe ASP data available from manufacturers generally is insufficient as a basis for determining payment and that it is seeking comments on how CMS can ensure more consistent, validated, and universal

50

Table of Contents

reporting. We have reported and continue to report ASP for PYLARIFY, have engaged with CMS on the methodology for reporting ASP, and we will continue to work with coalition partners and CMS to support using ASP to calculate payment for diagnostic radiopharmaceuticals in future years similar to the way Medicare Outpatient Prospective Payment System (“OPPS”) currently pays for other drugs, biologics, and therapeutic radiopharmaceuticals. However, we can give no assurances that we will be successful in those efforts or that the availability of TPT Status for other diagnostic radiopharmaceuticals will not continue to impact clinical decision making regarding which product to use for all patient populations, which could have an adverse effect on our business, results of operations, financial condition and cash flows.

Growth of PYLARIFY is also dependent on our ability to promote PYLARIFY to customers, to clinically and commercially differentiate PYLARIFY from other products on the market, to enter into and realize the benefits of strategic contracts with customers and to maintain PYLARIFY as the most utilized PSMA PET imaging agent in an increasingly competitive environment in which other PSMA PET imaging agents have been approved, for which discounts related to those other agents have been offered to customers and for which TPT Status may be available. PYLARIFY currently competes with three commercially available Gallium-68-based PSMA PET imaging agents, two from Telix Pharmaceuticals Limited and one from Novartis AG and an F-18 PSMA PET imaging agent from Blue Earth Diagnostics Ltd. (“Blue Earth”), as well as other non-PSMA PET imaging agents. The potential for future generic entrants to the market due to the expiry of PYLARIFY’s new chemical entity exclusivity period in 2026 could also generate increased competition for PYLARIFY. Growth and revenue contribution from PYLARIFY will also depend on our ability to clinically differentiate PYLARIFY from competitive products so that customers continue to choose PSMA PET with PYLARIFY for appropriate patients because of its clinical differentiation and despite the loss of TPT Status and a potential economic difference that could result for the approximately 20% of patients with traditional Medicare FFS in the hospital outpatient setting based on the CMS 2025 OPPS Rule, including through flexible and dependable access to PYLARIFY nationally, a best-in-class customer experience and continued promotion and education regarding PYLARIFY’s clinical and commercial attributes. Our ability to negotiate and realize the benefits from strategic contracts is also key to our ability to maintain and expand market share. Despite these efforts, we have seen net price compression and lost market share to certain competitors that have later approved products with TPT Status at a time when PYLARIFY’s TPT Status has expired, and we may experience further net price compression or lose market share to these or future competitive products due to reimbursement status due to the impact of any potential generic entrant to the market or the potential that additional rebates may be offered to customers, including when a PSMA PET imaging agent is purchased as one part of a broader portfolio of products. Such loss of market share could have an adverse impact on our business, results of operations, financial condition and cash flows.

Our success in growing PYLARIFY also depends, in part, on our successfully establishing the use of PYLARIFY for new patient populations, such as patients with favorable intermediate-risk prostate cancer, and potentially for updates to the label, including for patient selection for PSMA-targeted therapeutics. For example, we are conducting a clinical trial to determine whether PYLARIFY can detect the presence or absence of additional prostate cancer lesions in patients with favorable intermediate-risk prostate cancer, as well as how it may change the patient’s intended management, but cannot predict whether the outcome of this clinical trial will support such a use of PYLARIFY. Similarly, we believe the approval of PLUVICTO for the treatment of adult patients with PSMA-positive metastatic castration-resistant prostate cancer created a new addressable market for the use of PSMA PET imaging in patient selection for PSMA-targeted therapy. We can give no assurances as to how current clinical practice may evolve. To the extent we are unsuccessful in establishing the use of PYLARIFY in new patient populations, such lack of success could have an adverse impact on our business, results of operations, financial condition and cash flows.

We depend on some of our PMF partners to generate sales, accept, produce and deliver orders, collect payments and report related information for PYLARIFY.

PYLARIFY is sold in the U.S. to hospitals, independent imaging centers and government facilities and sales are generated through an internal PYLARIFY sales team, as well as sales teams at some of our PMF partners. We generally do not use group purchasing arrangements to sell PYLARIFY and require each customer to enter into a contract directly with us or our PMF partners. Our ability to continue to successfully grow PYLARIFY depends, in part, on our ability, and the ability of some of our PMF partners on our behalf, to continue to enter into commercially beneficial arrangements directly with the hospitals, independent imaging centers and government facilities that we serve. Any delay or inability to enter into these arrangements, including our ability to negotiate favorable financial terms in these agreements, or if, despite favorable financial terms, the customers do not continue to purchase PYLARIFY, could have an adverse impact on our business, results of operations, financial condition and cash flows.

We also depend on some of our PMF partners to accept, produce and deliver orders, invoice customers, collect payments and to report related information to us. To the extent our PMF partners are unsuccessful in generating sales, accepting, producing and delivering orders, invoicing customers, collecting payments or reporting to us, or where we are responsible, if we are unsuccessful in accepting orders, ensuring timely production and delivery of those orders by a PMF, or if invoices to customers or collection of payments is delayed, such an event could have a material adverse effect on our business, results of operations, financial condition and cash flows. We are in the process of transitioning responsibility for invoicing certain customers from a PMF partner to the Company. This transition includes potential risks, including risks from a disruption during the transition or our inability to seamlessly move from one invoicing system to the other. The transition will also require

51

Table of Contents

our customers to take certain actions to transition from the PMF to the Company when paying invoices which is out of our control. These risks, and other potential risks that we may not have accounted for as part of our transition planning, could result in delayed or inaccurate invoicing, loss of revenue, loss of customers or reputational harm which could have an adverse impact on our business, results of operations, financial condition and cash flows.

We and our PMF partners also use third-party software to accept orders placed by customers and to record shipping and administrative status of orders. We rely in part on information from third-party software and from our PMF partners in connection with how we report and collect payments for PYLARIFY. To the extent we are unable to accept orders or access, verify or reconcile data, such event could have a material adverse effect on our business, results of operations, financial condition and cash flows.

Potential generic competitors may seek to enter the market as a result of regulatory exclusivity expiration of PYLARIFY

PYLARIFY currently has six Orange Book-listed patents, the last of which expires in 2037. PYLARIFY also holds a five-year new chemical entity (“NCE”) regulatory exclusivity, which expires on May 26, 2026. As described further under Part I, Item 1., “Business - Regulatory Matters-Hatch Waxman Act,” of our Annual Report on Form 10-K (“Form 10-K”) for the year ended December 31, 2024 filed with the Securities and Exchange Commission (“SEC”) on February 26, 2025, the FDA is allowed to accept an Abbreviated New Drug Application (“ANDA”) or 505(b)(2) application one year prior to the NCE expiration date under certain circumstances, specifically, from a generic challenger that includes a “Paragraph IV” Certification against each of the six patents we have listed in the Orange Book. If a Paragraph IV Certification is made, we could elect to pursue Hatch-Waxman litigation and trigger the 30-month stay described under Part I, Item 1., “Business - Intellectual Property Matters – Patent-related Aspects of Regulatory Matters,” of our Form 10-K for the year ended December 31, 2024 filed with the SEC on February 26, 2025, during which period the FDA would be prohibited from granting full approval to the challenger’s application. As of the date of filing of this Form 10-Q, we have not received any notice of a Paragraph IV Certification, but we can give no assurance that we will not receive notice of a Paragraph IV Certification in the future. If an ANDA or 505(b)(2) applicant were to file prior to the expiration of our NCE regulatory exclusivity, and we were to timely sue pursuant to the Hatch-Waxman Act, then the automatic stay of FDA approval could run until November 26, 2028, calculated as 30 months from the NCE expiration date (May 26, 2026), unless prior to such date the generic challenger successfully invalidates or proves non-infringement of all six Orange Book-listed patents or the lawsuit is otherwise settled. If litigation is ongoing in November 2028, then any generic launch would be at risk of the litigation determining that the generic challenger was infringing one or more of our patents Patent litigation is complex and can be protracted and expensive, so if we were to receive such a notice and to challenge the applicant, this could have a negative effect on our business, results of operations and financial condition.

Our ability to grow Neuraceq as a commercial product is dependent on (A) the ability of PMFs to manufacture Neuraceq to meet product demand, including ensuring that Neuraceq is available at the specific time of day preferred by the end-user, (B) our ability to maintain adequate coding, coverage and payment for Neuraceq, (C) our ability to promote Neuraceq to customers and (D) our ability to clinically and commercially differentiate Neuraceq from competitive products.

Similar to PYLARIFY, Neuraceq is manufactured by a nationwide network of PMFs with radioisotope-producing cyclotrons that make F-18, which has a 110-minute half-life, so Neuraceq is manufactured and distributed rapidly to end-users, and each PMF manufacturing site has to be separately approved by the FDA. Currently, Neuraceq has a manufacturing footprint that is smaller than that of one of our competitors, and while we continue to seek qualification for additional PMFs in 2025 and 2026, we can give no assurance that additional PMFs will have the capacity to produce Neuraceq in addition to other products they may already produce, including other F-18-based products, the FDA will continue to approve PMFs in accordance with our expansion plans to meet product demand or that Neuraceq will be available at the specific time of day preferred by the end-users or that our expansion plans accurately predict demand growth. If production capacity is not available, or if FDA approval of manufacturing sites is delayed or withdrawn or if FDA requirements relating to site approval change impacting our ability to meet demand for Neuraceq or end users scheduling needs or if we invest to extend our PMF network and demand does not grow to meet the expanded capacity, our business, results of operations, financial condition and cash flows would be adversely affected.

Maintaining adequate coding, coverage, and payment for Neuraceq is critical, including not only coverage from Medicare, Medicaid and other government payors, as well as private payors, but also appropriate payment levels to adequately cover our customers’ costs of using Neuraceq in PET/ CT imaging procedures. Neuraceq was approved by the FDA in 2014. For approximately 75% of patients in the hospital outpatient setting, Neuraceq is paid based on its MUC, however, other competitive imaging agents are currently being paid based on a higher MUC rate. While we have engaged with CMS to support the use of ASP instead of MUC, we can give no assurances that CMS will move to the use of ASP in the near term or that the availability of a higher MUC payment rate for other diagnostic radiopharmaceuticals will not continue to impact clinical decision making regarding which product to use for all patient populations, which could have an adverse effect on our business, results of operations, financial condition and cash flows.

Growth of Neuraceq is also dependent on our ability to promote Neuraceq to customers, to clinically and commercially differentiate Neuraceq from other products on the market, and to use our current relationships with our customers to introduce Neuraceq to those customers.

52

Table of Contents

Neuraceq currently competes with two commercially available F-18 beta-amyloid-targeting PET imaging agents from Eli Lilly and Co (“Lilly”) and GE HealthCare. Growth and revenue contribution from Neuraceq will also depend on our ability to clinically differentiate Neuraceq from competitive products so that customers choose Neuraceq for appropriate patients because of its clinical differentiation and despite the disparity in MUC payment rates for Neuraceq compared to other products for the approximately 75% of patients in the hospital outpatient setting. Certain currently approved therapeutic products in the U.S. require confirmation of the presence of amyloid beta pathology prior to initiating treatment. If the prescribing information for these products were to change it could have an adverse effect on our business, results of operations, financial condition and cash flows.

We may not, or may take longer to, realize the expected benefits and opportunities related to, investments we have made to develop our new formulation of our PSMA PET Imaging Agent.

On August 6, 2025, we announced that the FDA had accepted our New Drug Application (“NDA”) for a new formulation of our F-18 PSMA PET imaging agent, filed by our subsidiary Aphelion, and that the FDA set a Prescription Drug User Fee Act (“PDUFA”) target action date of March 6, 2026. The new formulation was designed to optimize the manufacturing process and potentially increase batch size of the F-18 PSMA PET imaging agent by approximately 50%. If the NDA is approved, we plan to work closely with clinicians and PMF sites to ensure a smooth rollout of the new formulation, including providing clear guidance on ordering, handling, and clinical use to support continuity of care for patients, and we plan to apply for CMS reimbursement for the new formulation, including obtaining three years of TPT Status; however, we can provide no assurance that the new formulation will be approved by the FDA, that we will meet our timeline for our planned rollout, or that we will obtain TPT Status. Even if we do receive NDA approval, all of the risks described above with respect to our ability to grow PYLARIFY as a commercial product would also apply to our new formulation of our PSMA PET imaging agent, and we can provide no assurances that the anticipated increase in batch size or other expected improvements associated with the design of the new formulation will be realized or be viewed in the market as differentiating factors.

Our just-in-time manufacturing of radiopharmaceutical products, including PYLARIFY and Neuraceq (which we acquired on July 21, 2025 as part of our acquisition of Life Molecular), relies on the reliability of our equipment and processes, the timely receipt of radioactive raw materials and the timely shipment of finished goods, and any disruption of our supply or distribution networks could have a negative effect on our business.

Radiopharmaceutical products, including PYLARIFY, Neuraceq and our TechneLite generators, rely on radioisotopes with limited half-lives. As a result, we or our partners must manufacture, finish and distribute these products on a just-in-time basis, because the underlying radioisotope is in a constant state of decay. For example, the radioisotope used in PYLARIFY and Neuraceq is F-18, which has a 110 minute half-life, requiring that this product be manufactured and distributed within the same day to end-users. After being made on a cyclotron at a PMF, the F-18 is then combined with certain chemical ingredients in specially designed chemistry synthesis boxes to manufacture PYLARIFY or Neuraceq. The finished product is then quality control tested and transferred to a radiopharmacist who prepares and dispenses patient-specific doses from the final product. Similarly, with respect to our TechneLite generators, if we receive Mo-99 in the morning of a manufacturing day for TechneLite generators, then we will generally ship finished generators to customers by the end of the same business day. Shipment of generators may be by next day delivery services or by either ground or air custom logistics. Any delay in us receiving radioisotopes from suppliers or being able to have finished products delivered to customers because of weather or other unforeseen transportation issues could have a negative effect on our business, results of operations, financial condition and cash flows.

At the facility on our North Billerica campus, we manufacture TechneLite on an automated production line. As with all manufacturing facilities, equipment and infrastructure age and become subject to increasing maintenance and repair. If we or one of our PMF’s experience an event, including a labor dispute, natural disaster, fire, power outage, machinery breakdown, security problem, failure to meet regulatory requirements, product quality issue, technology transfer issue or other issue, we may be unable to manufacture the relevant products at previous levels or on the forecasted schedule, if at all. Due to the stringent regulations and requirements of the governing regulatory authorities regarding the manufacture of our products, we may not be able to quickly restart manufacturing at our facilities or at a PMF facility, or establish additional or replacement sources for certain products, components or materials.

We face significant competition in our business and may not be able to compete effectively.

The markets for our products are highly competitive and continually evolving. Our principal competitors for our current commercial products and leading clinical development candidates include large, global companies that are more diversified than we are and that have substantial financial, manufacturing, sales and marketing, distribution and other resources:

•
For PYLARIFY, our competitors currently include approved imaging agents from Telix Pharmaceuticals Limited, Novartis AG, and Blue Earth, a subsidiary of Bracco.

53

Table of Contents

•
For DEFINITY, our competitors currently include GE HealthCare and Bracco.
•
For Neuraceq, our competitors currently include Lilly and GE HealthCare

Any product candidates that we successfully develop and commercialize will compete with existing products and new products that may become available in the future, not only for customers but also for manufacturing resources, raw materials and, for our diagnostic imaging agents, PET scanner capacity. For example, for PNT2003, our principal competitors may include Novartis AG; ITM Radiopharma; Curium Pharma (“Curium”), and RayzeBio (acquired by Bristol Myers Squibb). For MK-6240 and NAV-4694, our principal competitors may include Lilly and GE HealthCare.

We cannot anticipate the actions of our current or future competitors in the same or competing modalities, such as significant price reductions on products that are competitive with our own, the ability to offer a portfolio of products and offer price reductions across a portfolio, development of new products that are more cost-effective or have superior performance than our current products, potential future products or the introduction of generic versions of our proprietary products, the ability to secure better manufacturing locations or times for production of current or future products that limit the availability of necessary raw materials, production equipment or, for our diagnostic agents, scanning equipment. In addition, distributors of our products could attempt to shift end-users to competing diagnostic modalities and products, or bundle the sale of a portfolio of products, in either case to the detriment of our specific products. Our current or future products could be rendered obsolete or uneconomical as a result of these activities.

Further, the radiopharmaceutical industry continues to evolve strategically, with several market participants recently acquired by larger companies that may have more significant resources than ours. In addition, the supply-demand dynamics of the industry are complex because of large market positions of some participants, legacy businesses, government subsidies (in particular, relating to the manufacture of radioisotopes), and group purchasing arrangements and there are often limited sources available for isotopes and raw materials used in the manufacturing of our product and product candidates. We cannot predict what impact new owners and new operators may have on the strategic decision-making of our competitors, customers and suppliers, and such decision-making could have a material adverse effect on our business, results of operations, financial condition and cash flows.

Risks Related to Reimbursement and Regulation

Reforms to the U.S. healthcare system, including changes to policies, guidelines and practices of regulatory authorities, may adversely affect our business.

A significant portion of our patient volume is derived from U.S. government healthcare programs, principally Medicare, which are highly regulated and subject to frequent and substantial changes. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the “Healthcare Reform Act”) substantially changed the way healthcare is financed by both governmental and private insurers. The law contains a number of provisions that affect coverage and reimbursement of drug products and medical imaging procedures performed in the U.S. Subsequently, the Medicare Access and CHIP Reauthorization Act of 2015 significantly revised the methodology for updating the Medicare physician fee schedule. In 2017, Congress enacted legislation that effectively eliminated the Healthcare Reform Act's “individual mandate” beginning in 2019. On July 4, 2025, President Trump signed into law the One Big Beautiful Bill Act (the “OBBBA”), which will reduce existing patient coverage under Medicaid. The expiration of certain subsidies for Marketplace coverage currently in place under the Healthcare Reform Act at the end of 2025 may also cause material coverage losses. The OBBBA further restricts Medicaid financing, which will decrease federal funds available to state Medicaid agencies and may result in reduced state Medicaid agency reimbursement rates. Congress continues to consider other healthcare reform legislation. There is no assurance that the Healthcare Reform Act, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative, judicial or administrative changes relating to healthcare reform will affect our business.

In addition, other legislative changes have been proposed and adopted since the Healthcare Reform Act was enacted. The Budget Control Act of 2011 and subsequent Congressional actions includes provisions to reduce the federal deficit. These provisions have resulted in the imposition of 2% reductions in Medicare payments to providers, which went into effect on April 1, 2013 and will remain in effect through fiscal year 2030. The imposition of the 2% payment adjustment had been suspended through March 31, 2022 and went into effect as of April 1, 2022. The Congressional Budget Office estimates that, absent future action, the OBBBA will lead to $490 billion in Medicare cuts from 2027 to 2034. Any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented and/or any significant taxes or fees that may be imposed on us, as part of any broader deficit reduction effort or legislative replacement to the Budget Control Act, could have an adverse impact on our business, results of operations, financial condition and cash flows.

Further, changes in payor mix and reimbursement by private third-party payors may also affect our business. Rates paid by some private third-party payors are based, in part, on established physician, clinic and hospital charges and are generally higher than Medicare payment

54

Table of Contents

rates. Reductions in the amount of reimbursement paid for diagnostic medical imaging procedures, including the elimination of any additional payment such as TPT Status, and changes in the mix of our patients between non-governmental payors and government sponsored healthcare programs and among different types of non-government payor sources, could have a material adverse effect on our business, results of operations, financial condition and cash flows.

The full impact on our business of healthcare reforms and other new laws, or changes in existing laws, the interpretations of those laws, or changes to the way regulations and regulatory guidance has been implemented, amended and interpreted, is uncertain. Nor is it clear whether additional legislative or executive branch changes will be adopted or how those changes would affect our industry in general or our ability to successfully commercialize our products or develop or commercialize new products. For example, recent government actions, including reductions in staff and department reorganizations, including those at the FDA, could adversely affect the timing of anticipated regulatory actions or their outcome, and could change historical practices relating to the application or interpretation of regulations relevant to our operations in ways that could have an adverse effect on our business. It is unclear exactly how changes implemented by the U.S. Government will affect the U.S. healthcare system, and what impact this will have on our business. If the reforms made by the OBBBA are implemented and result in predicted coverage losses, these changes could reduce the overall number of diagnostic medical imaging procedures performed, reduce reimbursement rates, or both.

55

Table of Contents

Risks Related to Our Business Operations and Financial Results

Changes to management, including turnover in our leadership and senior management team, could have an adverse effect on our business.

We have experienced, and may continue to experience, significant executive management changes, including the consolidation of roles and responsibilities. We recently announced the retirement of Brian Markison, our Chief Executive Officer (“CEO”) effective December 31, 2025, and the appointment of Mary Anne Heino, the Chair of our Board of Directors (“Board”), to serve as interim CEO on that date. We also announced that our President, Paul Blanchfield, accepted a role with another company and is leaving the Company. We also have experienced and may continue to experience the departure and transition of other members of the leadership team.

These changes in our management team resulting from the hiring or departure of executives could disrupt our business and involve inherent risk. Any failure to find a timely and suitable replacement and ensure an effective transition within executive leadership, including the effective onboarding, assimilation, and retention of our management team and key employees, could hinder our strategic planning, business execution and future performance. In addition, executive leadership transition periods can be disruptive and may result in a loss of personnel with deep institutional or technical knowledge, or result in changes to business strategy or objectives, and may negatively impact our operations and relationships with employees and third-parties due to increased or unanticipated expenses, operational inefficiencies, uncertainty regarding changes in strategy, decreased employee morale and productivity, and increased turnover.

Further, we have increased our dependency on the remaining members of our executive management team to facilitate a smooth transition in leadership roles. Our executive officers are at-will employees; as such, their employment with us could terminate at any time, and any such departure could be particularly disruptive in light of the recent leadership changes. If we are unable to mitigate these or other similar risks, our business, results of operations and financial condition may be adversely affected.

We may be adversely affected by prevailing economic conditions and financial, business and other factors beyond our control.

Our ability to attract and retain employees and customers, to invest in and grow our business, to maintain our desired levels of costs of goods sold and operating expenses and to meet our financial obligations depends on our operating and financial performance, which, in turn, is subject to numerous factors, including the prevailing economic conditions, changes to financial, business and regulatory expectations, and other factors beyond our control, such as the rate of unemployment, the number of uninsured persons in the U.S., inflationary pressures, escalating prices, including those that may occur as a result of tariff policies. We cannot anticipate all the ways in which the current or future economic climate, financial market conditions and government actions could adversely impact our business. We are exposed to risks associated with reduced profitability and the potential financial instability of our customers, many of which may be adversely affected by conditions in the financial markets. For example, unemployment and underemployment, and the resultant loss of insurance, may decrease the demand for healthcare services and pharmaceuticals, including our products. If fewer patients are seeking medical care because they do not have insurance coverage, our customers may experience reductions in revenues, profitability and/or cash flow that could lead them to modify, delay or cancel orders for our products or seek lower cost alternatives to our products where available. If customers are not successful in generating sufficient revenue, are precluded from securing financing from the financial markets, or lose or cannot secure funding from the government, they may not be able to pay, or may delay payment of, accounts receivable that are owed to us. Research programs that could benefit from our investigational or commercial products may slow or be discontinued if funding cannot be secured or is withdrawn, which could delay when the results of such research becomes available and when or how often our products are purchased by third parties for use in their research programs. This, in turn, could adversely affect our financial condition and liquidity. To the extent prevailing economic conditions result in fewer procedures being performed or fewer research programs being completed, our business, results of operations, financial condition and cash flows could be adversely affected.

In addition, we would expect our costs of goods sold and other operating expenses to change in the future in line with periodic inflationary changes. Because we intend to retain and continue to use our property and equipment, we believe that the incremental inflation related to the replacement costs of those items will not materially affect our operations. However, the rate of inflation affects our expenses, such as those for employee compensation, contract services, and transportation costs, which could increase our level of expenses and the rate at which we use our resources. Similarly, our operations and supply chain may subject us to tariffs and trade policies. For example, the U.S. government has increased, and has indicated a willingness to continue to increase, the use of tariffs by the United States. Such tariffs and any countermeasures taken by other countries could increase the cost of raw materials, components and equipment necessary for our operations, disrupt our global supply chain, create additional operational challenges or adversely impact our customers and business partners. While we generally believe that we will be able to offset the effect of inflationary and other changes by adjusting our product prices and implementing operating efficiencies, any material unfavorable changes in our costs of goods sold or other operating expenses, including from tariffs, could have a material adverse effect on our financial condition, results of operations and cash flows.

56

Table of Contents

An interruption in our ability to fulfill our obligations as a service provider or supplier to third parties, either through our contract development and manufacturing operations and/or in supplying our investigational products in support of research programs being conducted by third parties, may adversely affect our reputation and business.

We have obligations to perform development and manufacturing services for third parties that have contracted with Evergreen Theragnostics, Inc. (“Evergreen”) for these services. These services are conducted out of a single location. Any disruption in our operations, any failure to timely and cost-effectively secure necessary personnel, components or materials, any failure to comply with the stringent regulations and requirements of the FDA and other regulatory authorities regarding the manufacture and development of radiopharmaceutical products, may cause us to fail to meet our contractual obligations and may adversely affect our business.

We also have contractual commitments to supply our investigational products and certain of our commercial products to third parties as part of their own research programs. Our ability to supply these products may depend upon the ability of PMFs to manufacture the products to meet the requirements of each research program, including that the product be available at the specific time of day required by the third-party’s research protocol, which may include locations both within and outside of the United States. We may have limited alternative PMF facilities in certain locations in the event one or more facility is unable to timely manufacture and supply the relevant products, and it may not be possible to timely manufacture the relevant products at required levels or at all, which may cause us to fail to meet our contractual obligations and may adversely affect our business. These third-party research programs could be discontinued, which could adversely affect our financial condition or results of operations.

Our recent acquisitions, dispositions and other future strategic transactions may disrupt our ongoing business and create distractions for our management. Additionally, the risks related to these transactions, including the risk that we are unable to successfully integrate acquired businesses into our operations, the risk that we are unable to complete dispositions on the proposed terms or on the anticipated timeline, or at all, or are unable to realize the anticipated benefits that each transaction is predicted to bring, could adversely affect our business, financial condition or results of operations.

As a part of our growth strategy, we have made and may continue to make selected acquisitions of complementary businesses, such as our recent acquisitions of Life Molecular Imaging Ltd. (“Life Molecular”) in July 2025 and Evergreen in April 2025. In addition, as part of our broader strategy, in May 2025, we announced that we had entered into a definitive agreement to sell our single-photon emission computerized tomography (“SPECT”) business to SHINE Technologies, LLC (“SHINE”). These transactions, in addition to advancing our existing pipeline and focusing our operations, create multiple competing interests that are complex and time-consuming, which may distract our management and disrupt our ongoing business.

Our completed and any potential future acquisitions involve numerous risks and operational, financial, and managerial challenges, including the following, any of which could adversely affect our business, financial condition, or results of operations:

•
Coordinating or consolidating geographically separate organizations and integrating personnel with different business backgrounds and corporate cultures;
•
Integrating previously autonomous departments, including those in accounting and administrative functions;
•
Integrating financial information and management systems;
•
The pace of our acquisition activity and the related diversion of already limited resources and management and other personnel time;
•
Difficulties in integrating new operations, technologies, products, and personnel;
•
Inconsistencies in standards, controls, procedures, and policies;
•
Lack of synergies, if synergies are anticipated, or the inability to realize expected synergies and cost-savings;
•
Underperformance of any acquired technology, product candidate, or business relative to our expectations and the price we paid;
•
Managing the risks of entering markets or types of businesses in which we have limited or no direct experience;
•
Exposure to unforeseen liabilities;
•
The potential loss of key employees and strategic partners of acquired companies; and
•
Risks associated with acquiring intellectual property, including potential disputes regarding acquired companies’ intellectual property.

57

Table of Contents

In addition, the successful integration of acquired businesses requires significant efforts and expense across all operational areas, including research and development, manufacturing, sales and marketing, finance, legal, and information technologies. There can be no assurance that any of our acquisitions will be successful or will be, or will become or remain, profitable. Our failure to successfully address the foregoing risks may prevent us from achieving the anticipated benefits from any acquisition in a reasonable time frame, or at all.

Further, the pending disposition of our SPECT business to SHINE is subject to customary closing conditions. Such closing conditions may be time consuming, and we may not be able to complete the disposition on the proposed terms or in the anticipated timeline, or at all. Additionally, there may be unforeseen expenses related to this divestiture, or we may fail to realize the expected benefits of this transaction.

We may be unable to successfully integrate Life Molecular’s Alzheimer’s disease radiodiagnostic commercial infrastructure and grow the appropriate use of Neuraceq to detect beta-amyloid plaques in patients evaluated for Alzheimer’s disease.

We completed our acquisition of Life Molecular on July 21, 2025, which included the acquisition of Neuraceq, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer’s disease, as well as the addition of an Alzheimer’s disease radiodiagnostic commercial infrastructure, research and development capabilities, and an established international footprint.

If we are not able to continue to grow Neuraceq sales, which depend, in part, on the expansion of the Alzheimer’s disease therapeutic market, to integrate Life Molecular’s commercial infrastructure, to expand the PMF network where Neuraceq is currently produced in the U.S. and our ability to leverage both the PMF network in place for PYLARIFY in the U.S. and the network in place for Neuraceq to optimize the availability of both products across the U.S., or to grow Neuraceq where it is approved outside the U.S., we may not be able to continue to grow the revenue and cash flow of our business, which could have a negative effect on our business, results of operations and financial condition.

Our use of artificial intelligence (“AI”) or other emerging technologies could adversely impact our business and financial results.

We deploy AI and other emerging technologies in various facets of our operations and we continue to explore further use cases for AI. The rapid advancement of these technologies presents opportunities for us in research, manufacturing, commercialization, and other business activities but also entails risks, including that AI-generated content, analyses, or recommendations we utilize could be deficient, or that our competitors may more quickly or effectively adopt AI capabilities. Our use of AI or other emerging technologies could also exacerbate regulatory, cybersecurity and other significant risks.

Risks Related to our and our Strategic Partners’ Portfolios of Clinical Development Candidates

We may not, or may take longer to, realize the expected benefits and opportunities related to our acquisition of the rights to LNTH-2501.

In April 2025, we acquired Evergreen, including the rights to LNTH-2501. On October 30, 2025, we announced that the FDA had accepted our NDA for LNTH-2501 and has set a PDUFA target action date of March 29, 2026, but we can provide no assurance that LNTH-2501 will be approved by the FDA based on the data submitted or, if approved, that we will be successful in commercializing LNTH-2501.

We have been and expect to continue to be dependent on partners for the development of certain product candidates, which expose us to the risk of reliance on these partners.

In connection with our ongoing development activities, we currently depend, and expect to continue to depend, on numerous collaborators. For example, in addition to our collaboration with Curium on PYLCLARI in Europe, GE HealthCare on Flyrcado in the U.S. and piflufolastat in Japan and POINT Biopharma Global Inc. on PNT2002 and PNT2003, we have other collaborations to develop and commercialize products. In addition, certain clinical trials for our product candidates may be conducted by government-sponsored agencies, and consequently will be dependent on governmental participation and funding. These arrangements expose us to the same considerations we face when contracting with third parties for our own trials.

If any of our collaborators breach or terminate its agreement with us or otherwise fail to conduct successfully and in a timely manner the collaborative activities for which they are responsible, the preclinical or clinical development or commercialization of the affected product candidate or research program could be delayed or terminated. We generally do not control the amount and timing of resources that our collaborators devote to our programs or product candidates. We also do not know whether current or future collaboration partners, if any, might pursue alternative technologies or develop alternative products either on their own or in collaboration with others, including our competitors, as a means for developing treatments for the diseases or conditions targeted by our collaborative arrangements. Our collaborators are also subject to similar development, regulatory, manufacturing, cyber-security and competitive risks as us, which may further impede their ability to

58

Table of Contents

successfully perform the collaborative activities for which they are responsible. Setbacks of these types to our collaborators could have a material adverse effect on our business, results of operations and financial condition.

Risks Related to Our Capital Structure

Repurchases by us of our common stock may affect the value of our common stock.

We have from time to time engaged in repurchase programs of our common stock. In July 2025, our Board of Directors authorized a program to repurchase up to $400.0 million of shares of our common stock through December 31, 2027, via open market purchases, privately negotiated transactions, block trades or pursuant to trades intending to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, or through other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations (the “2025 Program”). As of September 30, 2025, we had repurchased a total of approximately 1.8 million shares under the 2025 Program for approximately $100.0 million, and approximately $300.0 million of shares of our common stock remain available for repurchase under the 2025 Program. Such repurchases could increase, or prevent a decrease in, the market price of our common stock, although there can be no assurance that an increase, or prevention of a decrease, would occur, and stockholders could prefer that we allocate our capital in a different manner, which could negatively impact the market price of our common stock.

59

Table of Contents

Item 2. Unregistere d Sales of Equity Securities and Use of Proceeds

Repurchases

The following table presents information with respect to purchases of common stock we made during the three months ended September 30, 2025. On July 31, 2025, our Board of Directors (the “Board”) authorized a program to repurchase up to $400.0 million of shares of our common stock through December 31, 2027 (the “2025 Program”). The 2025 Program replaces the program authorized by the Board in November 2024 for $250.0 million (the “2024 Program”), including the remaining unused amounts under the 2024 Program. The 2025 Program authorizes us to purchase shares of our common stock from time to time via open market purchases at prevailing market prices, in privately negotiated transactions, block trades, or pursuant to trades intending to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, or through other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations. The 2025 Program does not obligate us to acquire any particular amount of our common stock, and we may suspend or discontinue the 2025 Program at any time. The actual timing, manner, number and dollar amount of repurchase transactions will be determined by our management, in its discretion and will depend on a number of factors, including but not limited to, the market price of our common stock.

The 2015 Equity Incentive Plan, adopted by us on June 24, 2015, as amended on April 26, 2016 and as further amended on April 27, 2017, April 24, 2019, April 28, 2021, April 28, 2022, April 25, 2024, October 22, 2024 and April 28, 2025, provides for the withholding of shares to satisfy tax withholding obligations and the exercise price of stock options. It does not specify a maximum number of shares that can be withheld for this purpose. The shares of common stock withheld to satisfy tax withholding obligations may be deemed to be “issuer purchases” of shares that are required to be disclosed pursuant to this Item 2.

Period |  | Total Number of Shares Purchased(1) |  |  | Average Price Paid per Share |  |  | Total Number of Shares Purchased as Part of the 2025 Program(2) |  |  | Approximate Dollar Value of Shares that May Yet Be Purchased Under the 2025 Program(2)
July 2025 |  |  | 2,780 |  |  | $ | 78.46 |  |  |  | — |  |  | $400.0 million
August 2025 |  |  | 1,764,568 |  |  | $ | 56.93 |  |  |  | 1,755,654 |  |  | $300.0 million
September 2025 |  |  | 1,399 |  |  | $ | 51.88 |  |  |  | — |  |  | $300.0 million
Total |  |  | 1,768,747 |  |  |  |  |  |  | 1,755,654 |  |  | $300.0 million

(1)
Includes shares withheld to satisfy tax withholding amounts due from employees related to the receipt of stock which resulted from the exercise or vesting of equity awards.
(2)
Reflects shares of our common stock repurchased under the 2025 Program, which expires in December 2027.

Dividend Policy

We did not declare or pay any dividends, and we do not currently intend to pay dividends in the foreseeable future. We currently expect to retain future earnings, if any, for the foreseeable future, to finance the growth and development of our business and to repay indebtedness. Our ability to pay dividends is restricted by our financing arrangements. See Part I, Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations-Liquidity and Capital Resources-External Sources of Liquidity” of this Form 10-Q for further information.

Item 3. Default s Upon Senior Securities

None.

Item 4. Mine Safety Dis closures

Not applicable.

Item 5. Other Information

Rule 10b5-1 Trading Plans

During the third quarter of 2025, no ne of our directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934, as amended) adopted, modified, or terminated a Rule 10b5-1 trading arrangement.

60

Table of Contents

Item 6. Exhibits

|  |  |  | INCORPORATED BY REFERENCE
EXHIBIT NUMBER |  | DESCRIPTION OF EXHIBITS |  | FORM |  | FILE NUMBER |  | EXHIBIT |  | FILING DATE
10.1*# |  | Deed of Amendment and Restatement Relating to a Sale and Purchase Agreement entered into July 21, 2025, by and among Life Medical Group Limited and Life Healthcare Group Holdings Limited and Lantheus Radiopharmaceuticals UK Limited and Lantheus Medical Imaging. |  |  |  |  |  |  |  |
31.1* |  | Certification of Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a). |  |  |  |  |  |  |  |
31.2* |  | Certification of Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a). |  |  |  |  |  |  |  |
32.1** |  | Certification pursuant to 18 U.S.C. Section 1350. |  |  |  |  |  |  |  |
101.INS* |  | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document |  |  |  |  |  |  |  |
101.SCH* |  | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents |  |  |  |  |  |  |  |
104* |  | Cover Page Interactive Data File (embedded within the Inline XBRL document) |  |  |  |  |  |  |  |

* Filed herewith.

** Furnished herewith.

# Pursuant to Item 601(b)(10)(iv) of Regulation S-K promulgated by the SEC, certain portions of this exhibit have been redacted because the Company customarily and actually treats such omitted information as private or confidential and because such omitted information is not material.

61

Table of Contents

SIGN ATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

LANTHEUS HOLDINGS, INC.
By: |  | /s/ BRIAN MARKISON
Name: |  | Brian Markison
Title: |  | Chief Executive Officer (Principal Executive Officer)
Date: |  | November 6, 2025
LANTHEUS HOLDINGS, INC.
By: |  | /s/ ROBERT J. MARSHALL, JR.
Name: |  | Robert J. Marshall, Jr.
Title: |  | Chief Financial Officer and Treasurer (Principal Financial Officer)
Date: |  | November 6, 2025

62